WO1999065894A1 - Macrocyclic analogs and methods of their use and preparation - Google Patents

Macrocyclic analogs and methods of their use and preparation Download PDF

Info

Publication number
WO1999065894A1
WO1999065894A1 PCT/US1999/013677 US9913677W WO9965894A1 WO 1999065894 A1 WO1999065894 A1 WO 1999065894A1 US 9913677 W US9913677 W US 9913677W WO 9965894 A1 WO9965894 A1 WO 9965894A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
alkyl
added
compound
etoac
Prior art date
Application number
PCT/US1999/013677
Other languages
French (fr)
Inventor
Bruce A. Littlefield
Monica Palme
Boris M. Seletsky
Murray J. Towle
Melvin J. Yu
Wanjun Zheng
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999065894(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT99928746T priority Critical patent/ATE502932T1/en
Priority to KR1020007014229A priority patent/KR100798600B1/en
Priority to DK99928746.9T priority patent/DK1087960T3/en
Priority to AU45739/99A priority patent/AU762998B2/en
Priority to EP99928746A priority patent/EP1087960B1/en
Priority to JP2000554719A priority patent/JP4454151B2/en
Priority to NZ508597A priority patent/NZ508597A/en
Priority to DE69943296T priority patent/DE69943296D1/en
Priority to IL13996099A priority patent/IL139960A0/en
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Priority to BRPI9911326A priority patent/BRPI9911326B8/en
Priority to DE201112100031 priority patent/DE122011100031I1/en
Priority to HU0103357A priority patent/HU227912B1/en
Priority to CA002335300A priority patent/CA2335300C/en
Publication of WO1999065894A1 publication Critical patent/WO1999065894A1/en
Priority to NO20006316A priority patent/NO328280B1/en
Priority to HK01106122.7A priority patent/HK1035534A1/en
Priority to CY2011010C priority patent/CY2011010I2/en
Priority to LU91854C priority patent/LU91854I2/en
Priority to BE2011C028C priority patent/BE2011C028I2/en
Priority to NO2011018C priority patent/NO2011018I1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Definitions

  • Halichondrin B is a potent anticancer agent originally isolated from the marine sponge Halichondria okadai, and subsequently found in Axinella sp., Phakellia carteri, and Lissondendryx sp..
  • Halichondrin B has demonstrated in vitro inhibition of tubulin polymerization, microtubule assembly, beta s -tubulin crosslinking, GTP and vinblastine binding to tubulin, and tubulin-dependent GTP hydrolysis and has shown in vitro and in vivo anti-cancer properties.
  • halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity. These compounds are substantially smaller than halichondrin B.
  • the invention features a compound having the formula (I):
  • A is a C, 6 saturated or C 2 6 unsaturated hydrocarbon skeleton, the skeleton being unsubstituted or having between 1 and 13 substituents, preferably between 1 and 10 substituents, e.g., at least one substituent selected from cyano, halo, azido, Q,, and oxo.
  • Each Q is independently selected from OR,, SR,, SO 2 R,, OSO 2 R NR 2 R
  • Rule NR 2 (CO)R meaning NR,(CO)(CO)R NR 4 (CO)NR 2 R,, NR 2 (CO)OR,, (CO)ORlope O(CO)R (CO)NR 2 R,, and O(CO)NR,R,.
  • the number of substituents can be, for example, between 1 and 6, 1 and 8, 2 and 5, or 1 and 4.
  • R, R 2 , R 4 , R 5 , and R 6 is independently selected from H, C, 6 alkyl, C,
  • 6 haloalkyl C, 6 hydroxyalkyl, C, 6 aminoalkyl, C 6 10 aryl, C 6 10 haloaryl (e.g., p- fluorophenyl or p-chlorophenyl), C 6 10 hydroxyaryl, C, 4 alkoxy-C 6 aryl (e.g., p- methoxyphenyl, 3,4,5-t ⁇ methoxyphenyl, p-ethoxyphenyl, or 3,5-d ⁇ ethoxyphenyl), C 6 10 aryl-C, 6 alkyl (e.g., benzyl or phenethyl), C, 6 alkyl-C 6 10 aryl, C 6 10 haloaryl-C, 6 alkyl, C, 6 alkyl-C 6 10 haloaryl, (C, .
  • alkoxy-C 6 aryl)-C alkoxy-C 6 aryl)-C, . alkyl, C 2 9 heterocyclic radical, C 2 9 heterocyclic radical-C, 6 alkyl, C 2 9 heteroaryl, and C 2 9 heteroaryl-C, 6 alkyl.
  • R alkoxy
  • OR alkoxy
  • Examples of A include 2,3-d ⁇ hydroxypropyl, 2-hydroxyethyl, 3-hydroxy-4- perfluorobutyl, 2,4,5-t ⁇ hydroxypentyl, 3-am ⁇ no-2-hydroxypropyl, 1,2- dihydroxyethyl, 2,3-d ⁇ hyroxy-4-perflurobutyl, 3-cyano-2-hydroxypropyl, 2-am ⁇ no-l- hydroxy ethyl,
  • Q examples include -NH(CO)(CO)-(heterocycl ⁇ c radical or heteroaryl), -OSO 2 -(aryl or substituted aryl), -O(CO)NH-(aryl or substituted aryl), aminoalkyl, hydroxyalkyl, -NH(CO)(CO)-(aryl or substituted aryl), -NH(CO)(alkyl)(heteroaryl or heterocyclic radical), O(subst ⁇ tuted or unsubstituted alkyl)(subst ⁇ tuted or unsubstituted aryl), and -NH(CO)(alkyl)(aryl or substituted aryl).
  • Each of D and D' is independently selected from R, and OR, wherein R, is H, C, , alkyl, or C, . haloalkyl.
  • Examples of D and D' are methoxy, methyl, ethoxy, and ethyl.
  • one of D and D' is H.
  • the value for n is 1 or preferably 0, thereby forming either a six-membered or five-membered ⁇ ng. This ⁇ ng can be unsubstituted or substituted, e.g , where E is R 5 or OR 5 , and can be a heterocyclic radical or a cycloalkyl, e.g. where G is S, CH 2 , NR 6 , or preferably O.
  • Q is C, . alkyl, and is preferably methyl T is ethylene or ethenylene, optionally substituted with (CO)OR 7 , where R 7 is H or C, 6 alkyl.
  • X is H or C, 6 alkoxy.
  • the invention features compounds of sufficient stability to be suitable for pharmaceutical development.
  • the invention also features pharmaceutically acceptable salts of disclosed compounds, disclosed novel synthetic intermediates, pharmaceutical compositions containing one or more disclosed compounds, methods of making the disclosed compounds or intermediates, and methods of using the disclosed compounds or compositions.
  • Methods of use include methods for reversibly or irreversibly inhibiting mitosis in a cell, and for inhibiting cancer or tumor growth in vitro, in vivo, or in a patient.
  • the invention also features methods for identifying an anti-mitotic or anti-cancer agent, such as a reversible or, preferably, an irreversible agent.
  • FIG. 1 is a graph showing the percentage of cells which have completed mitosis and returned to the G, phase as a function of concentration of compound B 1939 in a mitotic block assay
  • the minimum concentration required for complete mitotic block at 0 hour is 10 nM.
  • the minimum concentration required for complete mitotic block at 10 hour (after washout) is also 10 nM.
  • the reversibility ratio is therefore 1 for B 1939.
  • Supe ⁇ mposed upon this graph is a curve showing the percentage of viable cells at 5 days as a function of concentration of compound B 1939. Viability drops to very low levels at the same concentration as the 10 hour mitotic block.
  • FIG. 2 is a graph showing the percentage of cells which have completed mitosis and returned to G, phase as a function of the concentration of compound B2042 in a mitotic block reversibility assay.
  • the minimum concentration required for complete mitotic block at 0 hour is 3 nM.
  • the minimum concentration required for complete mitotic block at 10 hour is 100 nM.
  • FIG 3 is a graph showing the average tumor volume in microhters as a function of time (days) in a LOX melanoma xenograft growth inhibition assay This illustrates the antitumor activity of a compound of formula (I), compound B 1939 Paclitaxel and a vehicle control were used.
  • FIG 4 is a graph showing the average body weight per mouse as a function of time (days) in the assay desc ⁇ bed in FIG 3
  • FIG 5 is a graph showing the average tumor volume in microhters as a function of time (days) in a COLO 205 human colon cancer xenograft growth inhibition assay, showing the antitumor activities of vinblastine and vinc ⁇ stine.
  • Hydrocarbon skeletons contain carbon and hydrogen atoms and may be linear, branched, or cyclic.
  • Unsaturated hydrocarbons include one, two, three or more C-C double bonds (sp 2 ) or C-C t ⁇ ple bonds (sp).
  • unsaturated hydrocarbon radicals include ethynyl, 2-propynyl, 1-propenyl, 2-butenyl, 1,3-butad ⁇ enyl, 2- pentenyl, vinyl (ethenyl), allyl, and isopropenyl.
  • bivalent unsaturated hydrocarbon radicals include alkenylenes and alky denes such as methy dyne, ethy dene, ethy dyne, viny dene, and isopropylidene.
  • compounds of the invention have hydrocarbon skeletons ("A" m formula (I)) that are substituted, e.g., with hydroxy, ammo, cyano, azido, heteroaryl, aryl, and other moieties desc ⁇ bed herein.
  • Alkoxy (-OR), alkylthio (-SR), and other alkyl-denved moieties (substituted, unsaturated. or bivalent) are analogous to alkyl groups (R).
  • Alkyl groups, and alkyl-denved groups such as the representative alkoxy, haloalkyl, hydroxyalkyl, alkenyl, alkyhdene, and alkylene groups, can be C 2 6 , C, 6 , C, ., or C 2 4 .
  • Alkyls substituted with halo, hydroxy, amino, cyano, azido, and so on can have 1, 2, 3, 4, 5 or more substituents, which are independently selected (may or may not be the same) and may or may not be on the same carbon atom
  • substituents which are independently selected (may or may not be the same) and may or may not be on the same carbon atom
  • haloalkyls are alkyl groups with at least one substituent selected from fluoro, chloro, bromo, and lodo.
  • Haloalkyls may have two or more halo substituents which may or may not be the same halogen and may or may not be on the same carbon atom Examples include chioromethyl, pe ⁇ odomethyl, 3,3-dichloropropyl, 1,3-difluorobutyl, and l-bromo-2- chloropropyl
  • Heterocyclic radicals and heteroaryls include furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathienyl, 2H-pyrrolyl, pyrrolyl, lmidazolyl (e.g., 1-, 2- or 4- lmidazolyl), pyrazolyl, isothiazolyl, isoxazolyl, py ⁇ dyl (e.g., 1-, 2-, or 3- py ⁇ dyl), pyrazinyl, py ⁇ midinyl, py ⁇ dazinyl, indolizmyl, isoindolyl, 3H-mdolyl, mdolyl (e.g., 1-, 2-, or 3- ⁇ ndolyl), indazolyl, pu ⁇ nyl, 4H-qumohx ⁇ nyl, isoquinolyl, quinolyl, phthalazinyl, nap
  • Heterocyclic radicals and heteroaryls may be linked to the rest of the molecule at any position along the ⁇ ng.
  • Heterocyclic radicals and heteroaryls can be C 2 9 , or smaller, such as C 3 6 , C 2 5 , or C 3 7
  • Aryl groups include phenyl, benzyl, naphthyl, tolyl, mesityl, xylyl, and cumenyl.
  • heterocyclic radical include those having 1, 2, 3, 4, or more substituents independently selected from lower alkyl, lower alkoxy, amino, halo, cyano, nitro, azido, and hydroxyl.
  • Heterocyclic radicals, heteroaryls, and aryls may also be bivalent substituents of hydrocarbon skeleton "A" in formula (I).
  • embodiments of the invention include compounds wherein n is 0; wherein each of D and D' is independently selected from R C, ⁇ alkoxy, and C, . haloalkyloxy; wherein R 5 is selected from H, C 2 6 alkyl, C, 6 haloalkyl, C, 6 hydroxyalkyl, C, 6 aminoalkyl, C 6 10 aryl, C 6 10 haloaryl, C 6 10 hydroxyaryl, C, , alkoxy-C 6 aryl, C 6 ]0 aryl-C, 6 alkyl, C, 6 alkyl-C 6 10 aryl, C ⁇ haloaryl-C, 6 alkyl, C, 6 alkyl-C 6 10 haloaryl, (C, .
  • alkyl C, 3 alkyl-C 6 aryl, C 6 haloaryl-C, .
  • combinations are the combination of (h)-(m), the combination of (a) and (b), the combination of (f) and (h), and the combination of (h) and where one of D and D' is methyl and the other is H.
  • Two particularly preferred compounds are B1793 and B 1939.
  • Another embodiment includes compounds wherein Q, is independently selected from OR,, SR,, SO 2 R,, and OSO 2 R,; and each R, is independently selected from C, 6 alkyl, C, 6 haloalkyl, C 6 aryl, C 6 haloaryl, C, . alkoxy-C 6 aryl, C 6 aryl-C, 3 alkyl, C, 3 alkyl-C 6 aryl, C 6 haloaryl-C, , alkyl, C, 3 alkyl-C 6 haloaryl, and (C, . alkoxy-C 6 aryl)-C, 3 alkyl.
  • inventions include compounds wherein: one of D and D' is alkyl or alkoxy, where n is 1; (f) as above, where n is 1; E is alkoxy, where n is 1; n is 0, where one of D and D' is hydroxy and the other is H; and (f) as above, where n is 1 and E is methyl
  • the invention also features compounds wherein: (1) A has at least one substituent selected from hydroxyl, amino, azido, halo, and oxo; (2) A is a saturated hydrocarbon skeleton having at least one substituent selected from hydroxyl, am o, and azido (e.g., B1793, B1939, B2042, B 1794, and B 1922); (3) A has at least two substituents independently selected from hydroxyl, amino, and azido (e.g., B2090 and B2136); (4) A has at least two substituents independently selected from hydroxyl and amino (e.g., B2042 and B2090); (5) A has at least one hydroxyl substituent and at least one amino substituent (e.g., B1939 and B2136); (6) A has at least two hydroxyl substituents (e.g., B1793 and B 1794); (7) A is a C 2 4 hydrocarbon skeleton that is substituted (e.g., B2004, B2037, B
  • (S)-hydroxyl is meant the configuration of the carbon atom having the hydroxyl group is (S).
  • Embodiments of the invention also include compounds which have at least two substituents on the carbon atoms (1) alpha and gamma, (2) beta and gamma, or preferably (3) alpha and beta to the carbon atom linking A to the ring containing G.
  • the alpha, beta, and gamma carbon atoms can have an (R) or (S) configuration
  • the invention further provides preferred compounds having the formula (1) -A, shown below, wherein the substituents are identical to those defined above.
  • the invention further features the following monosaccharide intermediate having formula (II):
  • R is methyl or methoxy
  • each of PI, P2, and P3 is independently selected from H and primary alcohol protecting groups.
  • the diol sidechain is below the plane of the page and OP2 is above the plane of the page.
  • Primary alcohol protecting groups include esters, ethers, silyl ethers, alkyl ethers, and alkoxyalkyl ethers. Examples of esters include formates, acetates, carbonates " , and sulfonates.
  • Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3- phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate, crotonate, 4-methoxy- crotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2- (trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl.
  • silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers.
  • Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives.
  • Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta- (trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers.
  • benzyl ethers include p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl.
  • each of PI and P2 are TBS and P3 is MPM (see alcohol 19 below).
  • formula (II) can be modified so the hydroxyethyl sidechain can also be a protected hydroxyl, - CH 2 CH 2 O-P4, wherein P4 is independently selected from values for PI.
  • a related intermediate is alcohol 17, where the hydroxyethyl sidechain is a hydroxymethyl sidechain.
  • a corresponding hydroxypropyl sidechain, or aminoalkyl side chain, can be similarly prepared.
  • PI and P2 taken together can be a diol protecting group, such as cyclic acetals and ketals (methylene, ethylidene, benzylidenes, isopropylidene, cyclohexylidene, and cyclopentylidene), silylene derivatives such as di-t-butylsilylene and 1,1,3,3-tetra- isopropylidisiloxanylidene derivatives, cyclic carbonates, and cyclic boronates.
  • cyclic acetals and ketals methylene, ethylidene, benzylidenes, isopropylidene, cyclohexylidene, and cyclopentylidene
  • silylene derivatives such as di-t-butylsilylene and 1,1,3,3-tetra- isopropylidisiloxanylidene derivatives
  • cyclic carbonates cyclic boronates.
  • Key fragment F-3 can be obtained by DIBALH reduction of the corresponding methyl ester, XF3, prepared according to the procedure of Stamos, et al (Scheme 2).
  • Aryl groups can be incorporated into the C32 sidechain (e.g. B2043) as exemplified in Scheme 7.
  • Intermediate B2318 was deprotected and the resulting diol oxidatively cleaved to the corresponding aldehyde Treatment with a G ⁇ gnard reagent (e g p-F-PhMgBr), separation of the resulting diastereomers and silylation furnished 204, which was converted to final product in a manner similar to that desc ⁇ bed in Scheme 6
  • Ether analogs can be prepared from B1793 by treatment with an approp ⁇ ate alkylating agent (e g Scheme 8) Similarly, sulfonates, esters, carbamates, etc. can be prepared from B1793 by treatment with an activated carbonyl component Oxidative diol cleavage and reduction or selective hydroxyl group oxidation could furnish de ⁇ vatives such as B2037 and B1934, respectively
  • one or more hydroxyl groups could be converted to the corresponding amino groups with subsequent coupling with an activated carbonyl component (Scheme 9)
  • Displacement of the sulfonyl intermediate (e.g. B1920) by carbon or heteroatom nucleophiles could also be readily accomplished (Scheme 10)
  • Fluo ⁇ ne atoms could be introduced as desc ⁇ bed m Schemes 12 - 14
  • T ⁇ ol denvatives could be similarly prepared from the tetrahydrofuran intermediate
  • allyltnbutylstannane addition to aldehyde X32 furnished homoallylic alcohol 33 that was earned to final compound in a similar manner to that descnbed in Scheme 6
  • t ⁇ ols could be further modified as exemplified in Scheme 6
  • the 1,3 diol de ⁇ vatives could be prepared from intermediates previously desc ⁇ bed
  • B2086 could be oxidatively cleaved and reduced to afford 1,3-d ⁇ ol B2091 (Scheme 16) Scheme 1
  • Triol 1 A solution of TBDPSCI (444 mL, 1.7 mol) in DMF (0.5 L) was added in three portions to a suspension of L-arabinose (250.0 g, 1.66 mol), imidazole (231.4 g, 3.40 mol) and DMF (2.5 L). The addition of each portion took 1.5 h with a 30 min and a 15 h interval separating the second and third portions, respectively. The resulting solution was stirred for 3 h, concentrated and purified by flash chromatography (5% to 33% EtOAc-hexanes) to provide triol 1 (394 g, 61%). Ac 2 0, pyridine
  • Triacetate 2 Acetic anhydride (6.06 mol) was added over 1.5 h to triol 1 (1.01 mol) in pyridine (1.0 L) at 15 °C. The solution was stirred for 1 h, concentrated and purified by flash chromatography (15% to 25% EtOAc-hexanes) to afford triacetate 2 (518 g, 97%).
  • Alcohol 5 Imidazole (16.75 g, 246 mmol) and TBSCI (16.08 g, 107 mmol) were added to a solution of diol 4a (33.86 g, 82 mmol) in CH 2 C1 2 (250 mL) at 0 °C. After 18 h at 0 °C and 5 h at rt, the reaction mixture was diluted with saturated aqueous NaHCO j (250 mL), stirred for 30 min and the layers were allowed to separate.
  • Methyl ether 6 Iodomethane (16.5 mL, 265 mmol) and NaH (60% in mineral oil, 5.28 g, 132 mmol) were added to a solution of alcohol 5 (34.93 g, 66 mmol), THF (320 mL) and DMF (80 mL) at 0 °C. After 19 h at 0 °C, the reaction was quenched with saturated aqueous NH 4 C1 and saturated aqueous Na 2 S 2 O 3 . The resulting mixture was stirred for 20 min and the layers were allowed to separate.
  • Alcohol 8 A solution of pivaloyl chloride (8.4 mL, 67 mmol) in pyridine (50 mL) was added over 1.5 h to a solution of diol 7 (12.24 g, 65 mmol) in pyridine (100 mL) at 0 °C. After 1 h at 0 °C and 18 h at rt, the mixture was diluted with saturated aqueous NH 4 C1 and extracted with EtOAc (3 x 800 mL). The combined organic layers were dried over Na 2 SO 4 , concentrated and purified by flash chromatography (50% EtOAc-hexanes) to furnish alcohol 8 (16.9 g, 96%).
  • Olefin 9 Benzyl bromide (62 mL, 521 mmol) and Bu 4 NHSO 4 (10.6 g, 31 mmol) were added to a solution of alcohol 8 (16.9 g, 62 mmol) in CH 2 C1 2 (100 mL) at 0 °C.
  • a solution of NaOH (9.95 g, 248 mmol) in H,O (10 mL) was added to the reaction mixture over 15 min. After 30 min at 0 °C and 18 h at rt, the reaction mixture was diluted with saturated aqueous NH 4 C1 and extracted with CH 2 C1 2 (3 x 100 mL). The combined organic layers were dried over Na ⁇ SO ⁇ concentrated and purified by flash chromatography (hexanes to 30% EtOAc-hexanes) to afford olefin 9 (22.1 g, 98%).
  • reaction mixture was warmed to rt, stirred for 1 h and extracted with EtOAc (3 x 300 mL). The combined organic layers were dried over Na 2 SO 4 , concentrated and purified by flash chromatography (5% isopropanol- CH 2 C1 2 ) to provide diol 10 (17.98 g, 75%).
  • Silyl ether 11 Imidazole (21 g, 308 mmol) and TBSCI (26.5 g, 176 mmol) were added to a solution of diol 10 (17.4 g, 44 mmol) in DMF (90 mL) at rt. After 18 h, the reaction mixture was diluted with saturated aqueous NaHCO, (250 mL), stirred for 1 h and extracted with CH,C (3 x 100 mL). The combined organic layers were dried over Na ⁇ SO ⁇ concentrated and purified by flash chromatography (5% EtOAc- hexanes) to afford silyl ether 11 (25.7 g, 94%).
  • Alcohol 12 A mixture of silyl ether 11 (21.2 g, 33.8 mmol), Pd(OH) 2 (20%, 4.7 g, 33.8 mmol) and EtOAc (200 mL) was stirred at rt under 1 atm H 2 for 3 h. The mixture was filtered through Celite, concentrated and purified by flash chromatography (10% to 20% EtOAc-hexanes) to afford alcohol 12 (17.4 g, 96%).
  • Tebbe reagent was prepared by stirring b ⁇ s(cyclopentad ⁇ enyl)t ⁇ tan ⁇ um (11.36 g, 45.6 mmol) and Me 3 Al (2.0 M in toluene, 45.6 mL, 91.2 mmol) for 4 days at rt.
  • This mate ⁇ al was cooled to -25 °C and a solution of crude ketone in THF (150 mL) was added.
  • the reaction mixture was warmed to 0 °C, stirred for 30 min, quenched by slow addition of 0.1 N NaOH (3.5 mL), and then stirred for an additional 20 min at rt.
  • the mixture was diluted with Et,O, filtered through Celite and concentrated. The residue was dissolved in CH 2 C1 2 , filtered through basic Al 2 Oforce concentrated and pu ⁇ fied by flash chromatography (5% EtOAc-hexanes) to give olefin 13 (12.8 g, 74% for two steps).
  • Alcohol 14 9-BBN (0.5 M in THF, 165 mL, 83 mmol) was added to a solution of olefin 13 (12.78 g, 24 mmol) in THF (280 mL) at 0 °C. After stirring for 5 h at rt, the reaction mixture was recooled to 0 °C at which time H 2 O (200 mL), THF (100 mL) and NaBO 3 »4 H 2 O (75 g) were added. The mixture was warmed to rt, stirred for 16 h and then concentrated. The aqueous residue was extracted with EtOAc (4 x 300 mL) and the combined organic layers were d ⁇ ed over Na ⁇ SO,,. Concentration and purification by flash chromatography (20% to 35% EtOAc-hexanes) afforded alcohol 14 (12.05 g, 91%).
  • the aldehyde was dissolved in Et 2 O-EtOH (1:1, 100 mL), cooled to 0 °C and treated with sodium borohyd ⁇ de (1.21 g, 32 mmol). The mixture was sti ⁇ ed for 20 mm, carefully diluted with saturated aqueous NELC1, stirred for 30 min at rt and extracted with CH 2 C1 2 (3 x 150 mL). The combined extracts were d ⁇ ed over N ⁇ SO ⁇ concentrated and pu ⁇ fied by flash chromatography (20% EtOAc-hexanes) to afford alcohol 15 (9.95 g, 85% for three steps).
  • Alcohol 17 LAH ( 1 M in THF, 22.5 mL, 22.5 mmol) was added to a solution of MPM-ether 16 ( 10.05 g, 15 mmol) in Et 2 O (1.0 L) at 0 °C. After 30 min, the reaction was cautiously quenched with H 2 O (1.3 mL), and 1 N aqueous NaOH (1.3 mL). After stirring for 1 h at rt, the suspension was filtered through Celite, concentrated and purified by flash chromatography (20% EtOAc-hexanes) to afford alcohol 17 (8.18 g, 93%).
  • Olefin 18 DMSO (5.8 mL, 82.4 mmol) was added to a solution of oxalyl chloride (3.6 mL, 41.2 mmol) in CH 2 C1 2 (100 mL) at -78 °C. After 15 min, a solution of alcohol 17 (7.94 g, 13.5 mmol) in CH 2 C1 2 (35 mL) was added to the reaction mixture. After stirring for 1 h, Et 3 N (17 mL, 122 mmol) was added, the mixture was warmed to 0 °C, sti ⁇ ed for 20 min, diluted with saturated aqueous NH 4 C1 and then extracted with CH,C1 2 (3 x 100 mL).
  • reaction mixture was stirred for 24 h, removed from the glove box, cooled to 0 °C, diluted with EtOAc (100 mL), quenched with saturated NH 4 C1 (200 mL) and stirred for 30 min.
  • EtOAc 100 mL
  • saturated NH 4 C1 200 mL
  • the separated aqueous phase was extracted with EtOAc (6x) and the combined organic layers were dried over Na,SO 4 concentrated and purified by column chromatography (20% to 30%) to give B2318 ( ⁇ 3 g) contaminated with close running impurities and the uncyclized intermediate (4.61 g).
  • B2316 TsCI (0.63 g, 3.30 mmol) was added to a solution of B2317 (1.60 g, 1.97 mmol) in CH 2 C1 2 (8 mL) and py ⁇ dine (2 mL) at rt. After stir ⁇ ng for 29 h, the reaction was quenched with saturated aqueous NaHCO 3 (30 mL) and H 2 O (10 mL). The separated aqueous layer was extracted with Et 2 O and the combined organic layers were d ⁇ ed over Na 2 SO 4 , concentrated and pu ⁇ fied by column chromatography (15% to 30% EtOAc-hexanes) to give B2316 (2.01 g, 92%) as an oil along with recovered B2317 (92 mg, 5.8%).
  • B2314 MMTrCI (0.70 g, 2.26 mmol) was added to a solution of B2315 (1.33 g, 1.51 mmol) in CH 2 C1 2 (25 mL) and iPr 2 NEt (0.79 mL, 4.53 mmol) at rt. The resulting mixture was stirred for 1 h and then poured into a mixture of saturated aqueous NaHCO 3 (20 mL), H 2 O (10 mL) and E ,O (50 mL). The separated aqueous layer was extracted with E O (3x). The combined organic phases were dried over Na 2 SO 4 , concentrated and purified by column chromatography (CH 2 C1 2 followed by 15% to 30% EtOAc-hexanes) to give B2314 (1.65 g, 95%) as a solid foam.
  • B2313 A mixture of B2314 (1.60 g, 1.39 mmol) and Nal (3.10 g, 20.8 mmol) in acetone (50 mL) was heated under reflux for 13 h. After cooling to rt, the reaction mixture was diluted with EtOAc, and concentrated. H 2 O (5 mL), brine (20 mL) and Na 2 S 2 O 3 (200 mg) were added and the resulting mixture was extracted with Et,O (4x). The combined extracts were dried over Na 2 SO 4 , concentrated and purified by column chromatography (10% EtOAc-hexanes) to give B2313 (1.50 g, 97%) as an oil.
  • B2305 and B2306 The mixture of B2307/B2308 (1.80 g, 1.05 mmol) was dissolved in EtOH (20 mL), treated with PPTS (10.0 mg, 0.04 mmol), stirred at rt for 11 h and then quenched with NaHCO 3 (20.0 mg, 0.24 mmol). After stirring for 15 min, the mixture was concentrated, azeotroped with toluene (15 mL), and purified by column chromatography (20% to 30% EtOAc-hexanes) to give a mixture of B2305 and B2306 (1.22 g, 81%) as a solid foam. Although the isomers could be separated by prep TLC (30% EtOAc-hexanes), they were carried forward as a mixture.
  • B2304 may be prepared as follows and in fact the synthesis described below is superior to that given above.
  • NMO N- methylmorpholine oxide
  • TPAP tetrapropylammonium perruthenate
  • NiCl 2 /CrCl 2 (1% w/w, 1.09 g, 8.86 mmol) was added to a solution of B2304 (1.01 g, 0.70 mmol) in THF (600 mL) and DMF (150 mL) at rt. After stirring for 2 days the reaction mixture was taken out of the glove box, cooled to 0 °C, quenched with saturated aqueous NH 4 C1 (300 mL) and stirred at 0 °C for 20 min. After addition of tLO (100 mL), the two layers were separated and the aqueous layer was extracted with EtOAc (5x).
  • B1918 A mixture of B1793 (2.0 mg, 2.74 ⁇ mol), NaIO 4 (35 mg, 0.16 mmol), MeOH (0.8 mL) and H 2 O (0.2 mL) was stirred at rt for 40 min. The reaction mixture was diluted with H 2 O (1 mL), extracted with CFLCl, (6x). dried over Na,SO 4 , concentrated and purified by column chromatography (5% MeOH-CH.CU) to give B1918 (1.9 mg, 100%).
  • Diol 201 TBAF (1 M in THF, 383 ⁇ L, 0.383 mmol) was added to a solution of X2318 (350-LS-218 )(80.8 mg, 0.0765 mmol) in THF (7 mL) and sti ⁇ ed at rt for 16 h. After partial concentration, the residue was loaded directly onto a SiO-, column packed using 30% EtOAc-hexanes. Gradient elution (30% EtOAc-hexanes to EtOAc) furnished diol 201 (49.7 mg, 92%).
  • Aldehyde 202 A mixture of diol 201 (49.7 mg, 0.0707 mmol), NaIO (100 mg, 0.47 mmol), MeOH (10 mL) and H : O (2.5 mL) was stirred at rt for 30 min. H,O was added and the mixture was extracted with CH 2 C1 2 (4x). The combined organic extracts were d ⁇ ed over Na,SO . concentrated and purified by column chromatography (30% EtOAc-hexanes) to provide aldehyde 202 (41.7 mg, 88%)
  • Alcohol 203 4-Fluorophenylmagnesium bromide (2 M in Et 2 O, 155 ⁇ L, 0.31 mmol) was added to a solution of aldehyde 202 (41.7 mg, 0.062 mmol) in THF (6 mL). After 15 min at rt, the reaction was quenched with saturated aqueous NH 4 C1 and extracted with CH 2 CU (4x). The combined organic extracts were dried over N ,SO 4 , concentrated and purified by preparative TLC (407c EtOAc-hexanes) to provide alcohol 203 (32.4 mg, 68%) as a 1: 1 mixture of C34 isomers. The minor undesired C27 isomer was separated at this stage and was also isolated as a 1:1 mixture of C34 isomers (8.4 mg, 18%).
  • Ether 204 Et,N (18 ⁇ L, 0.13 mmol) and TBSOTf (15 ⁇ L, 0.063 mmol) were added to a solution of alcohol 203 (32.4 mg, 0.042 mmol) in CH 2 C1 2 (5 mL) at 0 °C. After 20 min the reaction was quenched by the addition of saturated aqueous NH 4 C1 and extracted with CH ⁇ Cl, (3x). The combined organic extracts were dried over Na,SO 4 , concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide ether 204 (33.1 mg. 89% ).
  • Alcohol 205 LAH (1 M in THF, 113 ⁇ L, 0.113 mmol) was added dropwise to a solution of ether 204 (33.1 mg, 0.0375 mmol) in Et 2 O (10 mL) at 0 °C. After 20 min, H 2 O and 1 M NaOH were added and the mixture was stirred at rt for 10 min. Filtration through Celite, concentration and purification by column chromatography (40% EtOAc-hexanes) furnished alcohol 205 (28.4 mg, 95%).
  • Ether 206 Diisopropylethylamine (31 ⁇ L, 0.18 mmol) and MMTrCI (22 mg, 0.071 mmol) were added to a solution of alcohol 205 (28.4 mg, 0.0356 mmol) in
  • Alcohol 207 DDQ (40 mg, 0.18 mmol) was added to a solution of ether 206 (37 mg, 0.034 mmol) in CH 2 C1 2 (4 mL) and a 1: 10 mixture of tBuOH:pH 7 phosphate buffer (2 mL) at 0 °C. The mixture was stirred vigorously in the dark for 15 min. Three additional portions of DDQ (40 mg, 0.18 mmol) were added at 10 min intervals, then the reaction was diluted with saturated aqueous NaHCO, and extracted with CH 2 C1 2 (3x).
  • Alcohol X-20 NaIO 4 (1.16 g, 5.4 mmol) was added to a solution of diols 10 a, b (1.19 g. 3.0 mmol) in MeOH-H 2 O (4:1, 75 mL) at 0 °C.
  • the reaction mixture was allowed to warm to rt. After stirring for 40 min, the mixture was diluted with EtOAc, filtered through Celite, concentrated, and partitioned between brine and CH 2 CI ; .
  • the separated aqueous layer was extracted with CH,C1 2 (2x). The combined organic layers were dried over Na,SO and concentrated to furnish the crude aldehyde intermediate.
  • Silyl ether 21 Imidazole (0.94 g, 13.9 mmol) and TBSCI (0.59 g, 3.89 mmol) were added sequentially to a solution of alcohol X-20 (1.02 g, 2.78 mmol) in DMF (10 mL) at rt. After 14 h, the reaction mixture was diluted with saturated aqueous NH 4 C1 and extracted with EtOAc (3x). The combined organic extracts were washed with H 2 O, b ⁇ ne, d ⁇ ed over Na 2 SO 4 , concentrated and pu ⁇ fied by flash chromatography (5% to 15% EtOAc-hexanes) to afford silyl ether 21 (1.3 g, 98%).
  • Alcohol 22 A mixture of Pd(OH) 2 (20%, 0.8 g), silyl ether 21 (1.3 g, 2.70 mmol) and EtOAc (30 mL) was stirred for 1 h under 1 atm H 2 at rt, filtered through Celite, concentrated and purified by flash chromatography (20% to 40% EtOAc- hexanes) to afford alcohol 22 (0.96 g, 91%).
  • Tebbe reagent (14.9 mL, 9.0 mmol) was added over 10 mm to a solution of the crude ketone in THF (60 mL) at 0 °C. After 20 min, the reaction mixture was poured into Et 2 O (100 mL) that was precooled to -78 °C, quenched by slow addition of H O (30 mL), warmed to rt., stirred for 30 min and extracted with Et 2 O (4x). The combined extracts were washed with b ⁇ ne, d ⁇ ed over Na 2 SO 4 , concentrated and pu ⁇ fied by flash chromatography (10% EtOAc-hexanes) to afford the desired olefin contaminated by the gem-dimethyl product (1.07 g). This mixture was used directly in the next step.
  • Alcohol 26 Using the procedure previously desc ⁇ bed, alcohol 25 (604 mg, 1 49 mmol) was sequentially oxidized, isome ⁇ zed, and reduced. Pu ⁇ fication by flash chromatography (20% to 40% EtOAc-hexanes) afforded alcohol 26 (550 mg, 91% for three steps).
  • MPM-ether 27 BF,-OEt 2 (0.05 M in CH 2 C1 . 270 ⁇ L, 0.013 mmol) was added to a solution of alcohol 26 (545 mg, 1.35 mmol) and MPM-trichloroimidate (1.14 g, 4.0 mmol) in CH 2 C1 2 (40 mL) at 0 °C. After 1 h. the reaction was quenched with saturated aqueous NaHCO,, extracted with CH 2 C1 2 . dried over Na 2 SO 4 , concentrated and purified by flash chromatography (10% to 15% EtOAc-hexanes) to afford MPM-ether 27 (580 mg, 82%).
  • Alcohol 28 LAH (1 M in THF, 1.9 mL, 1.9 mmol) was added to a solution of MPM-ether 27 (580 mg, 1.11 mmol) in Et 2 O (100 mL) at 0 °C. After 30 min, the reaction was quenched carefully with H 2 O (0.5 mL), and 1 N aqueous NaOH (0.5 mL), stirred for 1 h at rt, filtered through Celite, concentrated and purified by flash chromatography (30% to 50% EtOAc-hexanes) to afford alcohol 28 (460 mg, 95%).
  • Olefin 29 DMSO (441 ⁇ L, 6.23 mmol) was added to a solution of oxalyl chloride (272 ⁇ L, 3.12 mmol) in CH 2 C1 2 (30 mL) at -78 °C. After 15 min, a solution of alcohol 28 (458 mg, 1.04 mmol) in CH 2 C1 2 (15 mL) was added to the reaction mixture. After stirring for 1 h at -78 °C, Et 3 N (1.3 mL, 9.35 mmol) was added. The reaction mixture was warmed to 0 °C, stirred for 10 min, diluted with saturated aqueous NH 4 C1 and extracted with CH 2 C1 2 (3x).
  • Alcohols 33a and 33b Dess-Martin pe ⁇ odinane (925 mg, 2.18 mmol) was added to a solution of alcohol 32 (309 mg, 0.727 mmol) in CH 2 C1 2 (19 mL) at rt. After 1 h, the reaction was diluted with Et 2 O and filtered through Celite. The filtrate was washed sequentially with a 1 :9 mixture of saturated aqueous NaHCO ⁇ Na ⁇ O j and brine, dried over Na ⁇ SO,,, concentrated and purified by flash chromatography (20% to 30% EtOAc-hexanes) to afford the desired aldehyde, which was taken immediately through the next step.
  • Diols 35a and 35b OsO 4 (0.1 M solution in toluene, 32 ⁇ L, 3.2 ⁇ mol) was added to a solution of K 2 CO 3 (168 mg, 1.22 mmol), K,Fe(CN) 6 (400 mg, 1.22 mmol),
  • Alcohol 37 Using the procedure described previously for the preparation of alcohol 28, compound 36 (161 mg, 0.192 mmol) afforded alcohol 37 (135 mg, 93%) after purification by flash chromatography (20% to 40% EtOAc-hexanes).
  • Aldehyde 38 Dess-Martin periodinane (227 mg, 0.535 mmol) was added to a solution of alcohol 37 (135 mg, 0.178 mmol) in CH 2 C1 2 (5 mL) at rt. After 1 h, the reaction mixture was diluted with E ,O and filtered through Celite. The filtrate was washed sequentially with a 1:9 mixture of saturated aqueous NaHCO ⁇ N& j S- , and brine, dried over N ⁇ SO,,, concentrated and purified by flash chromatography (10% to 20% EtOAc-hexanes) to afford aldehyde 38 (127 mg, 95%).
  • Alcohol 303 9-BBN (0.5 M in THF, 23 mL, 0.012 mol) was added dropwise over 30 mm to a solution of alkene 302 (1.51 g, 0.00386 mol) in THF (40 mL) at 0 °C. After stir ⁇ ng at rt for 80 m , the mixture was cooled to 0 °C and H 2 O (80 mL) was cautiously added followed by NaBO, » 4 H 2 O (4.2 g, 0.027 mol). The mixture was sti ⁇ ed vigorously at rt for 2.3 h, then extracted with EtOAc (3x). The combined organic extracts were washed with b ⁇ ne. d ⁇ ed over Na 2 SO 4 , concentrated and pu ⁇ fied by column chromatography (50% EtOAc-hexanes) to provide alcohol 303 (1.37 g, 87%).
  • Alcohol 305 TBAF (1 M in THF, 5 ⁇ L, 0.005 mmol) was added to a solution of aldehyde 304 (0.114 g, 0.27 mmol) in CF/TMS (0.5 M in THF, 1.1 mL, 0.54 mmol) at 0 °C. After 20 min, a second portion of TBAF (1 M in THF, 100 ⁇ L, 0.1 mmol) was added and the mixture was stirred for 10 min at which point excess TBAF (1 M in THF, 270 ⁇ L, 0.27 mmol) was added dropwise to cleave the intermediate silyl ether. After 30 min, the mixture was diluted with H,O and extracted with EtOAc (3x).
  • Silyl ether 306 TBSOTf (265 ⁇ L, 1.16 mmol) was added to a solution of alcohol 305 (123 mg, 0.257 mmol) and Et,N (430 ⁇ L, 3.08 mmol) in CH 2 C1 2 (8 mL) at 0 °C. After stirring at rt for 20 h, saturated aqueous NaHCO 3 was added, and the mixture was extracted with CH 2 C1 2 (3x). The combined organic extracts were washed with brine, dried over Na,SO 4 , concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide silyl ether 306 (148 mg, 97%).
  • Alcohol 307 LAH (1 M in THF. 220 ⁇ L, 0.22 mmol) was added dropwise to a solution of silyl ether 306 (131 mg, 0.22 mmol) in Et 2 O (5 mL) at 0 °C. After 20 min. H 2 O and 1 M NaOH were cautiously added. The mixture was sti ⁇ ed at rt 30 min, filtered through glass wool, concentrated and purified by column chromatography (50% EtOAc-hexanes) to provide alcohol 307 (112 mg, quant.).
  • Alcohol 310 9-BBN (0.5 M in THF, 17 mL, 8.45 mmol) was added dropwise to a solution of alkene 309 (1.06 g, 2.11 mmol) in THF (30 mL) at 0 °C. After stirring for 2.5 h at rt, the reaction was cooled to 0 °C and H 2 O (60 mL) followed by NaBO 3 »4 H 2 O (3.25 g, 21.1 mmol) were cautiously added. The mixture was stirred vigorously at rt for 2 h, then diluted with H 2 O and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over Na 2 SO 4 , concentrated and purified by column chromatography (20% to 30% EtOAc-hexanes) to provide alcohol 310 (0.920 g, 84%).
  • Pivaloate 311 A mixture of alcohol 310 (65.8 mg, 0.0126 mmol), pyridine (61 ⁇ L, 0.76 mmol) and PvCI (23 ⁇ L, 0.189 mmol) in CH 2 C1 2 (3 mL) was stirred at rt for 5 h. A second reaction utilizing alcohol 310 (0.92 g, 1.76 mmol) was run under similar conditions and both reactions were combined during the work-up: saturated aqueous NH 4 C1 was added and the mixture was extracted with CH 2 C1 2 (3x). The combined organic extracts were washed with brine, dried over Na 2 SO 4 , concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide pivaloate 311 (1.08 g, quant).
  • Ketone 313 Oxalyl chlo ⁇ de (21 ⁇ L, 0.12 mmol) was added dropwise to a solution of DMSO (34 ⁇ L, 0.48 mmol) in CH 2 C1 2 (3 mL) at -78 °C After 1 h, a solution of alcohol 312 (39.4 mg, 0.081 mmol) in CH 2 C1 2 (1 5 mL) was added and the mixture was sti ⁇ ed for 1.5 h. Et 3 N (100 ⁇ L, 0.73 mmol) was added, and after 10 mm the mixture was warmed to 0 °C. Saturated aqueous NH 4 C1 was added and the mixture was extracted with CH,C1 2 (3x).
  • Alcohol 316 Oxalyl chloride (246 ⁇ L, 2.82 mmol) was added dropwise to a solution of DMSO (400 ⁇ L, 5.64 mmol) in CH 2 C1 2 (40 mL) at -78 °C. After 1 h, a solution of alcohol 315 (0.47 g, 0.94 mmol) in CH 2 C1 2 (10 mL) was added and the mixture was stirred for 1 h. Et 3 N (1.2 mL, 8.5 mmol) was added, and after 10 min the mixture was warmed to 0 °C and stirred for 10 min. Saturated aqueous NH C1 was added and the mixture was extracted with CH 2 C1 2 (3x).
  • Ether 317 Alcohol 316 (60.7 mg, 0.12 mmol) and MPMOTCI (0.10 g, 0.36 mmol) were combined, azeotroped from toluene (3x) and dried under high vacuum overnight. CH 2 C1 2 (3 mL) was added and the mixture was cooled to 0 °C. BF,»OEL, (approx. 1 ⁇ L, 0.01 mmol) was added and after stirring for 10 min the reaction was quenched with saturated aqueous NH 4 C1.
  • Alcohol 318 LAH (1 M in THF, 104 ⁇ L, 0.104 mmol) was added dropwise to a solution of ether 317 (54 mg. 0.087 mmol) in Et 2 O (5 mL) at 0 °C. After 30 min, H 2 O and 1 M NaOH were cautiously added. The mixture was stirred at rt for 10 min, filtered through glass wool, concentrated and purified by column chromatography (30%-50% EtOAc-hexanes) to provide alcohol 318 (45.5 mg, 98%). Swern
  • Diol 402 A mixture of OsO 4 (1 xstal), alcohol 401 (605 mg, 1.28 mmol), 4- methyl-morpholme N-oxide (0.45 g, 3.84 mmol), acetone (30 mL) and H 2 O (6 mL) was stirred at rt for 29 h. Additional OsO 4 (3 xtals) and 4-methylmorphol ⁇ ne N-oxide (0.1 g, 0.8 mmol) were added and after 2 days saturated aqueous ⁇ a 2 S 2 O, was added. The mixture was extracted with CH 2 C1 2 (6x) and the combined organic extracts were dried over Na,SO 4 and concentrated.
  • the crude intermediate triol was immediately dissolved in 4:l ::MeOH:H 2 O (25 mL) and NaIO 4 (0.41 g. 1.9 mmol) was added. After stir ⁇ ng vigorously at rt for 2 h, the mixture was diluted with H 2 O, extracted with CH 2 C1 2 (3x) and the combined organic extracts were d ⁇ ed over Na 2 SO 4 and concentrated to provide the intermediate aldehyde which was immediately dissolved in 1:1 EtOH-Et 2 O (30 mL) and cooled to 0 °C. NaBH (48 mg. 1.3 mmol) was added and after 20 min the reaction was quenched with H 2 O and extracted with CH,C1., (4x). I'he combined organic extracts were dried over Na,SO 4 . concentrated and purified by column chromatography (50% EtOAc-hexanes) to provide diol 402 (485 mg, 80% for 3 steps).
  • Silyl ether 403 TBSOTf (2.3 mL, 10 mmol) was added dropwise to a mixture of diol 402 (485 mg, 1.0 mmol), Et,N (2.8 mL, 20 mmol) and CH 2 C1 2 (30 mL) at 0 °C. After stirring for 1 h at rt, saturated aqueous NH 4 C1 was added and the mixture was extracted with CH 2 C1 2 (3x). The combined organic extracts were washed with brine, dried over Na ⁇ SO,,, concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide silyl ether 403 (668 mg, 95%).
  • Alcohol 404 LAH (1 M in THF, 2.8 mL, 2.8 mmol) was added dropwise to a solution of silyl ether 403 (668 mg, 0.948 mmol) in ⁇ (60 mL) at 0 °C. After 15 min, H 2 O and 1 M NaOH were cautiously added. The mixture was stirred at rt for 20 min, filtered through glass wool, concentrated and purified by column chromatography (30% EtOAc-hexanes) to provide alcohol 404 (500 mg, 85%).
  • Alkene 406 «BuL ⁇ (1.63 M, 860 ⁇ L, 1.4 mmol) was added dropwise to a solution of CH,PPh,Br (500 mg, 1.4 mmol) in THF (15 mL) and DMSO (6 mL) at 0 °C. After 1 h, a solution of aldehyde 405 (486 mg) in THF (15 mL) was added. The reaction mixture was warmed to rt and sti ⁇ ed for 30 min.
  • Ester 407 9-BBN (0.5 M in THF, 9 0 mL, 4 5 mmol) was added dropwise to a solution of alkene 406 (0.460 g. 0.746 mmol) in THF (10 mL) at 0 °C. After warming to rt, the mixture was stirred for 3 h and two additional portions of 9-BBN (0.5 M in THF, 3.0 mL, 1.5 mmol) were added at 30 mm intervals. The reaction mixture was recooled to 0 °C. whereupon THF
  • Alcohol 408 A mixture of ester 407 (1 1 mg. 0.015 mmol) and Pd(OH)JC (10 mg) in EtOAc (500 ⁇ L) was stirred vigorously under a H 2 atmosphere at rt for 6 h. The mixture was filtered through Celite, concentrated and punfied by column chromatography (30% EtOAc-hexanes) to provide alcohol 408 (9 4 mg, quant).
  • Alcohol 410 9-BBN (0.5 M m THF, 1.5 mL, 0.72 mmol) was added dropwise to a solution of alkene 409 (0.144 g, 0.242 mmol) in THF (2 mL) at 0 °C. After warming to rt, the mixture was sti ⁇ ed for 3 h. The reaction mixture was recooled to 0 °C, whereupon THF (2 mL), H 2 O (2 mL) and NaBO,»4 H 2 O (0.38 g. 2 4 mmol) were cautiously added. The mixture was stirred vigorously at rt for 4 h, diluted with H 2 O and extracted with EtOAc (3x). The combined extracts were washed with b ⁇ ne, dried over Na 2 SO 4 , concentrated and pu ⁇ fied by column chromatography (20% EtOAc-hexanes) to provide alcohol 410 (0.140 g, 94%).
  • Alcohol 411 Oxalyl chlo ⁇ de (26 ⁇ L. 0.30 mL) was added dropwise to a solution of DMSO (43 ⁇ L, 0.60 mmol) in CH : C1 2 (4 mL) at -78 °C After 1 h. a solution of alcohol 410 (57 mg. 0.093 mmol) in CH ; Cl 2 (2 mL) was added. After 45 min. Et,N (125 ⁇ b? &.90 mmol) was added. After stir ⁇ ng at -78 °C for 10 min. the reaction mixture was warmed to 0 °C and stirred for an additional 10 min.
  • Diol 501 (64) Saturated aqueous NaHCO, (21 mL) and KBr (89 mg, 0.75 mmol) were added to a solution of diol 10 (1.35 g. 3.4 mmol) in CH 2 C1 2 (34 mL). The mixture was cooled to 0 °C, and 4-methoxy-2,2,6,6-tetramethyl-l-piperidinyloxy (0.05 M in CH,CI,, 7.45 mL, 0.37 mmol) and NaOCl (0.07 M in H,O, 5.6 mL, 0.39 mmol) were sequentially added.
  • Screening methods included a standard in vitro cell growth inhibition assay using DLD-1 human colon cancer cells (ATCC accession number CCL 221) in a 96-well microtiter plate format (Fmlay, G.J. et al Analytical Biochemistry 139.272-277, 1984), a U937 (ATCC accession number CRL 1593) mitotic block reversibility assay (desc ⁇ bed below), and in some cases, a LOX human melanoma tumor xenograft in vivo growth inhibition assay (see Table 1) Chemical stability to esterase degradation was also examined
  • Cells were resuspended in 25 mL of warm drug-free media and cent ⁇ fuged at 300 x g for 10 min at room temperature. After removing media from cell pellet, cells were resuspended in 35 mL of warm drug-free media, transfe ⁇ ed to fresh flasks, and a 10 mL sample of cells immediately removed from each flask, immediately processed as desc ⁇ bed below and stored for later cell cycle analysis (0 hours of drug washout).
  • Ethanol treated cells were cent ⁇ fuged 300 x g for 10 min, ethanol removed and cells then washed in 10 mL Phosphate Buffered Saline (PBS). Cells were resuspended in 0.5 mL of 0.2 mg/mL Ribonuclease A (Sigma No. R-5503) in PBS and incubated m 37 °C water bath for 30 mm.
  • PBS Phosphate Buffered Saline
  • PI propidium iodide
  • the intensity of propi ⁇ um iodide fluorescence for each cell was measured on a linear amplification scale with doublet events ignored using doublet disc ⁇ mination.
  • the results obtained from analyzing 15,000 cells were presented as a histogram with increasing fluorescence intensity on the x-axis and the number of cells at a particular intensity level on the y- axis.
  • the intensity of PI staining is dependent on the amount of DNA in the cell so it is possible to identify cells va ⁇ ous phases of the cell cycle, such as cells that have not yet synthesized DNA since the last mitosis (G, phase), cells that are in intermediate stages of DNA synthesis (S phase), and cells that have doubled their complement of DNA and are ready to divide (G 2 phase).
  • Cells that are blocked in the mitosis phase of the cell cycle also have double the amount of DNA compared to G, phase cells If all cells are blocked mitosis there are no G, phase cells, but if the block is removed when compound is removed, cells complete mitosis and reappear in the G, phase The number of cells so reappea ⁇ ng in the G, or Sphase is thus a measure of the number of cells which have recently completed mitosis. For each sample at 0 and 10 hours after compound removal, the percentage of cells completing mitosis was quantified (as the number of cells reappea ⁇ ng in the G, phase) and plotted as a function of the initial concentration of compound used du ⁇ ng the 12 hour pretreatment pe ⁇ od.
  • the percentage of cells still viable 5 days after drug washout was supe ⁇ mposed on the same graph, see, for example FIG. 1 and FIG. 2.
  • a ratio can be determined between the compound concentration required to completely block all cells in mitosis at 0 hour and the concentration required to maintain the block 10 hours after compound removal. This was taken as a measure of a compound's reversibility, with ratios close to or equal to one indicating likely potent in vivo anti-tumor compounds (see Table 1, columns 4- 6, and FIGS. 3 and 4).
  • B 1939 B1 40 B1942 B1963 BI 73 B1 84 B1987 B1988 B1990 B1991 B1992 B1998 B2003 B2004 B2008 B2010 B2011 B2013 B2014 B2015 B2016 B2019 B2034 B2035 B2037 B2039 B2042 B2043 B2070 B2073 B2086 B2088 B2090 B2091 B2102 B2136 B2294 B2320 B2330 B2336
  • the invention also features a method for identifying an agent that induces a sustained mitotic block in a cell after transient exposure of the cell to the agent
  • the invention features determining the relative reversibility of the test compound by relating the measurement of step (d) and the measurement of step (0. as desc ⁇ bed below This determination may be a ratio, or an a ⁇ thmetic difference, for example
  • the method includes
  • step (d) measuring the percentage of transiently-exposed cells from step (c) that have completed mitosis and returned to the G, phase (e.g., measuring a cell cycle marker, such as DNA-dependent PI fluorescence).
  • a cell cycle marker such as DNA-dependent PI fluorescence
  • One aspect of this screening method include the further steps of :
  • step (e) incubating a second sample of cells with a concentration of the test compound less than or equal to that used in step (a) for a time interval between that sufficient to empty the G, population and that equivalent to one cell cycle;
  • step (f) measuring the percentage of cells from step (e) that have completed mitosis and have returned to the G, phase;
  • the first and second cell samples are suspension culture cells selected from, for example, human leukemia, human lymphoma, murine leukemia, and murine lymphoma cells.
  • the first and second cell samples may be incubated simultaneously (steps (a) and (e)) or in separate portions.
  • Other embodiments further include before step (a), the step (i) of estimating a desirable time interval for incubating said first cell sample with a reversible mititotic blocking agent (or, alternatively, said test compound) to provide a satisfactory majority of cells collected at mitotic block; and wherein the incubation of step (a) is for the time interval estimated in step (i).
  • Another embodiment of the method further includes before step (c), the step (ii) of estimating a desirable time interval for the test compound-free incubation of step (c), said step (ii) comprising determining the time interval after which at least 80 % of the cells pretreated with a highly reversible antimitotic agent complete mitosis and reenter G, phase; and wherein the incubation of step (c) is for the time interval determined in step (ii).
  • Another embodiment of the method utilizes non- suspension culture cells from, for example, adherent human or murine cancer cells, harvested by any suitable means for detaching them from tissue culture flasks.
  • One aspect of the method further includes repeating steps (a) - (f) using a range of relative concentrations of test compound to determine what two substantially minimum concentrations of the test compound provide substantially complete mitotic block in step (d) and in step (f). respectively.
  • the ratio of these minimum sufficient concentrations is an index of reversibility (see detailed U937 protocol for preparation of exemplary dose-response curves).
  • concentrations may be determined by extrapolating curves of the percentage of cells (from steps (d) and (f)) as a function of concentration (e.g., by testing only a few concentrations, such as 3 or fewer), or by empirically testing a full range of concentrations.
  • substantially i ⁇ eversible antimitotic agents in other words, agents which continue to block mitosis in a cell which has been only transiently exposed to the agent, are likely to be more effective in vivo where natural processes, including multi- drug resistance (MDR) pumps and metabolic or other degradative pathways, prevent prolonged exposure.
  • MDR multi- drug resistance
  • the effectiveness of relatively reversible antimitotic agents may depend upon a period of sustained exposure.
  • Vinblastine 10 600 60 Highly Reversible Vincristine 10 10 1 Irreversible
  • the disclosed compounds have pharmacological activity, including anti-tumor and anti-mitotic activity as demonstrated in section D above.
  • tumors include melanoma, fibrosarcoma, monocytic leukemia, colon carcinoma, ovarian carcinoma, breast carcinoma, osteosarcoma, prostate carcinoma, lung carcinoma and ras-transformed fibroblasts.
  • compositions which include a compound of formula (I) and a pharmaceutically-acceptable carrier.
  • Compositions can also include a combination of disclosed compounds, or a combination of one or more disclosed compounds and other pharmaceutically-active agents, such as an anti-tumor agent, an immune-stimulating agent, an interferon, a cytokine, an anti-MDR agent or an anti-angiogenesis agent.
  • Compositions can be formulated for oral, topical, parenteral, intravenous, or intramuscular administration, or administration by injection or inhalation. Formulations can also be prepared for controlled-release, including transdermal patches.
  • a method for inhibiting tumor growth in a patient includes the step of administering to the patient an effective, anti-tumor amount of a disclosed compound or composition.
  • the invention also contemplates combination therapies, including methods of co-administering a compound of formula (I) before, during, or after administering another pharmaceutically active agent.
  • the methods of administration may be the same or different.
  • Inhibition of tumor growth includes a growth of the cell or tissue exposed to the test compound that is at least 20% less, and preferably 30%, 50%, or 75% less than the growth of the control (absence of known inhibitor or test compound).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.

Description

MACROCYCLIC ANALOGS AND METHODS OF THEIR USE AND PREPARATION
Background
The invention relates to pharmaceutically active macrolides. Halichondrin B is a potent anticancer agent originally isolated from the marine sponge Halichondria okadai, and subsequently found in Axinella sp., Phakellia carteri, and Lissondendryx sp..
A total synthesis of Halichondrin B was published in 1992 (Aicher, T.D. et al, J. Am. Chem. Soc. 114:3162-3164). Halichondrin B has demonstrated in vitro inhibition of tubulin polymerization, microtubule assembly, betas -tubulin crosslinking, GTP and vinblastine binding to tubulin, and tubulin-dependent GTP hydrolysis and has shown in vitro and in vivo anti-cancer properties.
Summary of the Invention
The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity. These compounds are substantially smaller than halichondrin B. The invention features a compound having the formula (I):
Figure imgf000003_0001
Formula (I) In formula (I), A is a C, 6 saturated or C2 6 unsaturated hydrocarbon skeleton, the skeleton being unsubstituted or having between 1 and 13 substituents, preferably between 1 and 10 substituents, e.g., at least one substituent selected from cyano, halo, azido, Q,, and oxo. Each Q, is independently selected from OR,, SR,, SO2R,, OSO2R NR2R„ NR2(CO)R„ NR,(CO)(CO)R NR4(CO)NR2R,, NR2(CO)OR,, (CO)OR„ O(CO)R (CO)NR2R,, and O(CO)NR,R,. The number of substituents can be, for example, between 1 and 6, 1 and 8, 2 and 5, or 1 and 4. Throughout the disclosure, numeπcal ranges are understood to be inclusive
Each of R,, R2, R4, R5, and R6 is independently selected from H, C, 6 alkyl, C,
6 haloalkyl, C, 6 hydroxyalkyl, C, 6 aminoalkyl, C6 10 aryl, C6 10 haloaryl (e.g., p- fluorophenyl or p-chlorophenyl), C6 10 hydroxyaryl, C, 4 alkoxy-C6 aryl (e.g., p- methoxyphenyl, 3,4,5-tπmethoxyphenyl, p-ethoxyphenyl, or 3,5-dιethoxyphenyl), C6 10 aryl-C, 6 alkyl (e.g., benzyl or phenethyl), C, 6 alkyl-C6 10 aryl, C6 10 haloaryl-C, 6 alkyl, C, 6 alkyl-C6 10 haloaryl, (C, . alkoxy-C6 aryl)-C, . alkyl, C2 9 heterocyclic radical, C2 9 heterocyclic radical-C, 6 alkyl, C2 9 heteroaryl, and C2 9 heteroaryl-C, 6 alkyl. There may be more than one R,, for example, if A is substituted with two different alkoxy (OR,) groups such as butoxy and 2-amιnoethyoxy.
Examples of A include 2,3-dιhydroxypropyl, 2-hydroxyethyl, 3-hydroxy-4- perfluorobutyl, 2,4,5-tπhydroxypentyl, 3-amιno-2-hydroxypropyl, 1,2- dihydroxyethyl, 2,3-dιhyroxy-4-perflurobutyl, 3-cyano-2-hydroxypropyl, 2-amιno-l- hydroxy ethyl,
3-azιdo-2-hydroxypropyl, 3,3-dιfluoro-2,4-dιhydroxybutyl, 2,4-dιhydroxybutyl, 2-hydroxy-2(p-fluorophenyl)-ethyl, -CH2(CO)(substιtuted or unsubstituted aryl), -CH2(CO)(alkyl or substituted alkyl, such as haloalkyl or hydroxyalkyl) and 3,3- dιfluoro-2-hydroxypent-4-enyl
Examples of Q, include -NH(CO)(CO)-(heterocyclιc radical or heteroaryl), -OSO2-(aryl or substituted aryl), -O(CO)NH-(aryl or substituted aryl), aminoalkyl, hydroxyalkyl, -NH(CO)(CO)-(aryl or substituted aryl), -NH(CO)(alkyl)(heteroaryl or heterocyclic radical), O(substιtuted or unsubstituted alkyl)(substιtuted or unsubstituted aryl), and -NH(CO)(alkyl)(aryl or substituted aryl).
Each of D and D' is independently selected from R, and OR,, wherein R, is H, C, , alkyl, or C, . haloalkyl. Examples of D and D' are methoxy, methyl, ethoxy, and ethyl. In some embodiments, one of D and D' is H. The value for n is 1 or preferably 0, thereby forming either a six-membered or five-membered πng. This πng can be unsubstituted or substituted, e.g , where E is R5 or OR5, and can be a heterocyclic radical or a cycloalkyl, e.g. where G is S, CH2, NR6, or preferably O. Each of J and J' is independently H, C, 6 alkoxy, or C, 6 alkyl; or J and J' taken together are =CH, or -O-(straιght or branched Ct 5 alkylene or alkylιdene)-O-, such as exocyc c methy dene, isopropylidene, methylene, or ethylene. Q is C, . alkyl, and is preferably methyl T is ethylene or ethenylene, optionally substituted with (CO)OR7, where R7 is H or C, 6 alkyl. Each of U and U' is independently H, C, 6 alkoxy, or C, 6 alkyl; or U and U' taken together are =CH2 or -O-(straιght or branched C, 5 alkylene or alkyhdene)-O-. X is H or C, 6 alkoxy. Each of Y and Y' is independently H or C, 6 alkoxy; or Y and Y' taken together are =O, =CH2, or -O-(straιght or branched C, 5 alkylene or alkyhdene)-O-. Each of Z and Z' is independently H or C, 6 alkoxy; or Z and Z' taken together are =O, =CH2, or -O-(straιght or branched C, 5 alkylene or alkylιdene)-O-.
The invention features compounds of sufficient stability to be suitable for pharmaceutical development. The invention also features pharmaceutically acceptable salts of disclosed compounds, disclosed novel synthetic intermediates, pharmaceutical compositions containing one or more disclosed compounds, methods of making the disclosed compounds or intermediates, and methods of using the disclosed compounds or compositions. Methods of use include methods for reversibly or irreversibly inhibiting mitosis in a cell, and for inhibiting cancer or tumor growth in vitro, in vivo, or in a patient. The invention also features methods for identifying an anti-mitotic or anti-cancer agent, such as a reversible or, preferably, an irreversible agent.
Bπef Descπption of the Figures
FIG. 1 is a graph showing the percentage of cells which have completed mitosis and returned to the G, phase as a function of concentration of compound B 1939 in a mitotic block assay The minimum concentration required for complete mitotic block at 0 hour is 10 nM. The minimum concentration required for complete mitotic block at 10 hour (after washout) is also 10 nM. The reversibility ratio is therefore 1 for B 1939. Supeπmposed upon this graph is a curve showing the percentage of viable cells at 5 days as a function of concentration of compound B 1939. Viability drops to very low levels at the same concentration as the 10 hour mitotic block.
FIG. 2 is a graph showing the percentage of cells which have completed mitosis and returned to G, phase as a function of the concentration of compound B2042 in a mitotic block reversibility assay. The minimum concentration required for complete mitotic block at 0 hour is 3 nM. The minimum concentration required for complete mitotic block at 10 hour is 100 nM. The reversibility ratio for B2042 is therefore 33 Supeπmposed on this graph is a curve showing the percentage of viable cells at 5 days as a function of concentration of compound B2042 Viability drops to very low levels at the same concentration as the 10 hour mitotic block FIG 3 is a graph showing the average tumor volume in microhters as a function of time (days) in a LOX melanoma xenograft growth inhibition assay This illustrates the antitumor activity of a compound of formula (I), compound B 1939 Paclitaxel and a vehicle control were used.
FIG 4 is a graph showing the average body weight per mouse as a function of time (days) in the assay descπbed in FIG 3
FIG 5 is a graph showing the average tumor volume in microhters as a function of time (days) in a COLO 205 human colon cancer xenograft growth inhibition assay, showing the antitumor activities of vinblastine and vincπstine.
Detailed Descπption of the Invention
A. Definitions B Halichondrin Analogs
C Synthesis of Halichondrin Analogs
D. Pharmacological Activity
E. Uses
A. Definitions
The following terms are defined m part below and by their usage herein Hydrocarbon skeletons contain carbon and hydrogen atoms and may be linear, branched, or cyclic. Unsaturated hydrocarbons include one, two, three or more C-C double bonds (sp2) or C-C tπple bonds (sp). Examples of unsaturated hydrocarbon radicals include ethynyl, 2-propynyl, 1-propenyl, 2-butenyl, 1,3-butadιenyl, 2- pentenyl, vinyl (ethenyl), allyl, and isopropenyl. Examples of bivalent unsaturated hydrocarbon radicals include alkenylenes and alky denes such as methy dyne, ethy dene, ethy dyne, viny dene, and isopropylidene. In general, compounds of the invention have hydrocarbon skeletons ("A" m formula (I)) that are substituted, e.g., with hydroxy, ammo, cyano, azido, heteroaryl, aryl, and other moieties descπbed herein. Hydrocarbon skeletons may have two germnal hydrogen atoms replaced with oxo, a bivalent carbonyl oxygen atom (=O), or a nng-forming substituent, such as -O- (straight or branched alkylene or alkylιdene)-O- to form an acetal or ketal C, 6 alkyl includes linear, branched, and cyclic hydrocarbons, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, sec- pentyl, neo-pentyl, tert-pentyl, cyclopentyl, hexyl, isohexyl, sec-hexyl, cyclohexyl, 2- methylpentyl, tert-hexyl, 2,3-dιmethylbutyl, 3,3-dιmethylbutyl, 1,3-dιmethylbutyl, and 2,3-dιmethyl but-2-yl. Alkoxy (-OR), alkylthio (-SR), and other alkyl-denved moieties (substituted, unsaturated. or bivalent) are analogous to alkyl groups (R). Alkyl groups, and alkyl-denved groups such as the representative alkoxy, haloalkyl, hydroxyalkyl, alkenyl, alkyhdene, and alkylene groups, can be C2 6, C, 6, C, ., or C2 4. Alkyls substituted with halo, hydroxy, amino, cyano, azido, and so on can have 1, 2, 3, 4, 5 or more substituents, which are independently selected (may or may not be the same) and may or may not be on the same carbon atom For example, haloalkyls are alkyl groups with at least one substituent selected from fluoro, chloro, bromo, and lodo. Haloalkyls may have two or more halo substituents which may or may not be the same halogen and may or may not be on the same carbon atom Examples include chioromethyl, peπodomethyl, 3,3-dichloropropyl, 1,3-difluorobutyl, and l-bromo-2- chloropropyl
Heterocyclic radicals and heteroaryls include furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathienyl, 2H-pyrrolyl, pyrrolyl, lmidazolyl (e.g., 1-, 2- or 4- lmidazolyl), pyrazolyl, isothiazolyl, isoxazolyl, pyπdyl (e.g., 1-, 2-, or 3- pyπdyl), pyrazinyl, pyπmidinyl, pyπdazinyl, indolizmyl, isoindolyl, 3H-mdolyl, mdolyl (e.g., 1-, 2-, or 3-ιndolyl), indazolyl, puπnyl, 4H-qumohxιnyl, isoquinolyl, quinolyl, phthalazinyl, naphthyπdinyl, quinoxalinyl, quinazolyinyl, cinno nyl, pteπdmyl, pyrro nyl, pyrrolid yl, lmidazolidinyl, pyrazolidmyl, pyrazo nyl, pipeπdyl, piperazinyl, indolinyl, isoindolinyl, and morpho nyl. Heterocyclic radicals and heteroaryls may be linked to the rest of the molecule at any position along the πng. Heterocyclic radicals and heteroaryls can be C2 9, or smaller, such as C3 6, C2 5, or C3 7
Aryl groups include phenyl, benzyl, naphthyl, tolyl, mesityl, xylyl, and cumenyl.
It is understood that "heterocyclic radical", "aryl", and "heteroaryl" include those having 1, 2, 3, 4, or more substituents independently selected from lower alkyl, lower alkoxy, amino, halo, cyano, nitro, azido, and hydroxyl. Heterocyclic radicals, heteroaryls, and aryls may also be bivalent substituents of hydrocarbon skeleton "A" in formula (I).
B. Hahchondπn Analogs
Referπng to formula (I) in the Summary section, embodiments of the invention include compounds wherein n is 0; wherein each of D and D' is independently selected from R C, ~ alkoxy, and C, . haloalkyloxy; wherein R5 is selected from H, C2 6 alkyl, C, 6 haloalkyl, C, 6 hydroxyalkyl, C, 6 aminoalkyl, C6 10 aryl, C6 10 haloaryl, C6 10 hydroxyaryl, C, , alkoxy-C6 aryl, C6 ]0 aryl-C, 6 alkyl, C, 6 alkyl-C6 10 aryl, C^ haloaryl-C, 6 alkyl, C, 6 alkyl-C6 10 haloaryl, (C, . alkoxy-C6 aryl)-C, , alkyl, C2 9 heterocyclic radical, C2 „ heterocyclic radical-C, 6 alkyl, C2 9 heteroaryl, and C2 9 heteroaryl-C, 6 alkyl; and combinations thereof Other embodiment includes compounds having one or more of the following characteπstics (a) wherein A is a C, 6 saturated or C2 6 unsaturated hydrocarbon skeleton, the skeleton having at least one substituent selected from cyano, halo, azido, Q,, and oxo; (b) each Q, is independently selected from OR,, SR,, SO2R,, OSO2R,, NR2R„ NR2(CO)R,, NR2(CO)R„ and O(CO)NR2R,; (c) Z and Z' taken together are =O or =CH2; (d) wherein each Q, is independently selected from OR,, SR,, SO2R,, OSO2Rp NH(CO)R„ NH(CO)(CO)R,, and O(CO)NHR,; (e) each R, is independently selected from C, 6 alkyl, C, 6 haloalkyl, C6 aryl, C6 haloaryl, C, 3 alkoxy-C6 aryl, C6 aryl-C, . alkyl, C, 3 alkyl-C6 aryl, C6haloaryl-C, . alkyl, C, 3alkyl-C6 haloaryl, (C, 3 alkoxy-C6 aryl)-C, . alkyl, C2 9 heterocyclic radical, C2 9 heteroaryl, and C2 9 heteroaryl- C, 6 alkyl; (f) one of D and D' is methyl or methoxy and the other is H; (g) n is 0; (h) G is O; (l) J and J' taken together are =CH2; (j) Q is methyl; (k) T is ethylene; (1) U and U' taken together are =CH2 ; (m) X is H; (n) each of Y and Y' is H; and (o) Z and Z' taken together are =O. Examples of combinations are the combination of (h)-(m), the combination of (a) and (b), the combination of (f) and (h), and the combination of (h) and where one of D and D' is methyl and the other is H. Two particularly preferred compounds are B1793 and B 1939.
Another embodiment includes compounds wherein Q, is independently selected from OR,, SR,, SO2R,, and OSO2R,; and each R, is independently selected from C, 6 alkyl, C, 6 haloalkyl, C6 aryl, C6 haloaryl, C, . alkoxy-C6 aryl, C6 aryl-C, 3 alkyl, C, 3 alkyl-C6 aryl, C6 haloaryl-C, , alkyl, C, 3 alkyl-C6 haloaryl, and (C, . alkoxy-C6 aryl)-C, 3 alkyl. Other embodiments include compounds wherein: one of D and D' is alkyl or alkoxy, where n is 1; (f) as above, where n is 1; E is alkoxy, where n is 1; n is 0, where one of D and D' is hydroxy and the other is H; and (f) as above, where n is 1 and E is methyl
The invention also features compounds wherein: (1) A has at least one substituent selected from hydroxyl, amino, azido, halo, and oxo; (2) A is a saturated hydrocarbon skeleton having at least one substituent selected from hydroxyl, am o, and azido (e.g., B1793, B1939, B2042, B 1794, and B 1922); (3) A has at least two substituents independently selected from hydroxyl, amino, and azido (e.g., B2090 and B2136); (4) A has at least two substituents independently selected from hydroxyl and amino (e.g., B2042 and B2090); (5) A has at least one hydroxyl substituent and at least one amino substituent (e.g., B1939 and B2136); (6) A has at least two hydroxyl substituents (e.g., B1793 and B 1794); (7) A is a C2 4 hydrocarbon skeleton that is substituted (e.g., B2004, B2037, B1920, B2039, B2070, B2090, and B2043), (8) A is a C, hydrocarbon skeleton that is substituted (e.g., B1793, B1920, B1984, B1988, B 1939, B 1940, B2014); (9) A has an (S)-hydroxyl alpha to the carbon atom linking A to the πng containing G (e.g., B1793, B1939 or B1920) or an (R)-hydroxyl (e.g B2102, B2013, B2042); and (10) A is a C, 6 saturated hydrocarbon skeleton having at least one substituent selected from hydroxyl and cyano (e.g., B2013, B2037, B2102, B2086, and B2091). By (S)-hydroxyl is meant the configuration of the carbon atom having the hydroxyl group is (S). Embodiments of the invention also include compounds which have at least two substituents on the carbon atoms (1) alpha and gamma, (2) beta and gamma, or preferably (3) alpha and beta to the carbon atom linking A to the ring containing G. The alpha, beta, and gamma carbon atoms can have an (R) or (S) configuration
The invention further provides preferred compounds having the formula (1) -A, shown below, wherein the substituents are identical to those defined above.
Figure imgf000009_0001
The invention further features the following monosaccharide intermediate having formula (II):
Figure imgf000009_0002
Formula (II)
wherein R is methyl or methoxy, and each of PI, P2, and P3 is independently selected from H and primary alcohol protecting groups. Preferably, the diol sidechain is below the plane of the page and OP2 is above the plane of the page. Primary alcohol protecting groups include esters, ethers, silyl ethers, alkyl ethers, and alkoxyalkyl ethers. Examples of esters include formates, acetates, carbonates", and sulfonates. Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3- phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate, crotonate, 4-methoxy- crotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2- (trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl.
Examples of silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta- (trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of benzyl ethers include p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl. Preferably, each of PI and P2 are TBS and P3 is MPM (see alcohol 19 below). In one aspect, formula (II) can be modified so the hydroxyethyl sidechain can also be a protected hydroxyl, - CH2CH2O-P4, wherein P4 is independently selected from values for PI. A related intermediate is alcohol 17, where the hydroxyethyl sidechain is a hydroxymethyl sidechain. A corresponding hydroxypropyl sidechain, or aminoalkyl side chain, can be similarly prepared.
PI and P2, taken together, can be a diol protecting group, such as cyclic acetals and ketals (methylene, ethylidene, benzylidenes, isopropylidene, cyclohexylidene, and cyclopentylidene), silylene derivatives such as di-t-butylsilylene and 1,1,3,3-tetra- isopropylidisiloxanylidene derivatives, cyclic carbonates, and cyclic boronates.
Methods of adding and removing such hydroxyl protecting groups, and additional protecting groups, are well-known in the art and available, for example, in P.J. Kocienski, Protecting Groups, Thieme, 1994, and in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis. 2nd edition, John Wiley & Sons, 1992. The following section provides representative syntheses of intermediates of formula (II) and halichondrin analogs of formula (I).
C. Synthesis of Halichondrin Analogs
An overview is provided below, followed by synthetic schemes 1-16, and several detailed protocols.
Compounds of general formula 4 can be prepared by the route outlined in Scheme 1. Key fragment F-2 exemplified by vinyl iodide compound X2 can be prepared according to the procedure of Kishi, et al (Total synthesis of halichondrin B and norhalichondrin B. Aicher, T. D.; Buszek, K. R.; Fang, F. G.; Forsyth, C. J.; Jung, S. H.; Kishi, Y.; Matelich, M. C; Scola, . M.; Spero, D. M.; Yoon, S. K. J. Am. Chem. Soc. 1992, 114, 3162-4).
Figure imgf000011_0001
Vinyl Iodide X2
Figure imgf000011_0002
XF3
Key fragment F-3 can be obtained by DIBALH reduction of the corresponding methyl ester, XF3, prepared according to the procedure of Stamos, et al (Scheme 2).
[Synthetic studies on halichondrins: a practical synthesis of the C.1-C.13 segment.
Stamos, D. P.; Kishi, Y. Tetrahedron Lett. 1996, 37, 8643-8646]. Synthesis of key fragment F-1 exemplified by compound 20 can be synthesized as described in Scheme
3 or Scheme 4.
Using B1793 as a representative example, coupling of the three key fragments proceeded as outlined in Scheme 5: Nozaki-Hiyama-Kishi coupling of fragments 20 and X2 followed by intramolecular Williamson ether formation furnished tetrahydropyran B2318. Protecting group modification as described in Scheme 5 or alternatively in Scheme 6 afforded primary iodide B2313. Halogen-metal exchange reaction and coupling with key fragment F-3 furnished a mixture of diastereomeric alcohols B2308. Additional protecting group manipulation and oxidation followed by an intramolecular Nozaki-Hiyama-Kishi reaction afforded an intermediate, which when oxidized and treated with TBAF underwent intramolecular hetero-Michael ring closure. PPTs mediated acetal formation furnished B1793.
Aryl groups can be incorporated into the C32 sidechain (e.g. B2043) as exemplified in Scheme 7. Intermediate B2318 was deprotected and the resulting diol oxidatively cleaved to the corresponding aldehyde Treatment with a Gπgnard reagent (e g p-F-PhMgBr), separation of the resulting diastereomers and silylation furnished 204, which was converted to final product in a manner similar to that descπbed in Scheme 6
Ether analogs can be prepared from B1793 by treatment with an appropπate alkylating agent (e g Scheme 8) Similarly, sulfonates, esters, carbamates, etc. can be prepared from B1793 by treatment with an activated carbonyl component Oxidative diol cleavage and reduction or selective hydroxyl group oxidation could furnish deπvatives such as B2037 and B1934, respectively
Alternatively, one or more hydroxyl groups could be converted to the corresponding amino groups with subsequent coupling with an activated carbonyl component (Scheme 9) Displacement of the sulfonyl intermediate (e.g. B1920) by carbon or heteroatom nucleophiles could also be readily accomplished (Scheme 10)
C31 methyl analogs can be prepared as outlined in Scheme 11 Indium mediated coupling of an allyl bromide ester with 2,3-O-(3-ιsopropyhdιne)-D- glyceraldehyde furnished lactone 103. Hetero Michael addition, lactone reduction, Wittig coupling and intramolecular Michael addition furnished tetrahydrofuran 107 Pummerer rearrangement, protecting group adjustment and DIBALH reduction furnished key fragment 1 (e g., 114), which was converted to final compound in a manner analogous to that descπbed in Scheme 6
Fluoπne atoms could be introduced as descπbed m Schemes 12 - 14
Beginning with the appropπate tetrahydrofuran intermediate, fluonnated key fragment 1 was obtained and earned to final compound in a manner analogous to that illustrated in Scheme 6
Tπol denvatives could be similarly prepared from the tetrahydrofuran intermediate For example, as outlined in Scheme 15 allyltnbutylstannane addition to aldehyde X32 furnished homoallylic alcohol 33 that was earned to final compound in a similar manner to that descnbed in Scheme 6 These tπols could be further modified as exemplified in Scheme 6
The 1,3 diol deπvatives could be prepared from intermediates previously descπbed For example, B2086 could be oxidatively cleaved and reduced to afford 1,3-dιol B2091 (Scheme 16) Scheme 1
Figure imgf000013_0001
Figure imgf000013_0002
Scheme 2
Figure imgf000014_0001
Scheme 3
Figure imgf000015_0001
1)PvCI
2) BnBr
Figure imgf000015_0002
Figure imgf000015_0003
Scheme 4
Figure imgf000016_0001
1)PvCI
2) MPMOTCI
Figure imgf000016_0002
1)LAH
Figure imgf000016_0003
1 ) Swern
Figure imgf000016_0004
Scheme 5
Figure imgf000017_0001
X2 B2318
Figure imgf000017_0002
B2313
Figure imgf000017_0003
B2307, B2308 Scheme 6
Figure imgf000018_0001
X2 BX2318
Figure imgf000018_0002
BX2313
Figure imgf000018_0003
BX2308 Scheme 7
ers
Figure imgf000019_0001
Figure imgf000019_0002
B2318 204
17 Scheme 8
Figure imgf000020_0001
Scheme 9
Figure imgf000021_0001
Scheme 10
Figure imgf000022_0001
Scheme 11
DHSPh
2) DIBALH
Figure imgf000023_0001
Figure imgf000023_0002
102 103
Figure imgf000023_0003
Figure imgf000023_0004
TBSO
Figure imgf000023_0005
114
110
Scheme 12
Figure imgf000024_0001
Figure imgf000024_0002
22 Scheme 13
Figure imgf000025_0001
1 ) 9-BBN 1) MPMOTCI
2) Swern 2) LAH
3) Et3N 3) separate isomers
4) NaBH4
Figure imgf000025_0002
4) Dess-Martin
Figure imgf000025_0003
X412 Scheme 14
Figure imgf000026_0001
PM HO
Figure imgf000026_0002
24 Scheme 15
Figure imgf000027_0001
) MPMOTCI ) LAH ) Swern ) Wittig ) 9-BBN
Figure imgf000027_0002
1) TBSOTf
Figure imgf000027_0003
2) AD
3) separate isomers
33
Figure imgf000027_0004
35 a, major, upper C36-isomer 38 35b, minor, lower C36-isomer
25 Scheme 16
Figure imgf000028_0001
EXPERIMENTAL SECTION
Synthesis of Key Fragment F-3:
DIBALH
Figure imgf000029_0001
Figure imgf000029_0002
XF-3 F-3
Key Fragment F-3. DIBALH (1 M in toluene, 3.86 mL) was added to a solution of XF-3 (1,46 g, 1.93 mmol) in toluene (37 mL) at -78 °C. After stirring for 10 min, the reaction was quenched by careful addition of MeOH (0.46 mL) and H2O (0.21 mL), warmed to rt and stirred for 15 min. The white suspension was filtered through Celite with 1 : 1 CtLClJEtjO. The filtrate was concentrated and purified by column chromatography (10% EtOAc-hexanes) to give key fragment F-3 (1.34 g, 96%) as an oil.
Synthesis of B1793:
TBDPSCI
Figure imgf000029_0004
Figure imgf000029_0003
L-arabinose
Triol 1 A solution of TBDPSCI (444 mL, 1.7 mol) in DMF (0.5 L) was added in three portions to a suspension of L-arabinose (250.0 g, 1.66 mol), imidazole (231.4 g, 3.40 mol) and DMF (2.5 L). The addition of each portion took 1.5 h with a 30 min and a 15 h interval separating the second and third portions, respectively. The resulting solution was stirred for 3 h, concentrated and purified by flash chromatography (5% to 33% EtOAc-hexanes) to provide triol 1 (394 g, 61%). Ac20, pyridine
Figure imgf000030_0001
Figure imgf000030_0002
Triacetate 2 Acetic anhydride (6.06 mol) was added over 1.5 h to triol 1 (1.01 mol) in pyridine (1.0 L) at 15 °C. The solution was stirred for 1 h, concentrated and purified by flash chromatography (15% to 25% EtOAc-hexanes) to afford triacetate 2 (518 g, 97%).
Figure imgf000030_0003
Diacetates 3 Allyltrimethylsilane (1.11 mol) followed by BF3»OEt, (1.11 mmol) was added over 1.5 h to triacetate 2 (164 g, 0.32 mol) in toluene (1.5 L) at 0 °C. The orange solution was stirred for 1 h at 0 °C and for 2 h at rt. The mixture was slowly poured into saturated aqueous NaHCO3 (1.7 L) at 0 °C and stirred for 30 min. The separated aqueous layer was extracted with EtOAc (3 x 600 mL) and the combined organic layers were dried over Na2SO4, concentrated and purified by flash chromatography (5% to 10% EtOAc-hexanes) to furnish a mixture of diacetates 3 (108 g, 69%).
Figure imgf000030_0004
4a 4b
Diol 4a Solid K2CO3 (72 mmol) was added to diacetates 3 (108 g, 218 mmol) in MeOH (0.5 L) at rt. The suspension was stirred for 2.5 h and then concentrated. The orange residue was suspended in saturated aqueous NH4C1 (150 mL), extracted with EtOAc (3 x 150 mL) and the combined organic layers were dried over Na2SO4, concentrated and purified by flash chromatography (15% to 50% EtOAc-hexanes) to afford alpha-isomer 4a (33.86 g, 37%), and beta-isomer 4b (58 g, 63%). TBSCI
Figure imgf000031_0002
Figure imgf000031_0001
Alcohol 5 Imidazole (16.75 g, 246 mmol) and TBSCI (16.08 g, 107 mmol) were added to a solution of diol 4a (33.86 g, 82 mmol) in CH2C12 (250 mL) at 0 °C. After 18 h at 0 °C and 5 h at rt, the reaction mixture was diluted with saturated aqueous NaHCOj (250 mL), stirred for 30 min and the layers were allowed to separate. The aqueous layer was extracted with EtOAc (3 x 250 mL) and the combined organic layers were dried over Na^SO^ concentrated and purified by flash chromatography (2% to 50% EtOAc-hexanes) to furnish alcohol 5 (36.0 g, 83%).
Figure imgf000031_0003
Methyl ether 6 Iodomethane (16.5 mL, 265 mmol) and NaH (60% in mineral oil, 5.28 g, 132 mmol) were added to a solution of alcohol 5 (34.93 g, 66 mmol), THF (320 mL) and DMF (80 mL) at 0 °C. After 19 h at 0 °C, the reaction was quenched with saturated aqueous NH4C1 and saturated aqueous Na2S2O3. The resulting mixture was stirred for 20 min and the layers were allowed to separate. The aqueous phase was extracted with EtOAc (3 x 200 mL) and the combined organic layers were dried over NajSO^ concentrated and purified by flash chromatography (3% EtOAc- hexanes) to afford methyl ether 6 (34.23 g, 96%).
Figure imgf000031_0004
Diol 7 HCI (37% aqueous solution, 12.75 mL, 153 mmol) was added to a solution of methyl ether 6 (32.93 g, 61 mmol) in MeOH (110 mL) at rt. After 17 h,
NaHCO3 (17 g) was added to the reaction mixture. The mixture was stirred for 30 min, concentrated, suspended in EtOAc and filtered. The filtrate was concentrated and purified by flash chromatography (50% EtOAc-hexanes to EtOAc) to give diol 7 ( 10.0 g, 87%).
Figure imgf000032_0001
8
Alcohol 8 A solution of pivaloyl chloride (8.4 mL, 67 mmol) in pyridine (50 mL) was added over 1.5 h to a solution of diol 7 (12.24 g, 65 mmol) in pyridine (100 mL) at 0 °C. After 1 h at 0 °C and 18 h at rt, the mixture was diluted with saturated aqueous NH4C1 and extracted with EtOAc (3 x 800 mL). The combined organic layers were dried over Na2SO4, concentrated and purified by flash chromatography (50% EtOAc-hexanes) to furnish alcohol 8 (16.9 g, 96%).
Figure imgf000032_0002
8
Olefin 9 Benzyl bromide (62 mL, 521 mmol) and Bu4NHSO4 (10.6 g, 31 mmol) were added to a solution of alcohol 8 (16.9 g, 62 mmol) in CH2C12 (100 mL) at 0 °C. A solution of NaOH (9.95 g, 248 mmol) in H,O (10 mL) was added to the reaction mixture over 15 min. After 30 min at 0 °C and 18 h at rt, the reaction mixture was diluted with saturated aqueous NH4C1 and extracted with CH2C12 (3 x 100 mL). The combined organic layers were dried over Na^SO^ concentrated and purified by flash chromatography (hexanes to 30% EtOAc-hexanes) to afford olefin 9 (22.1 g, 98%).
Figure imgf000032_0003
Diol 10 OsO4 (0.1 M solution in toluene, 7.3 mL, 0.73 mmol) and a solution of olefin 9 (24.9 g, 69 mmol) in t-BuOH (165 mL) were added to a solution of K2CO, (31.2 g, 161 mmol), K,Fe(CN)6 (74.4 g, 161 mmol), (DHQ)2PYR ( 1.33 g, 1.50 mmol), H > (500 mL) and t-BuOH (330 mL) at 0 °C. After 3 h at 0 °C. Na2S2O5 • 5 H,O (37.3 g, 150 mmol) was added. The reaction mixture was warmed to rt, stirred for 1 h and extracted with EtOAc (3 x 300 mL). The combined organic layers were dried over Na2SO4, concentrated and purified by flash chromatography (5% isopropanol- CH2C12) to provide diol 10 (17.98 g, 75%).
Figure imgf000033_0001
1 0 1 1
Silyl ether 11 Imidazole (21 g, 308 mmol) and TBSCI (26.5 g, 176 mmol) were added to a solution of diol 10 (17.4 g, 44 mmol) in DMF (90 mL) at rt. After 18 h, the reaction mixture was diluted with saturated aqueous NaHCO, (250 mL), stirred for 1 h and extracted with CH,C (3 x 100 mL). The combined organic layers were dried over Na^SO^ concentrated and purified by flash chromatography (5% EtOAc- hexanes) to afford silyl ether 11 (25.7 g, 94%).
Figure imgf000033_0002
Alcohol 12 A mixture of silyl ether 11 (21.2 g, 33.8 mmol), Pd(OH)2 (20%, 4.7 g, 33.8 mmol) and EtOAc (200 mL) was stirred at rt under 1 atm H2 for 3 h. The mixture was filtered through Celite, concentrated and purified by flash chromatography (10% to 20% EtOAc-hexanes) to afford alcohol 12 (17.4 g, 96%).
Figure imgf000033_0003
1 2 1 3
Olefin 13 4-Methylmorpholine N-oxide (7.66 g, 65 mmol) and TPAP (1.15 g, 3.26 mmol) was added in four portions over 20 min to a solution of alcohol 12 (17.4 g, 32.5 mmol) in CH2C12 (145 mL) at 0 °C After 20 min, the reaction mixture was diluted with Et,O (50 mL) and saturated aqueous Na2S2O5 (50 mL) and filtered through Celite. The organic layer was separated, washed sequentially with saturated aqueous CuSO4-bπne (1:1) and bπne, dπed over Na,SO4, filtered through Celite, and concentrated to afford the desired crude ketone.
Tebbe reagent was prepared by stirring bιs(cyclopentadιenyl)tιtanιum (11.36 g, 45.6 mmol) and Me3Al (2.0 M in toluene, 45.6 mL, 91.2 mmol) for 4 days at rt. This mateπal was cooled to -25 °C and a solution of crude ketone in THF (150 mL) was added. The reaction mixture was warmed to 0 °C, stirred for 30 min, quenched by slow addition of 0.1 N NaOH (3.5 mL), and then stirred for an additional 20 min at rt. The mixture was diluted with Et,O, filtered through Celite and concentrated. The residue was dissolved in CH2C12, filtered through basic Al2O„ concentrated and puπfied by flash chromatography (5% EtOAc-hexanes) to give olefin 13 (12.8 g, 74% for two steps).
Figure imgf000034_0001
13 14
Alcohol 14 9-BBN (0.5 M in THF, 165 mL, 83 mmol) was added to a solution of olefin 13 (12.78 g, 24 mmol) in THF (280 mL) at 0 °C. After stirring for 5 h at rt, the reaction mixture was recooled to 0 °C at which time H2O (200 mL), THF (100 mL) and NaBO3»4 H2O (75 g) were added. The mixture was warmed to rt, stirred for 16 h and then concentrated. The aqueous residue was extracted with EtOAc (4 x 300 mL) and the combined organic layers were dπed over Na^SO,,. Concentration and purification by flash chromatography (20% to 35% EtOAc-hexanes) afforded alcohol 14 (12.05 g, 91%).
Figure imgf000034_0002
1 4 15
Alcohol 15 DMSO (9 mL, 127 mmol) was added to a solution of oxalyl chloπde (5.6 mL, 64 mmol) m CH2C12 (350 mL) at -78 °C After stirπng for 15 mm, a solution of alcohol 14 (11.7 g, 0.021 mmol) in CH2C12 (50 mL) was added and stirπng was continued for 1 h, after which Et3N (26.7 mL, 192 mmol) was added The reaction mixture was warmed to 0 °C, stirred for 15 min, diluted with saturated aqueous NH4C1, and extracted with CH,CL (3 x 200 mL). The combined organic layers were dπed over Na2SO4 and concentrated to furnish the desired crude aldehyde
This mateπal was dissolved in CH2C12 (200 mL) and treated with Et3N (20 mL) at rt. After stirπng overnight, the reaction mixture was diluted with saturated aqueous NH4C1 and extracted with CH2C12 (3 x 200 mL). The combined organic layers were dπed over NajSO^ concentrated and filtered through a short SιO2 column (20% EtOAc- hexanes) to afford the crude epimeπzed product.
The aldehyde was dissolved in Et2O-EtOH (1:1, 100 mL), cooled to 0 °C and treated with sodium borohydπde (1.21 g, 32 mmol). The mixture was stiπed for 20 mm, carefully diluted with saturated aqueous NELC1, stirred for 30 min at rt and extracted with CH2C12 (3 x 150 mL). The combined extracts were dπed over N^SO^ concentrated and puπfied by flash chromatography (20% EtOAc-hexanes) to afford alcohol 15 (9.95 g, 85% for three steps).
MPMOTCI
Figure imgf000035_0002
Figure imgf000035_0001
15 1 6
MPM-ether 16 BF3OEt2 (0.1 M in CH2C12, 1.8 mL, 0.18 mmol) was added to a solution of alcohol 15 (9.87 g, 18 mmol), MPM-tπchloroimidate (4.9 mL, 27 mmol) and CH2C12 (175 mL) at 0 °C. After 40 min, a second portion of BF3 »OEL, (0.1 M in CH2C12, 0.9 mL, 0.09 mmol) was added to the reaction mixture. After 20 min, the reaction was quenched with saturated aqueous NH4C1, stirred for 1 h at rt and diluted with E^O (600 mL). The organic layer was separated and the aqueous layer was extracted with Et^O (150 mL). The combined organic extracts were washed sequentially with 0.1 N aqueous NaOH, saturated aqueous NaHCO3, bπne, dried over Na2SO4, concentrated and purified by flash chromatography (20% EtOAc-hexanes) to give MPM-ether 16 (10.20 g, 85%).
Figure imgf000035_0003
1 6 1 7
Alcohol 17 LAH ( 1 M in THF, 22.5 mL, 22.5 mmol) was added to a solution of MPM-ether 16 ( 10.05 g, 15 mmol) in Et2O (1.0 L) at 0 °C. After 30 min, the reaction was cautiously quenched with H2O (1.3 mL), and 1 N aqueous NaOH (1.3 mL). After stirring for 1 h at rt, the suspension was filtered through Celite, concentrated and purified by flash chromatography (20% EtOAc-hexanes) to afford alcohol 17 (8.18 g, 93%).
1 ) Swern
Figure imgf000036_0002
2) Wittig
Figure imgf000036_0001
1 7 18
Olefin 18 DMSO (5.8 mL, 82.4 mmol) was added to a solution of oxalyl chloride (3.6 mL, 41.2 mmol) in CH2C12 (100 mL) at -78 °C. After 15 min, a solution of alcohol 17 (7.94 g, 13.5 mmol) in CH2C12 (35 mL) was added to the reaction mixture. After stirring for 1 h, Et3N (17 mL, 122 mmol) was added, the mixture was warmed to 0 °C, stiπed for 20 min, diluted with saturated aqueous NH4C1 and then extracted with CH,C12 (3 x 100 mL). The combined organic extracts were dried over Na2SO4, concentrated and filtered through a short SiO2 column (20% EtOAc-hexanes) to furnish the desired crude aldehyde. n-BuLi (1.6 M, 20 mL, 30 mmol) was added dropwise to a solution of CH3PPh3Br (10.1 g, 30 mmol) in THF (350 mL) and DMSO (100 mL) at 0 °C. After 1 h, a solution of the crude aldehyde in THF (50 mL) was added. The reaction mixture was warmed to rt and stirred for 3 h. Saturated aqueous NH4C1 was added and the mixture was extracted with EtOAc (3 x 500 mL). The combined extracts were washed with brine, dried over Na2SO4, concentrated and purified by flash chromatography (7% EtOAc-hexanes) to afford olefin 18 (5.57 g, 71% yield for 2 steps).
Figure imgf000036_0003
18 1 9 Alcohol 19 9-BBN (0.5 M in THF, 65 mL. 33 mmol) was added to a solution of olefin 18 (5 56 g, 9.6 mmol) in THF (85 mL) at 0 °C The mixture was stirred for 5 h at rt and then recooled to 0 °C. H2O (200 mL). THF (100 mL), and NaBO,»4 H2O (30 g) were sequentially added. After stirπng overnight at rt, the organic volatiles were removed under reduced pressure. The aqueous residue was extracted with EtOAc (3 x 200 mL) and the combined organic layers were dπed over Na2SO4. Concentration and puπfication by flash chromatography (30% EtOAc-hexanes) afforded alcohol 19 (12.05 g, 92%-)
Swern
Figure imgf000037_0002
Figure imgf000037_0001
1 9 20
Aldehyde 20. DMSO (1.36 mL, 19.2 mmol) was added dropwise over 4 mm to a solution of oxalyl chloπde (1.26 mL, 14 4 mmol) in CH2C12 (120 mL) at -78 °C After stirπng for 10 min, a solution of alcohol 19 (5.76 g, 9.61 mmol) m CH2C12 (20 mL) was added via cannula. The transfer was completed by πnsing with additional CH2C12 (2 x 5 mL). After stirπng for 20 mm, the mixture was treated with Et3N (5 36 mL, 38.4 mmol) and stirred for 10 min at -78 °C, 30 nun at 0 °C and 10 min at rt. The reaction mixture was poured into saturated aqueous NaHCO3 (200 mL) and the separated aqueous layer was extracted with CH2C12 (3x) followed by EtOAc (100 mL). The combined organic phases were dπed over Na,SO4, concentrated and puπfied by column chromatography (10% to 20% EtOAc-hexanes) to furnish aldehyde compound 20 (5.28 g, 92%) as an oil.
Figure imgf000037_0003
20 B2318
B2318. 0.1% NιCl2/CrCl2 (w/w, 3.21 g) and 1% NιCl2/CrCl2 (w/w, 4.31 g) was added to a solution of aldehyde 20 (3 73 g, 6.25 mmol), key fragment F-2 exemplified by vinyl iodide X2. (5.10 g, 9 16 mmol), THF (85 mL) and DMF (21 mL) at rt in a glove box. The reaction mixture was stirred for 24 h, removed from the glove box, cooled to 0 °C, diluted with EtOAc (100 mL), quenched with saturated NH4C1 (200 mL) and stirred for 30 min. The separated aqueous phase was extracted with EtOAc (6x) and the combined organic layers were dried over Na,SO4 concentrated and purified by column chromatography (20% to 30%) to give B2318 (~3 g) contaminated with close running impurities and the uncyclized intermediate (4.61 g). The latter (4.61 g, 4.48 mmol,) was dissolved in THF (150 mL), cooled to 0 °C and treated with KHMDS (0.5 M in toluene, 14 mL, 7.0 mmol) over a 2 min period. After stirring at 0 °C for 15 min, the reaction was quenched with saturated aqueous NH4C1 (150 mL) and warmed to rt. The separated aqueous layer was extracted with EtOAc (3x) and the combined organic phases were dried over Na;,SO4, concentrated and combined with the partially purified product obtained above. Column chromatography (10% EtOAc-hexanes) afforded B2318 (3.17 g, 55%) as an inseparable -3: 1 mixture of C27 diastereomers.
Figure imgf000038_0001
B2318 B2317
B2317. DDQ (1.45 g, 6.42 mmol) was added portion-wise over 30 min to a stirred solution of B2318 (3.12 g, 3.35 mmol) in CH2C12 (50 mL) and pH 7 phosphate buffer (5 mL) at rt. The reaction was quenched with saturated aqueous NaHCO3 (50 mL), stirred for 5 min, diluted with additional saturated aqueous NaHCO3 (100 mL), H2O (200 mL) and extracted with Et,O (5x). The combined organic phases were dried over Na^SO^ concentrated and purified by column chromatography (15% to 30%
EtOAc-hexanes) to give recovered B2318 (1.40 g) and a mixture of the C27 isomeric products. The recovered B2318 was resubmitted to the reaction conditions described above to afford additional product. Recovered starting material was again cycled through the deprotection conditions. All of the desired material was combined and separated by MPLC to afford B2317 (1.65 g, 61%).
Figure imgf000039_0001
B2317 B2316
B2316 TsCI (0.63 g, 3.30 mmol) was added to a solution of B2317 (1.60 g, 1.97 mmol) in CH2C12 (8 mL) and pyπdine (2 mL) at rt. After stirπng for 29 h, the reaction was quenched with saturated aqueous NaHCO3 (30 mL) and H2O (10 mL). The separated aqueous layer was extracted with Et2O and the combined organic layers were dπed over Na2SO4, concentrated and puπfied by column chromatography (15% to 30% EtOAc-hexanes) to give B2316 (2.01 g, 92%) as an oil along with recovered B2317 (92 mg, 5.8%).
B2316 B2315
B2315. LAH (1 M in THF, 2.61 mL, 2.61 mmol) was added over 1 mm to a solution of B2316 (1.68 g, 1.74 mmol) in Et2O (80 mL) at 0 °C. After stirπng for 7 min, the reaction was quenched by careful addition of MeOH (0.42 mL, 10.4 mmol) and H2O (0.19 mL, 10 mmol), warmed to rt and stirred for 20 min. Filtration through Celite with 1 : 1 CH^Cl,-Et2O, concentration and puπfication by column chromatography (30% to 40% EtOAc-hexanes) gave B2315 (1.38 g, 90%) as an oil.
Figure imgf000040_0001
B2315 B2314
B2314. MMTrCI (0.70 g, 2.26 mmol) was added to a solution of B2315 (1.33 g, 1.51 mmol) in CH2C12 (25 mL) and iPr2NEt (0.79 mL, 4.53 mmol) at rt. The resulting mixture was stirred for 1 h and then poured into a mixture of saturated aqueous NaHCO3 (20 mL), H2O (10 mL) and E ,O (50 mL). The separated aqueous layer was extracted with E O (3x). The combined organic phases were dried over Na2SO4, concentrated and purified by column chromatography (CH2C12 followed by 15% to 30% EtOAc-hexanes) to give B2314 (1.65 g, 95%) as a solid foam.
Figure imgf000040_0002
B2314 B2313
B2313. A mixture of B2314 (1.60 g, 1.39 mmol) and Nal (3.10 g, 20.8 mmol) in acetone (50 mL) was heated under reflux for 13 h. After cooling to rt, the reaction mixture was diluted with EtOAc, and concentrated. H2O (5 mL), brine (20 mL) and Na2S2O3 (200 mg) were added and the resulting mixture was extracted with Et,O (4x). The combined extracts were dried over Na2SO4, concentrated and purified by column chromatography (10% EtOAc-hexanes) to give B2313 (1.50 g, 97%) as an oil.
Figure imgf000041_0001
B2313 B2307, B2308
B2308. Tert-BuLi (1.7 M in pentane, 1.00 mL, 1.7 mmol) was added over 1 min to a solution of B2313 (0.90 g, 0.81 mmol) in Et2O (14 mL) at -78 °C. After stirring for 9 min, the mixture was transferred via cannula over 4 min to a solution of key fragment F-3 (0.83 g, 1.14 mmol) in Et2O (4 mL) at -78 °C. The transfer was completed by rinsing with additional Et,O (2 mL). The resultant mixture was stirred at - 78 °C for 5 min and then at 0 °C for 10 min, quenched with saturated aqueous NaHCO, (30 mL) and warmed to rt. The separated aqueous layer was extracted with Et2O (3x) and the combined organic phases were dried over Na^SO,, and concentrated. The residue was combined with those of other two batches (corresponding to 0.11 g and 0.44 g of B2313) and purified by column chromatography (10% to 20% EtOAc- hexanes) to give a mixture of B2307 and B2308 (1.86 g, 83%) as a solid foam. Although the isomers could be separated by prep TLC (20% EtOAc-hexanes), they were carried forward as a mixture.
Figure imgf000042_0001
B2308 B2305, B2306
B2305 and B2306. The mixture of B2307/B2308 (1.80 g, 1.05 mmol) was dissolved in EtOH (20 mL), treated with PPTS (10.0 mg, 0.04 mmol), stirred at rt for 11 h and then quenched with NaHCO3 (20.0 mg, 0.24 mmol). After stirring for 15 min, the mixture was concentrated, azeotroped with toluene (15 mL), and purified by column chromatography (20% to 30% EtOAc-hexanes) to give a mixture of B2305 and B2306 (1.22 g, 81%) as a solid foam. Although the isomers could be separated by prep TLC (30% EtOAc-hexanes), they were carried forward as a mixture.
Figure imgf000043_0001
B2305, B2306 B2304
B2304. A mixture of B2305/B2306 (1.16 g, 0.68 mmol), and Dess-Martin periodinane (0.61 g, 1.44 mmol) in CH2C12 (35 mL) was stirred at rt for 1 h. Additional Dess-Martin periodinane (0.54 g, 1.27 mmol) was added to the mixture and stirring was continued for an additional 1 h. The mixture was diluted with Et ) (100 mL), stirred for 20 min and filtered through Celite with Et^O. The colorless filtrate was washed with saturated aqueous NaHCO3 (100 mL) and the separated aqueous layer was extracted with E^O (3X). The combined organic phases were dried over Na^O^ concentrated and purified by column chromatography (10% to 15% EtOAc-hexanes) to give B2304 (0.98 g, 84%) as a solid foam.
Alternatively, B2304 may be prepared as follows and in fact the synthesis described below is superior to that given above.
Figure imgf000043_0002
B2317 ER804025 To a solution of the alcohol, 2.4 g mg, in methylene chloride,""29 mfc, was added tfiflic anhydride, 770 mg. The mixture was stirred for 15 minutes, extracted with saturated sodium bicarbonate, dried and chromatrographed to give 2.737 g, 100%.
Figure imgf000044_0001
ER804025 ER804026
To a solution of the mesylate, 405 mg, in DMF, 0.06 mL, was added di- isopropylethylamine, 0.130 mL, followed by benzenethiol, 0.061 mL. After 4 hours and after 22 hours, additional amine, 0.03 mL, and benzenethiol, 0.015 mL, were added. After 24 hours, the mixture was diluted with 5% ethyl acetate/hexane, 1 mL and chromatographed to give 409 mg.
Figure imgf000044_0002
ER804026 ER804027
To a solution of the sulfide, 1.97 g, in acetonitrile, 16 mL, was added N- methylmorpholine oxide (NMO), and then a solution of 1.02 g, tetrapropylammonium perruthenate(VII), (TPAP), 38 mg, in acetonitrile, 1 mL. After 3.5 hours at room temperature, the mixture was heated to 40 °C for 1 hour. The mixture was cooled and aqueous satd. Sodium thiosulfate was added and the mixture partitioned between water and ethyl acetate. The usual work-up gave 1.567 g of a brown oil. DIBAL
Figure imgf000045_0001
Figure imgf000045_0002
ER804027 ER804028
To a solution of the pivaloate ester, 1.567 g, in methylene chloride, 11.2 mL, at - 78 ° C in was added DIBAL, 2.5 mL of a 1 M solution in toluene. After 15 minutes, additional DIBAL, 0.8 mL, was added. After an additional 5 minutes, methanol, 0.46 mL, was slowly added followed by water, 0.2 mL. The mixture was filtered through Celite and chromatographed to give 1.386 g of an oil.
Figure imgf000045_0003
ER804028 F-3
Figure imgf000045_0004
To a solution of the sulfone, 36 mg, in DME, 1 mL, at -40 ° C was added n- butyllithium, 2.8 equivalents. After 35 minutes, a solution of the aldehyde, 42 mg, in DME, 0.5 mL) was added. After 40 minutes, saturated aqueous ammonium chloride was added and the mixture extracted with ethyl acetate. The usual work-up, followed by chromatography gave 52 mg of an oil.
Figure imgf000046_0001
ER804029 ER804030
To a solution of the alcohol, 42 mg, in methylene chloride, 2 mL, was added the Dess Martin reagent, 36.4 mg. The mixture was stirred for 30 minutes and ether was added. The mixture was filtered through Celite, washed with saturated sodium bicarbonate, with saturated sodium thiosulfate, worked up in the usual way and chromatographed to give 38 mg of an oil.
Figure imgf000046_0002
ER804030 B2304
Preparation of Sml2 Solution
A solution of 1,2-di-iodoethane in 10 mL of THF was added to a suspension of Sm, 0.16 g, in THF, 1 mL. The mixture was stirred for 1 hour.
An aliquot of this solution, 0.03 mL, was added to a solution of the sulfone in THF at -78 ° C. After 5 minutes, additional Sml reagent, 0.05 mL, as added. After a few additional minutes, more reagent, 0.25 mL, was added. The cooling bath was removed and saturated aqueous sodium bicarbonate, 3 mL, was added. The mixture was partitioned between ether and water and the usual work-up gave 9.1 mg, 81%, of an oil.
Figure imgf000047_0001
B2304 B2302, B2303
B2302 and B2303. In a glove box, NiCl2/CrCl2 (1% w/w, 1.09 g, 8.86 mmol) was added to a solution of B2304 (1.01 g, 0.70 mmol) in THF (600 mL) and DMF (150 mL) at rt. After stirring for 2 days the reaction mixture was taken out of the glove box, cooled to 0 °C, quenched with saturated aqueous NH4C1 (300 mL) and stirred at 0 °C for 20 min. After addition of tLO (100 mL), the two layers were separated and the aqueous layer was extracted with EtOAc (5x). The combined organic phases were washed with brine, dried over Na2SO4, concentrated and purified by column chromatography (15% EtOAc-hexanes) to furnish a mixture of B2302 and B2303 (0.84 g, 92%) as a solid foam. Although the isomers could be separated by prep TLC (20% EtOAc-hexanes), they were carried forward as a mixture.
Figure imgf000048_0001
B2302, B2303 B2301
B2301. A mixture of B2302/B2303 (0.79 g, 0.60 mmol) and Dess-Martin periodinane (0.26 g, 0.60 mmol) in CH2C12 (30 mL) at rt was stirred for 30 min. Additional Dess-Martin periodinane (0.26 g, 0.60 mmol) was added to the mixture and stirring was continued for additional 1.5 h. The mixture was then diluted with E^O (100 mL), stirred for 15 min and filtered through Celite. The filtrate was washed with saturated aqueous NaHCO3 (100 mL) and the separated aqueous layer was extracted with E^O (3x). The combined organic phases were dried over N^SO^ concentrated and purified by column chromatography (10% to 15% EtOAc-hexanes) to give B2301 (0.67 g, 85%) as an oil.
Figure imgf000049_0001
B2301 B 1793
B1793. TBAF (1 M in THF containing 0.5 M imidazole HCI, 4.60 mL, 4.60 mmol) was added over 2 min to a solution of B2301 (0.62 g, 0.48 mmol,) in THF (29 mL) at rt and the resulting mixture was stirred for 18 h. After dilution with hexanes (10 mL), the reaction mixture was directly loaded onto a SiO2 column packed with 50% EtOAc-hexanes and eluted with 50% EtOAc-hexanes (1 L) followed by 10% MeOH/EtOAc to collect a mixture of intermediates. After solvent removal, the residue was dissolved in CH,C12 (15 mL) and treated with PPTS (645 mg). After stirring for 1 h at rt, additional PPTS (414 mg) was added and the resulting white suspension was stirred for 4.5 h. The reaction mixture was then directly loaded onto a SiO2 column packed with 70% EtOAc-hexanes and eluted with 70% EtOAc/hexanes (0.5 L), EtOAc (1 L). Elution with 5% to 10% MeOH/EtOAc furnished pure B1793 (181 mg) and elution with 15% MeOH-EtOAc gave additional semi-pure product, which after purification by preparative TLC (10% MeOH-EtOAc) provided additional pure B1793 (42 mg). B1793 (total 223 mg, 64%) was obtained as a white solid. HRMS: calcd for C40H58O12 + Na 753.3826. Found: 753.3808. Synthesis of B1794:
Figure imgf000050_0001
Arabinose B 1794
B1794. Except for stereochemical and protecting group differences (Schemes 3 and 5), arabinose was converted to B1794 m a manner similar to that descπbed for B1793 (see schemes 4 and 5). HRMS: calcd for C^H^Oj., + Na 753.3826. Found: 753.3856.
Synthesis of Representative B1793 Analogs:
Figure imgf000050_0002
B 1793 B1920: R = H B1921: R = Ts B1920 and B1921 TsCI (9.9 mg, 0.052 mmol) was added to a solution of diol B1793 (7.6 mg, 0.010 mmol) in CH2C12 (1 mL) and pyridine (0.1 mL) at rt. After 48 h, the reaction was quenched with a 1:4 mixture of saturated aqueous NaHCO3-brine and extracted with CH2CU (4x). The combined extracts were dried over Na2SO4 and concentrated. Purification by preparative TLC (80% EtOAc-hexanes) afforded monotosylate B1920 (6.0 mg, 67%), and ditosylate B1921 (1.8 mg, 18%).
Figure imgf000051_0001
B 1793 B2294
B2294 MsCI (0.3 M in CH2C12, 98 μL, 0.030 mmol) was added dropwise over 40 min to a mixture of collidine (7 μL, 0.054 mmol), B1793 (20.8 mg, 0.028 mmol) and CH,C12 (1 mL) at 0 °C. After 76 h at 4 °C, the reaction was quenched with a 1 :4 mixture of saturated aqueous NaHCO3-brine and extracted with CH2C12 (4x). The combined extracts were dried over Na2SO4 and concentrated. The crude product was dissolved in toluene (3 mL) concentrated and purified by preparative TLC (1.5% MeOH-EtOAc) to afford mesylate B2294 (21.4 mg, 95%).
Figure imgf000052_0001
B2014 B2015
B2014 and B2015 A 0.016 M solution of 4-fluorobenzyl bromide in Et2O (800 μL, 13 μmol) and Ag2O (10 mg, 43 μmol) were each added in three portions at 1 h intervals to a rt solution of B1793 (1.7 mg, 2.3 μmol) in Et2O (1.2 mL). The mixture was protected from light, stirred for 7 h and then filtered through Celite. Concentration and purification by preparative TLC (EtOAc) afforded primary ether B2014 (1.1 mg, 56%), and secondary ether B2015 (0.6 mg, 31%). HRMS (FAB): calcd for C47H63FO12 + Na 861.4201. Found: for B2014 861.4178, for B2015 861.4160.
Figure imgf000053_0001
General. A mixture of B1793 (1 mg, 1.37 micromol), Et3N (10 microL, 72 micromol) and ArNCO (2 to 4 equiv.) in CH2C12 (0.2 mL) was stirred at rt for 4 h to overnight until the reaction was judged to be complete by TLC. The reaction mixture was diluted with saturated NaHCO3 (3 mL), extracted with CH2C12 (3x) and EtOAc (2x), dried over Na2SO4 and purified by preparative TLC (5% MeOH-CH2Cl2) to afford the products:
B1984. (1.0 mg, 86%) HRMS (FAB): calcd for C47H63NO13 + Na 872.4197. Found: 872.4214.
B1990. (1.1 mg, 92%) HRMS (FAB): calcd for C47H62ClNO13 + Na 906.3807. Found: 906.3826.
B1992. (1.0 mg, 83%) HRMS (FAB): calcd for C48H65NO14 + Na 902.4303. Found: 902.4269.
Figure imgf000054_0001
B 1793 B2042
B2042 DEAD (0.4 M in ether, 50 μL, 19 μmol) was added to a solution of B1793 (2.0 mg, 2.7 μmol), triphenylphosphine (5 mg, 19 μmol), 4-nitrobenzoic acid (3.2 mg, 19 μmol) and Et,O (500 μL) at rt. After 22 h, the reaction mixture was loaded directly onto a preparative TLC plate and eluted with 60% EtOAc-hexanes to give the intermediate diester (3.0 mg). This material was taken up in MeOH (300 μL) and treated with K2CO3 (approximately 1 mg). After stirring at rt for 30 min, the reaction mixture was diluted with brine and extracted with CH2C12 (5x). The combined extracts were dried over Na^SO^ concentrated and purified by preparative TLC (5% MeOH-EtOAc) to afford B2042 (1.2 mg, 60% for two steps). HRMS (FAB): calcd for C^H^O,, + Na 753.3826. Found: 753.3810.
Figure imgf000055_0001
B 1793 B1896, B1897
B1896 and B1897. NaBH4 (3 mg, 0.08 mmol) was added to a solution of B1793 (2.30 mg, 3.15 μmol) in 1:1 CH2Cl2-MeOH (0.2 mL) at rt. Concentration of the reaction mixture and purification by preparative TLC (8% MeOH-EtOAc) provided B1896 (0.80 mg, 35%) and B1897 (2:1 mixture, 0.15 mg, 6.5%). HRMS (FAB) for B1896: calcd for C40H60OI2 + Na 755.3983. Found: 753.3969.
Figure imgf000055_0002
B1793 B 1918
B1918. A mixture of B1793 (2.0 mg, 2.74 μmol), NaIO4 (35 mg, 0.16 mmol), MeOH (0.8 mL) and H2O (0.2 mL) was stirred at rt for 40 min. The reaction mixture was diluted with H2O (1 mL), extracted with CFLCl, (6x). dried over Na,SO4, concentrated and purified by column chromatography (5% MeOH-CH.CU) to give B1918 (1.9 mg, 100%).
Figure imgf000056_0001
B 1918 B2037
B2037. A 0.034 M solution of NaBH4 (0.1 mL, 3.4 μmol) in EtOH was added portion-wise to a solution of B1918 (1.9 mg, 2.72 μmol) in MeOH (0.8 mL) and CH2C12 (0.2 mL) at -78 °C to rt until the reaction was judged to be complete by TLC. The reaction was quenched with saturated aqueous NH4C1 (2 mL) at -78 °C, warmed to rt, extracted with CH2C12 (6x), dried over Na2SO4 and purified by preparative TLC (5% MeOH- CH2C12) to afford B2037 (1.7 mg, 89%). HRMS (FAB): calcd for C39H56Oπ + Na 723.3720. Found: 723.3749.
Figure imgf000057_0001
B1793 B2035
B2035
NaIO4 (35 mg, 0.16 mmol) was added to a solution of B1793 (1.7 mg, 0.0023 mmol), MeOH (800 μL) and H2O (200 μL) and after 15 min, the mixture was diluted with H2O and extracted with CH2C12 (5x). The organic extracts were dried over Na,SO4, concentrated and the intermediate aldehyde was immediately dissolved in DMF (300 μL). 3-Bromo-3,3-difluoropropene (3μL, 0.023 mmol) and indium powder (3 mg, 0.23 mmol) were added and after 24 h additional 3-bromo-3,3-difluoropropene (1 μL, 0.008 mmol) was added. After 18 h, H2O was added the mixture was extracted with EtOAc (3x). The combined organic extracts were washed successively with H2O and brine, dried over Na^SO,,, concentrated and purified by preparative TLC (80% EtOAc-hexanes) to provide B2035 (0.74 mg, 41% for 2 steps) as a mixture of isomers. HRMS (FAB): calcd for C42H58F2Oπ + Na 799.3845. Found: 799.3883.
Figure imgf000058_0001
B 1793 B2011: X = H B2008: X = F
B2008, B2011
NaBH4 (2 mg, 0.05 mmol) was added to a solution of B1793 (2.2 mg, 0.003 mmol) in 1:1 CH2Cl2-MeOH (200 μL) at rt. After 15 min saturated aqueous NH4C1 and H2O were added, and the mixture was extracted with CH2C12 (6x) and EtOAc (2x). The combined organic extracts were dried over Na,SO4, concentrated and purified by column chromatography (10% MeOH-EtOAc) to provide an intermediate triol, which was dissolved in MeOH (800 μL) and H2O (200 μL). NaIO4 (35 mg, 0.16 mmol) was added and after 20 min, the mixture was diluted with H2O and extracted with CH2C12 (6x). The organic extracts were dried over Na,SO4, concentrated and the intermediate aldehyde was immediately dissolved in THF (500 μL). 4-Fluorophenylmagnesium bromide (2M in Et2O, 12 μL, 0.024 mmol) was added and after 20 min the reaction was quenched with saturated aqueous NH4C1. The mixture was extracted with CH2C12 (6x) and the combined organic extracts were dried over Na,SO4 and concentrated. Purification by preparative TLC (EtOAc) provided the desired product as a mixture of 4 isomers (1.32 mg, 55% for 3 steps). Dess-Martin periodinane (~3 mg, 0.007 mmol) was added to a solution of the above product (0.95 mg, 0.0012 mmol) in CH2C12 (300 μL) and the mixture was stirred at rt for 20 min. Additional Dess-Martin periodinane (~3 mg, 0.007 mmol) and CFLC1-, (300 μL) were added and after another 40 min Et2O, saturated aqueous NaHCO, (4 mL) and saturated aqueous Na,S2O3 (1 mL) were added. The mixture was extracted with Et,O (3x) and the combined extracts were washed with brine, dried over Na2SO4, concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide B2008 (0.58 mg, 61%). HRMS (FAB): calcd for C45H57FOπ + Na 815.3783. Found: 815.3758.
B2011. In an analogous manner, B1793 (1.9 mg, 0.003 mmol) was converted to B2011 (0.87 mg, 42% for 4 steps). HRMS (FAB): calcd for C45H5gO„ + Na 797.3877. Found: 797.3877.
Figure imgf000059_0001
B 1920 B2013
B2013
A solution of B 1920 (1.4 mg, 0.0016 mmol), KCN (1 mg, 0.016 mmol) and DMSO
(500 μL) was heated at 60 °C for 8 h. After cooling to rt, H2O was added and the mixture was extracted with EtOAc (3x). The combined organic extracts were washed successively with H2O and brine, dried over Na2SO4 , concentrated and purified by preparative TLC (80% EtOAc-hexanes) to provide B2013 (0.78 mg, 67%). HRMS (FAB): calcd for C41H57NOu + Na 762.3829. Found: 762.3848.
Figure imgf000060_0001
B 1920 X1920
X 1920
A mixture of B1920 (1.3 mg, 1.47 μmol), Nal (30 mg, excess) and acetone (1 mL) was stirred at 60 °C for 3.5 h. After cooling to rt, the reaction mixture was diluted with saturated aqueous NaHCO3 (3 mL), extracted with CH2C12 (5x) and EtOAc, dried over Na2SO4 and purified by column chromatography (50% EtOAc-CH2Cl2 to 80% EtOAc- hexanes) to give the iodide X1920 (1.3 mg, 100%).
Figure imgf000060_0002
X 1920 B1998: Ar = p-Cl-Ph B2010: Ar = -MeO-
Ph
B2019: Ar = 2- imidazole
General. A mixture of iodide X1920 (1.0 equiv.), iPr2EtN (11 to 22 equiv.), ArSH (9 to 46 equiv.) and DMF (0.3 mL) was stirred at rt until the reaction was judged to be complete by TLC (typically 24 to 48 h). The reaction mixture was diluted with saturated aqueous NaHCO3 (2 mL), extracted with CH2C12 and EtOAc, dried over
Na2SO4 and purified by preparative TLC (80% EtOAc-hexanes or 5% MeOH-CH2Cl2) to afford the sulfide products:
B1998. (1.3 mg gave 1.1 mg, 85%) HRMS (FAB): calcd for C46H61ClOπS + Na 897.3521. Found: 897.3533. B2010. (1.1 mg gave 0.7 mg, 59%). HRMS (FAB): calcd for C47H64O)2S +
Na 875.4016. Found: 875.4057.
B2019. (1.1 mg gave 0.7 mg, 61%) MS (FAB): M + Na
Figure imgf000061_0001
B1998: Ar = p-Cl-Ph B2016: Ar = p-Cl-Ph B2010: Ar = p-MeO-Ph B2030: Ar = p-MeO-
Ph
General. A 0.01 M solution of mCPBA (1.2 equiv.) in CH2C1: was added to a solution of a sulfide (1.0 equiv.) in CH2C12 (0.5 mL) at 0 °C for 30 min. The reaction mixture was diluted with saturated NaHCO, (2 mL), extracted with CH2C1: and EtOAc, dπed over Na,SO4 and puπfied by preparative TLC (80% EtOAc-hexanes or EtOAc) to afford the products
B2016. (0 9 mg gave 0 7 mg, 74%)
B2030. (1.0 mg gave 0.6 mg, 61%) HRMS (FAB) calcd for C47H64O14S + Na 907.3914 Found 907.3950.
Figure imgf000062_0001
B 1793 B 1934
B1934. TBDPSCI (3.0 μL, 12 μmol) was added to a solution of B1793 (1.3 mg, 1.78 μmol), imidazole (10 mg, 166 μmol) and DMF (0 10 mL) at rt. After stirπng for 1 h, the reaction mixture was diluted with saturated aqueous NaHCO3 (2 mL), extracted with CH2C12 (3x) and EtOAc (2x), dπed over Na2SO4 and puπfied by preparative TLC (5% MeOH-CH2Cl2) to give the intermediate silyl ether (1.3 mg, 77%).
This mateπal was dissolved m Ct^Cl, (0.5 mL) and treated with Dess-Martin penodmane (10 mg, 24 μmol) for 1.5 h at rt, diluted with Et:O and filtered through Celite. The filtrate was concentrated and puπfied by preparative TLC (50% EtOAc- hexanes) to afford the diketone intermediate (1.0 mg, 77%), which was dissolved in THF (0.5 mL) and treated with 0.02 M TBAF containing 0 01 M imidazole hydrochloπde (THF solution, 75 μL, 1.5 μmol) at rt for 15 min The reaction mixture was eluted through a SιO2 column (50% EtOAc-hexanes to 5% MeOH-CH2Cl2) and the desired product was further puπfied by preparative TLC (5% MeOH-CH2Cl2) to afford B1934 (0.75 mg, 100%) HRMS (FAB): calcd for C40H,6O1 : + Na 751.3669. Found: 751.3690 Synthesis of B1939:
Figure imgf000063_0001
B2294 B 1922
B1922 Tetra-n-butylammonium azide (0.2 M in DMF, 0.5 mL, 0.10 mmol) was added to a solution of mesylate B2294 (21.4 mg, 0.026 mmol) in DMF (2 mL) at rt. After stirring at 83 °C for 3.5 h, the reaction mixture was cooled to rt, diluted with toluene, concentrated and purified by preparative TLC (80% ethyl acetate-hexanes) to furnish B1922 (18 mg, 92%).
Figure imgf000063_0002
B 1922 B 1939 B1939 Me3P (1 M in THF) and H > (0.8 mL) were sequentially added to a solution of azide B1922 (24.6 mg, 0.032 mmol) in THF (3.2 mL) at rt. The mixture was stirred for 22 h, diluted with toluene, concentrated and purified by flash chromatography [step gradient, 10% MeOH-EtOAc followed by MeOH-EtOAc-30% aqueous NH4OH (9:86:5)] to provide the desired primary amine (23.3 mg), which by 'H-NMR contained -1% trimethylphosphine oxide. Lyophilization from benzene and standing under high vacuum for 2 d furnished B1939 (20.3 mg, 87%).
Synthesis of Representative B1939 Analogs:
B1930, B1940, B1973, B1987, B1988, B1991, B2003, B2004
Figure imgf000064_0001
B1930 Me3P (1 M in THF, 13 μL, 0.013 mmol) was added to a solution of B1922 (1.6 mg, 2.1 μmol), THF (400 μL) and H2O (100 μL) at rt. The mixture was stirred for 22 h. diluted with toluene, concentrated, and azeotropically dπed with toluene (2x) to give the crude amine which was used directly in the next step.
EDC (0.06 M in CH,Cl:, 100 μL. 11 μmol) was added to a solution of the crude amine. benzoylformic acid (0.8 mg, 5.3 μmol) and CH2C12 (200 μL) at rt. After 30 min, the reaction was quenched with a 1 :4 mixture of saturated aqueous NaHCO,-bπne and extracted with CH^C12 (5x). The combined extracts were dried over N ,SO4 and concentrated and purified by preparative TLC (EtOAc) to afford B1930 (1.5 mg. 83% for two steps). HRMS (FAB): calcd for C48H63NOn + Na 884.4197. Found: 884.4166.
B1940 Using the procedure described above for B1930, B1922 was reduced, coupled with 3-pyridylacetιc acid hydrochloride and purified by preparative TLC [(MeOH-EtOAc-30% aqueous NH4OH (9:86:5)] to afford B1940 (0.8 mg, 67 % for two steps). HRMS (FAB): calcd for C47H64N2O12 + Na 871.4357. Found: 871.4362.
B1973 Using the procedure descπbed above, B1922 (0.9 mg, 1.2 μmol) was reduced, coupled with phenylacetic acid and puπfied by preparative TLC (5% MeOH- EtOAc) to afford B1973 (0.44 mg, 44 % for two steps). HRMS (FAB): calcd for C48H65NO12 + Na 870.4404. Found: 870.4447.
B1987 Using the procedure described above, B1922 (0.9 mg, 1.2 μmol) was reduced, coupled with 3-indoleglyoxylιc acid and puπfied by preparative TLC (3% MeOH-EtOAc) to afford B1987 (0.8 mg, 75 % for two steps). HRMS (FAB): calcd for C50H64N2O12 + Na 923.4306. Found: 923.4338.
B1991 Using the procedure descπbed above, B1922 ( 1.0 mg, 1.3 μmol) was reduced, coupled with 4-chlorobenzoιc acid and puπfied by preparative TLC (3% MeOH- EtOAc) to afford B1991 (0.8 mg, 70 % for two steps). HRMS (FAB): calcd for C47H62ClNO12 + Na 890.3858. Found: 890.3843.
B2003 Using the procedure descπbed above, B1922 (1.0 mg, 1.3 μmol) was reduced, coupled with 3,4,5-tπmethoxybenzoylformιc acid and purified by preparative TLC (EtOAc) to afford B2003 (0.7 mg, 56 % for two steps). HRMS (FAB): calcd for CSIH69NO16 + Na 974.4514. Found: 974.4525.
B2004 Using the procedure descnbed above, B1922 ( 1.0 mg, 1.3 μmol) was reduced, coupled with 3,4,5-tπmethoxybenzoιc acid and purified by preparative TLC (5cλ MeOH-EtOAc) to afford B2004 (0.7 mg, 58 % for two steps). HRMS (FAB): calcd for C49Hc«NOπ + Na 946.4565. Found- 946.4599.
Figure imgf000066_0001
B 1930 B 1988
B1988 Dess-Martin periodinane (1 mg, 2.3 μmol) was added to a solution of B1930 (0.80 mg, 0.93 μmol) in CH2C1, (500 μL) at rt. After 1 h, the reaction was diluted with Et,O and filtered through Celite. The filtrate was washed sequentially with a 1:9 mixture of saturated aqueous NaHCOj-N^S ), and brine, dried over Na2SO4, concentrated and purified by preparative TLC (80% EtOAc-hexanes) to afford B1988 (0.45 mg, 56%). HRMS (FAB): calcd for C48H0INO,3 + Na 882.4041. Found: 884.4012.
Synthesis of B2090:
Figure imgf000067_0001
1 0 1 102 103
Compound 103. Indium powder (1.35 g, 1 1.8 mmol) was added to a solution of 102 (3.38 g, 17.6 mmol) in DMF (20 mL) at rt. After stirring for 30 min, the reaction mixture was cooled to 0 °C. Neat aldehyde 101 (3.72 g. 28.6 mmol) was then added and the mixture was stirred overnight while allowing the temperature to warm to rt. The reaction mixture was recooled to 0 °C and then quenched carefully with saturated aqueous NH4C1 (100 mL). After stirπng for 30 min, the resulting mixture was extracted with Et2O (3x), dried over Na2SO4, concentrated and purified by column chromatography (10% to 20% EtOAc-hexanes) to give pure crystalline 103 (2.20 g, 59%).
Figure imgf000067_0002
103 104 105
Compound 104. Et3N (72μL, 0.51 μmol) was added to a solution of 103 (1.09 g, 5.13 mmol) and thiophenol (0.63 mL, 7.16 mmol) in CH2C12 and the resulting mixture was stirred at 0 °C for 1 h. Filtration through SiO: gave a mixture of 104 and 105, which after MPLC (15% to 20% EtOAc-hexanes) afforded 104 (0.53 g, 32%) and 105 (0.92 g, 56%).
Figure imgf000068_0001
1 0 4 1 0 6
Compound 106. DIBALH (1 M in toluene, 3.28 mL, 3.28 mmol) was added to a solution of 104 (0.53 g, 1.64 mmol) in toluene (10 mL) at -78 °C and the mixture was stiπed at -78°C for 10 min. The reaction was quenched by careful addition of MeOH (0.40 mL,
9.84 mmol) and H2O (0.17 mL, 9.84 mmol). warmed to rt and stirred for 20 min. The white suspension was filtered through a mixture of Celite and SiO2 with 1:1 CH,Cf- Et2O and concentrated to give 106 (0.53 g, 100%) as an oil.
Figure imgf000068_0002
106 107
Compound 107. A mixture of 106 (0.53 g, 1.64 mmol) and ethyl
(triphenylphosphoranylιdene)acetate (1.15 g, 3.29 mmol) in toluene (10 mL) was heated to 80 °C for 15 h. The mixture was cooled to rt and DBU (25 μL. 0.16 mmol) was introduced. The mixture was heated to 80 °C for 1.5 h, cooled to rt, concentrated and puπfied by column chromatography (10% to 20% EtOAc-hexanes) to give 107 (0.54 g, 83%) as an oil (3: 1 ratio of α:β isomers).
Figure imgf000068_0003
107 108
Compound 108. A solution of mCPBA (-55%. 450 mg 4.5 mL CH2C12, 1.44 mmol) was added to a solution of 107 (0.54 g, 1.36 mmol) in CH2C12 (10 mL) at -78 °C. The reaction mixture was diluted with saturated aqueous NaHCO, (50 mL), H2O (10 mL), and Et2O (60 mL) and then warmed to rt. The separated aqueous layer was extracted with EtOAc (4x) and the combined organic phases were dried over Na2SO4, concentrated and purified by column chromatography (50% EtOAc-hexanes) to give 108 (0.51 g. 92%) as an oil.
Figure imgf000069_0001
108 109
Compound 109. A mixture of 108 (0.51 g, 1.24 mmol) and NaOAc (1.00 g, 12.4 mmol) in AcO (10 mL) was stiπed at 140 °C for 12 h, cooled to rt and then concentrated. The residue was partitioned between saturated aqueous NaHCO, (20 mL) and Et^O (30 mL), and stiπed vigorously at rt for 30 min. The separated aqueous layer was extracted with Et.,0 (2x), and the combined organic phases were dried over Na-,SO4, concentrated and purified by column chromatography (5% to 15% EtOAc- hexanes) to give 109 (0.41 g, 73%) as an oil.
Figure imgf000069_0002
109 110
Compound 110. A mixture of 109 (0.41 g, 0.91 mmol ) and K:CO, (44.3 mg, 0.32 mmol) in EtOH (5 mL) was heated to 60-70 °C for 1 d. After cooling to rt, the reaction mixture was concentrated and eluted through a SiO2 column (10% to 20% EtOAc- hexanes) to give the partially puπfied aldehyde intermediate. This mateπal was dissolved EtOH (2.5 mL), treated with NaBH (50 mg, 1.32 mmol) and stiπed at rt for 30 min. The mixture was concentrated and puπfied by column chromatography (40% EtOAc-hexanes) to give 110 (181 mg. 66%).
MPMOTCI
Figure imgf000070_0001
Figure imgf000070_0002
1 10 1 1 1
Compound 111. BF,*OEt2 (0.05 M in CH2C12, 175 μL, 8.75 μmol) was added to a solution of 110 (181 mg, 0.60 mmol) and p-methoxybenzyl 2,2,2- trichloroacetimidate (0.50 mL, 1.80 mmol) in CH2C12 (5 mL) at 0 °C. The resulting mixture was stiπed for 1.5 h at 0 °C and for 2 h at rt until the reaction was complete. The mixture was quenched with saturated aqueous NaHCO, (25 mL) and extracted with Et,O (5x). The combined organic phases were dπed over Na2SO4, concentrated and purified by column chromatography (CH2C12 and then 20% EtOAc-hexanes) to give semi-pure 111 (0.37 g, >100%) as an oil.
Figure imgf000070_0003
111 112
Compound 112. A mixture of 111 (0.37 g. max = 0.60 mmol) and TsOH»H,O (36 mg) in EtOH (5 mL) was stirred initially at rt overnight and then at 60 °C for 1 h Additional TsOH»H2O (31 mg) was added at rt and the reaction mixture was stirred for 1 h at rt The mixture was then concentrated, quenched with saturated aqueous NaHCO, and extracted with EtOAc (5x) The combined organic phases were dried over Na-,SO4. concentrated and purified by column chromatography (20% to 50%
EtOAc-hexanes and then 5% MeOH-CH:Cl2) to give 112
(121 mg. 53%) as an oil along with recovered 111 (49 mg, 21%).
Figure imgf000071_0001
112 113
Compound 113. TBSOTf (250 μL, 1.09 mmol) was added to a solution of
112 (121 mg, 0.32 mmol) and Et3N (176 μL, 1.26 mmol) in CH2C12 at 0 °C and the resulting mixture was stiπed for 25 min. The reaction was quenched with saturated aqueous NaHCO3 (15 mL) and the separated aqueous layer was extracted with ether (3x). The combined organic phases were dried over Na,SO4, concentrated and purified by column chromatography (5% to 10% EtOAc/hexanes) to give 113 (165 mg, 85%) as an oil.
DIBALH
Figure imgf000071_0003
Figure imgf000071_0002
113 1 14
Compound 114. DIBALH (1 M in toluene, 0.54 mL, 0.54 mmol) was added to a solution of 113 (165 mg, 0.27 mmol) in toluene (5 mL) at -78 °C and the resulting mixture was stirred at -78 °C for 10 min. The reaction was quenched by careful addition of MeOH (65 μL, 0.81 mmol) and H2O (29 μL, 0.81 mmol), warmed to rt and stiπed for 25 min. The white suspension was filtered through Celite with 1:1 CH2C1,- Et2O. Concentration and purification by column chromatography (10%> to 20% EtOAc- hexanes) gave 114 (153 mg. 100%) as an oil.
Figure imgf000072_0001
114 B2090
B2090. In a manner similar to that described in Scheme 6 for the synthesis of B1794, intermediate 114 was converted to B2090. HRMS (FAB): calcd for
C39H56Oπ+Na 723.3720. Found: 723.3731.
Figure imgf000072_0002
B2090 B2136
B2136. In a manner analogous to that of B1939, B2090 was converted to B2136. HRMS (FAB): calcd for C„HS7NO10 + Na 722.3880. Found: 722.3907. Synthesis of B2039/B2043:
Figure imgf000073_0001
X2318 201
Diol 201 TBAF (1 M in THF, 383 μL, 0.383 mmol) was added to a solution of X2318 (350-LS-218 )(80.8 mg, 0.0765 mmol) in THF (7 mL) and stiπed at rt for 16 h. After partial concentration, the residue was loaded directly onto a SiO-, column packed using 30% EtOAc-hexanes. Gradient elution (30% EtOAc-hexanes to EtOAc) furnished diol 201 (49.7 mg, 92%).
Figure imgf000073_0002
201 202
Aldehyde 202 A mixture of diol 201 (49.7 mg, 0.0707 mmol), NaIO (100 mg, 0.47 mmol), MeOH (10 mL) and H:O (2.5 mL) was stirred at rt for 30 min. H,O was added and the mixture was extracted with CH2C12 (4x). The combined organic extracts were dπed over Na,SO . concentrated and purified by column chromatography (30% EtOAc-hexanes) to provide aldehyde 202 (41.7 mg, 88%)
Figure imgf000074_0001
202 203
Alcohol 203 4-Fluorophenylmagnesium bromide (2 M in Et2O, 155 μL, 0.31 mmol) was added to a solution of aldehyde 202 (41.7 mg, 0.062 mmol) in THF (6 mL). After 15 min at rt, the reaction was quenched with saturated aqueous NH4C1 and extracted with CH2CU (4x). The combined organic extracts were dried over N ,SO4, concentrated and purified by preparative TLC (407c EtOAc-hexanes) to provide alcohol 203 (32.4 mg, 68%) as a 1: 1 mixture of C34 isomers. The minor undesired C27 isomer was separated at this stage and was also isolated as a 1:1 mixture of C34 isomers (8.4 mg, 18%).
Figure imgf000074_0002
203 204
Ether 204 Et,N (18 μL, 0.13 mmol) and TBSOTf (15 μL, 0.063 mmol) were added to a solution of alcohol 203 (32.4 mg, 0.042 mmol) in CH2C12 (5 mL) at 0 °C. After 20 min the reaction was quenched by the addition of saturated aqueous NH4C1 and extracted with CH^Cl, (3x). The combined organic extracts were dried over Na,SO4, concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide ether 204 (33.1 mg. 89% ).
Figure imgf000075_0001
204 205
Alcohol 205 LAH (1 M in THF, 113 μL, 0.113 mmol) was added dropwise to a solution of ether 204 (33.1 mg, 0.0375 mmol) in Et2O (10 mL) at 0 °C. After 20 min, H2O and 1 M NaOH were added and the mixture was stirred at rt for 10 min. Filtration through Celite, concentration and purification by column chromatography (40% EtOAc-hexanes) furnished alcohol 205 (28.4 mg, 95%).
Figure imgf000075_0002
205 206
Ether 206 Diisopropylethylamine (31 μL, 0.18 mmol) and MMTrCI (22 mg, 0.071 mmol) were added to a solution of alcohol 205 (28.4 mg, 0.0356 mmol) in
CH2C12 (4 mL) at 0 °C. After 15 h at rt, H2O was added and the mixture was extracted with CH2C12 (3x). The combined extracts were washed with brine, dried over Na^O^ concentrated and purified by preparative TLC (40% EtOAc-hexanes) to provide ether 206 as a -1.5: 1 mixture of C34 epimers (45 mg, quant), which contained a small amount of close-running impurities.
Figure imgf000076_0001
206 207
Alcohol 207 DDQ (40 mg, 0.18 mmol) was added to a solution of ether 206 (37 mg, 0.034 mmol) in CH2C12 (4 mL) and a 1: 10 mixture of tBuOH:pH 7 phosphate buffer (2 mL) at 0 °C. The mixture was stirred vigorously in the dark for 15 min. Three additional portions of DDQ (40 mg, 0.18 mmol) were added at 10 min intervals, then the reaction was diluted with saturated aqueous NaHCO, and extracted with CH2C12 (3x). The combined organic extracts were washed with brine, dried over Na2SO4, concentrated and purified by preparative TLC (30% EtOAc-hexanes) to provide alcohol 207 (19.2 mg, 59%) as well as recovered ether 206 (9.7 mg, 26%).
Figure imgf000076_0002
207 208A and 208B
Mesylates 208A and 208B Et,N (19 μL, 0.13 mmol) and Ms2O (10 mg, 0.056 mmol) were sequentially added to a solution of alcohol 207 (21.3 mg, 0.022 mmol) in CH2C12 (6 mL) at 0 °C. After 30 min, saturated aqueous NaHCO, was added and the mixture was extracted with CH,C12 (3x). The combined extracts were washed with brine, dried over Na2SO4. concentrated and purified by preparative TLC (30% EtOAc-hexanes) to provide mesylates 208A (11.7 mg, 51%) and 208B (6.5 mg, 28%) as single C34 isomers.
Figure imgf000077_0001
208A and 208B B2039, B2043
B2039 and B2043. In a manner similar to that described in Scheme 6 for the synthesis of B1794, both diastereomers 208A and 208B were independently converted to B2039 and B2043. HRMS (FAB): calcd for C45H59FOπ + Na 817.3939. Found: for B2039 817.3896, B2043 817.3910.
Synthesis of B2086, B2088, B2091
Figure imgf000077_0002
10a, 10b X- 20
Alcohol X-20 NaIO4 (1.16 g, 5.4 mmol) was added to a solution of diols 10 a, b (1.19 g. 3.0 mmol) in MeOH-H2O (4:1, 75 mL) at 0 °C. The reaction mixture was allowed to warm to rt. After stirring for 40 min, the mixture was diluted with EtOAc, filtered through Celite, concentrated, and partitioned between brine and CH2CI;. The separated aqueous layer was extracted with CH,C12 (2x). The combined organic layers were dried over Na,SO and concentrated to furnish the crude aldehyde intermediate.
NaBH4 (228 mg, 6.0 mmol) was added to a solution of the aldehyde in MeOH- E O (1: 1 , 40 mL) at 0 °C. The mixture was stirred for 30 min, carefully quenched with saturated aqueous NH C1, stiπed for 20 min at rt and extracted with CH,C1, (3x). The combined extracts were dπed over Na2SO4, concentrated and puπfied by flash chromatography (40% to 50%- EtOAc-hexanes) to afford alcohol X-20 (1.02 g. 939c for two steps).
TBSCI
Figure imgf000078_0001
Figure imgf000078_0002
20 21
Silyl ether 21 Imidazole (0.94 g, 13.9 mmol) and TBSCI (0.59 g, 3.89 mmol) were added sequentially to a solution of alcohol X-20 (1.02 g, 2.78 mmol) in DMF (10 mL) at rt. After 14 h, the reaction mixture was diluted with saturated aqueous NH4C1 and extracted with EtOAc (3x). The combined organic extracts were washed with H2O, bπne, dπed over Na2SO4, concentrated and puπfied by flash chromatography (5% to 15% EtOAc-hexanes) to afford silyl ether 21 (1.3 g, 98%).
Figure imgf000078_0003
21 22
Alcohol 22 A mixture of Pd(OH)2 (20%, 0.8 g), silyl ether 21 (1.3 g, 2.70 mmol) and EtOAc (30 mL) was stirred for 1 h under 1 atm H2 at rt, filtered through Celite, concentrated and purified by flash chromatography (20% to 40% EtOAc- hexanes) to afford alcohol 22 (0.96 g, 91%).
Figure imgf000078_0004
22 25 Alcohol 25 4-Methylmorphohne N-oxide (980 mg. 8 4 mmol) and TPAP (131 mg, 3.26 mmol) were added sequentially to a solution of alcohol 22 (1.78 g, 4.6 mmol) in CH2CK (45 mL) at rt A cold bath was necessary to control the exotherm. After 20 min, the reaction mixture was diluted with hexanes, filtered through a short SιOτ column (15% EtOAc-hexanes) and concentrated to give the crude ketone.
Tebbe reagent (14.9 mL, 9.0 mmol) was added over 10 mm to a solution of the crude ketone in THF (60 mL) at 0 °C. After 20 min, the reaction mixture was poured into Et2O (100 mL) that was precooled to -78 °C, quenched by slow addition of H O (30 mL), warmed to rt., stirred for 30 min and extracted with Et2O (4x). The combined extracts were washed with bπne, dπed over Na2SO4, concentrated and puπfied by flash chromatography (10% EtOAc-hexanes) to afford the desired olefin contaminated by the gem-dimethyl product (1.07 g). This mixture was used directly in the next step.
9-BBN (0.5 M in THF, 11 6 mL, 5.8 mmol) was added to a solution of the olefin in THF (15 mL) at 0 °C The reaction mixture was allowed to warm to rt, stirred for 5 h and then recooled to 0 °C H2O (60 mL), THF (60 mL) and NaBO,»4 H2O (5.7 g) were added. After stirπng for 5 h at rt, the THF was removed under reduced pressure and the aqueous residue was extracted with EtOAc (4x). The combined organic extracts were washed with bπne, dπed over Na2SO4, concentrated and puπfied by flash chromatography (20% to 40% EtOAc-hexanes) to furnish alcohol 25 (605 mg, 18% for three steps).
Figure imgf000079_0001
25 26
Alcohol 26 Using the procedure previously descπbed, alcohol 25 (604 mg, 1 49 mmol) was sequentially oxidized, isomeπzed, and reduced. Puπfication by flash chromatography (20% to 40% EtOAc-hexanes) afforded alcohol 26 (550 mg, 91% for three steps).
Figure imgf000079_0002
26 27
MPM-ether 27 BF,-OEt2 (0.05 M in CH2C1 . 270 μL, 0.013 mmol) was added to a solution of alcohol 26 (545 mg, 1.35 mmol) and MPM-trichloroimidate (1.14 g, 4.0 mmol) in CH2C12 (40 mL) at 0 °C. After 1 h. the reaction was quenched with saturated aqueous NaHCO,, extracted with CH2C12. dried over Na2SO4, concentrated and purified by flash chromatography (10% to 15% EtOAc-hexanes) to afford MPM-ether 27 (580 mg, 82%).
Figure imgf000080_0001
27 28
Alcohol 28 LAH (1 M in THF, 1.9 mL, 1.9 mmol) was added to a solution of MPM-ether 27 (580 mg, 1.11 mmol) in Et2O (100 mL) at 0 °C. After 30 min, the reaction was quenched carefully with H2O (0.5 mL), and 1 N aqueous NaOH (0.5 mL), stirred for 1 h at rt, filtered through Celite, concentrated and purified by flash chromatography (30% to 50% EtOAc-hexanes) to afford alcohol 28 (460 mg, 95%).
Figure imgf000080_0002
28 29
Olefin 29 DMSO (441 μL, 6.23 mmol) was added to a solution of oxalyl chloride (272 μL, 3.12 mmol) in CH2C12 (30 mL) at -78 °C. After 15 min, a solution of alcohol 28 (458 mg, 1.04 mmol) in CH2C12 (15 mL) was added to the reaction mixture. After stirring for 1 h at -78 °C, Et3N (1.3 mL, 9.35 mmol) was added. The reaction mixture was warmed to 0 °C, stirred for 10 min, diluted with saturated aqueous NH4C1 and extracted with CH2C12 (3x). The combined organic extracts were dried over Na2SO4, concentrated and filtered through a short SiO2 column (20% to 30% EtOAc- hexanes) to provide the crude aldehyde. N-BuLi (1.63 M, 1.4 mL, 2.28 mmol) was added dropwise to a solution of CH,PPh,Br (815 mg, 2.28 mmol), THF (20 mL) and DMSO (7.5 mL) at 0 °C. After 1 h. a solution of the aldehyde in THF (10 mL) was added. The reaction mixture was warmed to rt and stirred for 3 h. Saturated aqueous NH4C1 was added and the mixture was extracted with EtOAc (4x). The combined organic extracts were washed with H,O, brine, dried over Na2SO4, concentrated and purified by flash chromatography (10% to 15% EtOAc-hexanes) to afford olefin 29 (380 mg, 95% yield for 2 steps).
Figure imgf000081_0001
29 3 1
Compound 31 9-BBN (0.5 M in THF, 6 mL, 3 mmol) was added to a solution of olefin 29 (370 mg, 0.85 mmol) in THF (7 mL) at 0 °C. The mixture was allowed to warm to rt and stiπed for 1 h. After recooling to 0 °C, H2O (30 mL), THF (20 mL), and NaBO,»4 H2O (2.8 g) were added. After stirring for 3 h at rt, the THF was removed under reduced pressure. The aqueous residue was extracted with EtOAc (4x), dried over Na;,SO4, concentrated and purified by flash chromatography (25% to 50% EtOAc-hexanes) to afford alcohol 30 which was used directly in the next step.
Pivaloyl chloride (157 μL, 1.27 mmol) was added to a solution of alcohol 30 in CH2Cl2-pyridine (1:1 mixture, 10 mL) at rt. After 18 h, additional pivaloyl chloride (100 μL, 0.81 mmol) was added. After 1 h, the reaction mixture was cooled to 0 °C, quenched with MeOH (0.5 mL), concentrated, diluted with brine and extracted with CH2C12 (4x). The combined organic extracts were dried over Na^SO.,, concentrated and purified by flash chromatography (10% to 15% EtOAc-hexanes) to afford compound 31 (410 mg, 90% for two steps).
Figure imgf000081_0002
3 1 32 Alcohol 32 TBAF ( 1 M in THF, 1.14 mL. 1.14 mmol) was added to a solution of 31 (410 mg. 0.761 mmol) in THF (5 mL) at rt Atter 1.5 h. the reaction mixture was concentrated and puπfied by flash chromatography (40% EtOAc-hexanes to 100% EtOAc) to afford alcohol 32 (320 mg, 100%).
Figure imgf000082_0001
32 33a: C34 α-OH 33b: C34 β-OH
Alcohols 33a and 33b Dess-Martin peπodinane (925 mg, 2.18 mmol) was added to a solution of alcohol 32 (309 mg, 0.727 mmol) in CH2C12 (19 mL) at rt. After 1 h, the reaction was diluted with Et2O and filtered through Celite. The filtrate was washed sequentially with a 1 :9 mixture of saturated aqueous NaHCO^Na^Oj and brine, dried over Na^SO,,, concentrated and purified by flash chromatography (20% to 30% EtOAc-hexanes) to afford the desired aldehyde, which was taken immediately through the next step.
BF,»OEt, (135 μL, 1.1 mmol) was added to a solution of the crude aldehyde, tri-n-butylallyltin (337 μL, 1.08 mmol) and CH2C12 (16 mL) at -78 °C. After 1 h, the reaction was quenched with saturated aqueous NaHCO, and extracted with CH2C1^ (3x). The combined organic extracts were dried over Na^SO.,, concentrated and purified by MPLC (25% to 30% EtOAc-hexanes) to afford the major, more polar alcohol 33a (165 mg, 49% for two steps) and the minor less polar product 33b (90 mg, 27% for two steps).
TBSOTf
Figure imgf000082_0003
Figure imgf000082_0002
33a 34
Compound 34. TBSOTf (163 μL, 0.710 mmol) was added to a solution of alcohol 33a (165 mg, 0.355 mmol). Et,N (247 μL, 1.78 mmol) and CH,C1, (5 mL) at 0 °C. After 25 min. the reaction was quenched with saturated aqueous NaHCO,. extracted with CH,C1Λ (3x), dried over Na,SO , concentrated and purified by flash chromatography (15% to 20% EtOAc-hexanes) to afford compound 34 (200 mg. 98%).
Figure imgf000083_0001
34 35a and 35b
Diols 35a and 35b OsO4 (0.1 M solution in toluene, 32 μL, 3.2 μmol) was added to a solution of K2CO3 (168 mg, 1.22 mmol), K,Fe(CN)6 (400 mg, 1.22 mmol),
(DHQ)2PYR (11 mg, 12 μmol), H2O (3.2 mL) and t-BuOH (2.2 mL) at 0 °C. Then a solution of olefin 34 (200 mg, 0.345 mmol) in t-BuOH (1 mL) was added to the reaction mixture. After 5 h at 0 °C, Na2S2O5 »5 H2O (200 mg) was added. The reaction mixture was warmed to rt, stirred for 30 min and extracted with CH2C12 (5x). The combined organic extracts were washed with brine, dried over Na^SO^ concentrated and purified by preparative TLC (70% EtOAc- hexanes) to afford the major, less polar diol 35a (118 mg, 56%), and minor, more polar diastereomeric product 35b (74 mg, 35%). The individual diastereomers were each carried forward separately.
TBSOTf
Figure imgf000083_0002
Figure imgf000083_0003
35a 36
Compound 36. TBSOTf (177 μL, 0.77 mmol) was added to a solution of diol 35a (118 mg, 0.192 mmol), Et3N (267 μL, 1.92 mmol) and CH2C12 (5 mL) at 0 °C. After 25 min. the reaction was quenched with saturated aqueous NaHCO,, extracted with CH2C12 (3x), dried over Na2SO4, concentrated and purified by flash chromatography (10% to 15% EtOAc-hexanes) to afford compound 36 (161 mg, 100%).
Figure imgf000084_0001
36 37
Alcohol 37 Using the procedure described previously for the preparation of alcohol 28, compound 36 (161 mg, 0.192 mmol) afforded alcohol 37 (135 mg, 93%) after purification by flash chromatography (20% to 40% EtOAc-hexanes).
Dess-Martin
Figure imgf000084_0002
Figure imgf000084_0003
37 38
Aldehyde 38 Dess-Martin periodinane (227 mg, 0.535 mmol) was added to a solution of alcohol 37 (135 mg, 0.178 mmol) in CH2C12 (5 mL) at rt. After 1 h, the reaction mixture was diluted with E ,O and filtered through Celite. The filtrate was washed sequentially with a 1:9 mixture of saturated aqueous NaHCO^N&jS- , and brine, dried over N^SO,,, concentrated and purified by flash chromatography (10% to 20% EtOAc-hexanes) to afford aldehyde 38 (127 mg, 95%).
Figure imgf000084_0004
38 B2086, B2102
B2086, B2102. Each of the diastereomers obtained above were separately carried to final product in a manner similar to that described in scheme 6 for B1794. Diastereomer 35a afforded B2086. Diastereomer 35b afforded B2102.
Figure imgf000085_0001
B2086 B2088
B2088 NaIO4 was added to a solution of B2086 (1 mg, 1.29 μmol) in MeOH- H2O (4:l,
1 mL) at rt. After 30 min, the reaction mixture was diluted with H,O, extracted with CH2C1, (6x), dried over Na2SO4, and concentrated to afford B2088 (1.2 mg).
Figure imgf000085_0002
B2088 B2091
B2091 NaBH (0.013 M in EtOH, 20 μL. 0.27 μmol) was added to a solution of B2088 (1 mg, 1.29 μmol) in MeOH-CH2Cl2 (4: 1, 0.5 mL) at -78 °C. Additional NaBH was periodically added with close monitoπng of the reaction by TLC (total of 220 μL of the NaBH4 solution was required) The reaction mixture was quenched at 0 °C with saturated aqueous NH4C1. stirred for 20 mm at rt and extracted with CH2C12 (6χ) The combined extracts were dπed over Na2SO , concentrated and puπfied by preparative TLC (7% MeOH-EtOAc) to furnish B2091 (0.40 mg, 50%).
Synthesis of B1933:
Figure imgf000086_0001
302 303
Alcohol 303 9-BBN (0.5 M in THF, 23 mL, 0.012 mol) was added dropwise over 30 mm to a solution of alkene 302 (1.51 g, 0.00386 mol) in THF (40 mL) at 0 °C. After stirπng at rt for 80 m , the mixture was cooled to 0 °C and H2O (80 mL) was cautiously added followed by NaBO,»4 H2O (4.2 g, 0.027 mol). The mixture was stiπed vigorously at rt for 2.3 h, then extracted with EtOAc (3x). The combined organic extracts were washed with bπne. dπed over Na2SO4, concentrated and puπfied by column chromatography (50% EtOAc-hexanes) to provide alcohol 303 (1.37 g, 87%).
Figure imgf000086_0002
303 304
Aldehyde 304 Oxalyl chloπde (88 μL, 1.00 mmol) was added dropwise to a solution of DMSO (142 μL, 2.00 mmol) in CH2C12 (20 mL) at -78 °C. After 30 mm, a solution of alcohol 303 (137 mg, 0.335 mmol) in CH2C12 (5 mL) was added and stirred at -78 °C for 1 h. Et,N (420 μL, 3.01 mmol) was added and after 10 min the reaction was stirred for 10 min at 0 °C at which point saturated aqueous NH4C1 was added and the resulting mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with bπne. dπed over Na2SO , concentrated and puπfied by flash chromatography (50% EtOAc-hexanes) to provide intermediate aldehyde 304 (0.114 g, 84%) which was immediately used in the next step
Figure imgf000087_0001
304 305
Alcohol 305 TBAF (1 M in THF, 5 μL, 0.005 mmol) was added to a solution of aldehyde 304 (0.114 g, 0.27 mmol) in CF/TMS (0.5 M in THF, 1.1 mL, 0.54 mmol) at 0 °C. After 20 min, a second portion of TBAF (1 M in THF, 100 μL, 0.1 mmol) was added and the mixture was stirred for 10 min at which point excess TBAF (1 M in THF, 270 μL, 0.27 mmol) was added dropwise to cleave the intermediate silyl ether. After 30 min, the mixture was diluted with H,O and extracted with EtOAc (3x). The organic extracts were washed with H2O, brine, dried over NabSO^ concentrated and purified by column chromatography (50% EtOAc-hexanes) to provide alcohol 305 (123 mg, 95%) as an inseparable 1 : 1 mixture of isomers.
Figure imgf000087_0002
305 306
Silyl ether 306 TBSOTf (265 μL, 1.16 mmol) was added to a solution of alcohol 305 (123 mg, 0.257 mmol) and Et,N (430 μL, 3.08 mmol) in CH2C12 (8 mL) at 0 °C. After stirring at rt for 20 h, saturated aqueous NaHCO3 was added, and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with brine, dried over Na,SO4, concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide silyl ether 306 (148 mg, 97%).
Figure imgf000087_0003
306 307
Alcohol 307 LAH (1 M in THF. 220 μL, 0.22 mmol) was added dropwise to a solution of silyl ether 306 (131 mg, 0.22 mmol) in Et2O (5 mL) at 0 °C. After 20 min. H2O and 1 M NaOH were cautiously added. The mixture was stiπed at rt 30 min, filtered through glass wool, concentrated and purified by column chromatography (50% EtOAc-hexanes) to provide alcohol 307 (112 mg, quant.).
1 ) Swern
2) Wittig
Figure imgf000088_0001
Figure imgf000088_0002
307 309
Alkene 309 Oxalyl chloride (58 μL, 0.66 mmol) was added dropwise to a solution of DMSO (94 μL, 1.3 mmol) in CH2C12 (10 mL) at -78 °C. After 30 min, a solution of alcohol 307 (112 mg, 0.22 mmol) in CH2C12 (3 mL) was added. After 1 h, Et3N (276 μL, 1.98 mmol) was added, and after 10 min at -78 °C the reaction was stirred at 0 °C for 10 min. Saturated aqueous NH4C1 was added and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with brine, dried over Na2SO4, concentrated and purified by flash chromatography (50% EtOAc- hexanes) to provide aldehyde 308 (101 mg, 91%) which was immediately used in the next step.
TϊBuLi (1.63 M in THF, 200 μL, 0.33 mmol) was added dropwise to a solution of CH,PPh,Br (118 mg, 0.33 mmol) in THF (3 mL) and DMSO (1.2 mL) at 0 °C. After 70 min, a solution of aldehyde 308 (101 mg, 0.20 mmol) in THF (3 mL) was added and after 10 min at
0 °C, the reaction was stirred at rt for 1 h. Saturated aqueous NH4C1 was added and the mixture was extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over NabSO^ concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide alkene 309 (90.9 mg, 90%).
Figure imgf000089_0001
309 310
Alcohol 310 9-BBN (0.5 M in THF, 17 mL, 8.45 mmol) was added dropwise to a solution of alkene 309 (1.06 g, 2.11 mmol) in THF (30 mL) at 0 °C. After stirring for 2.5 h at rt, the reaction was cooled to 0 °C and H2O (60 mL) followed by NaBO3»4 H2O (3.25 g, 21.1 mmol) were cautiously added. The mixture was stirred vigorously at rt for 2 h, then diluted with H2O and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over Na2SO4, concentrated and purified by column chromatography (20% to 30% EtOAc-hexanes) to provide alcohol 310 (0.920 g, 84%).
Figure imgf000089_0002
310 31 1
Pivaloate 311 A mixture of alcohol 310 (65.8 mg, 0.0126 mmol), pyridine (61 μL, 0.76 mmol) and PvCI (23 μL, 0.189 mmol) in CH2C12 (3 mL) was stirred at rt for 5 h. A second reaction utilizing alcohol 310 (0.92 g, 1.76 mmol) was run under similar conditions and both reactions were combined during the work-up: saturated aqueous NH4C1 was added and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with brine, dried over Na2SO4, concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide pivaloate 311 (1.08 g, quant).
Figure imgf000089_0003
311 312 Alcohol 312 A mixture of ether 311 (0 811 g. 1 33 mmol). DDQ (6.1 g, 27 mmol) and 10 1 tBuOH: pH 7 phosphate buffer (42 mL) in CH:C12 (84 mL) was stirred vigorously in the dark at rt for 1.5 h, at which point additional DDQ (1.0 g, 4 4 mmol) was added After 1 h, saturated aqueous NaHCO, was added and the mixture was extracted with CH,CK (4x). The combined organic extracts were washed successively with saturated aqueous NaHCO, and bπne, dπed over Na2SO4, concentrated and puπfied by column chromatography (20% EtOAc-hexanes) to provide alcohol 312 (0.56 g, 87%) as well as recovered starting mateπal 311 (97 mg, 12%).
Figure imgf000090_0001
Ketone 313 Oxalyl chloπde (21 μL, 0.12 mmol) was added dropwise to a solution of DMSO (34 μL, 0.48 mmol) in CH2C12 (3 mL) at -78 °C After 1 h, a solution of alcohol 312 (39.4 mg, 0.081 mmol) in CH2C12 (1 5 mL) was added and the mixture was stiπed for 1.5 h. Et3N (100 μL, 0.73 mmol) was added, and after 10 mm the mixture was warmed to 0 °C. Saturated aqueous NH4C1 was added and the mixture was extracted with CH,C12 (3x). The combined organic extracts were washed with bπne, dπed over Na^SO4, concentrated and puπfied by flash chromatography (30% EtOAc-hexanes) to provide ketone 313 (36.6 mg, 93%) which was used immediately
Figure imgf000090_0002
Tebbe
Figure imgf000090_0004
Figure imgf000090_0003
313 314
Alkene 314 Tebbe reagent (-0.65 M toluene, 720 μL, 0 47 mmol) was added dropwise to a solution of ketone 313 (151 mg, 0 31 mmol) in THF (5 mL) at 0 °C. After 15 mm. H,O was cautiously added and the mixture was extracted with EtOAc (3x). The combined organic extracts were washed with bπne, dπed over Na,SO4, concentrated and purified by column chromatography (10% EtOAc-hexanes) to provide alkene 314 (139 mg, 93%).
Figure imgf000091_0001
314 315
Alcohol 315 9-BBN (0.5 M in THF, 6.0 mL, 2.9 mmol) was added dropwise to a solution of alkene 314 (468 mg, 0.97 mmol) in THF (10 mL) at 0 °C. The mixture was stirred at rt for 2 h at which point additional 9-BBN (0.5 M in THF, 500 μL, 0.25 mmol) was added. After 2.5 h, the mixture was cooled to 0 °C and H,O (10 mL) followed by NaBO3»4 H2O (1.5 g, 9.7 mmol) were cautiously added. The mixture was stirred vigorously at rt for 5 h, diluted with H2O and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over N ,SO4, concentrated and purified by column chromatography (gradient 20% to 30% EtOAc- hexanes) to provide alcohol 315 (0.47 g, 97%).
Figure imgf000091_0002
315 316
Alcohol 316 Oxalyl chloride (246 μL, 2.82 mmol) was added dropwise to a solution of DMSO (400 μL, 5.64 mmol) in CH2C12 (40 mL) at -78 °C. After 1 h, a solution of alcohol 315 (0.47 g, 0.94 mmol) in CH2C12 (10 mL) was added and the mixture was stirred for 1 h. Et3N (1.2 mL, 8.5 mmol) was added, and after 10 min the mixture was warmed to 0 °C and stirred for 10 min. Saturated aqueous NH C1 was added and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with brine, dried over Na2SO4 and concentrated. The crude aldehyde was stiπed in CH2C12 (20 mL) and Et,N (2 mL) at rt overnight. Saturated aqueous NH4C1 was added and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with brine, dried over Na2SO4, concentrated and purified by flash chromatography (30% EtOAc-hexanes) provided the epimerized aldehyde which was immediately dissolved in 1 :1 Et2O:EtOH (10 mL) and cooled to 0 °C. NaBH4 (35 mg, 0.94 mmol) was added and after 10 min the reaction was quenched with saturated aqueous NH4C1. The mixture was extracted with EtOAc (3x) and the combined organic extracts were washed with brine, dried over Na2SO4, concentrated and purified by column chromatography (30% EtOAc-hexanes) to provide alcohol 316 (0.410 g, 87% yield for 3 steps).
MPMOTCI
Figure imgf000092_0001
Figure imgf000092_0002
316 317
Ether 317 Alcohol 316 (60.7 mg, 0.12 mmol) and MPMOTCI (0.10 g, 0.36 mmol) were combined, azeotroped from toluene (3x) and dried under high vacuum overnight. CH2C12 (3 mL) was added and the mixture was cooled to 0 °C. BF,»OEL, (approx. 1 μL, 0.01 mmol) was added and after stirring for 10 min the reaction was quenched with saturated aqueous NH4C1. The mixture was extracted with CH2C12 (3x) and the combined extracts were washed with brine, dried over Na2SO4, concentrated and purified by preparative TLC (30% EtOAc-hexanes) to provide ether 317 (55.4 mg, 74%).
Figure imgf000092_0003
317 318
Alcohol 318 LAH (1 M in THF, 104 μL, 0.104 mmol) was added dropwise to a solution of ether 317 (54 mg. 0.087 mmol) in Et2O (5 mL) at 0 °C. After 30 min, H2O and 1 M NaOH were cautiously added. The mixture was stirred at rt for 10 min, filtered through glass wool, concentrated and purified by column chromatography (30%-50% EtOAc-hexanes) to provide alcohol 318 (45.5 mg, 98%). Swern
Figure imgf000093_0001
Figure imgf000093_0002
318 319
Aldehyde 319 Oxalyl chloπde (1 1 μL, 0.13 mmol) was added dropwise to a solution of DMSO (18 μL, 0.25 mmol) CH2C12 (2 mL) at -78 °C. After 1.8 h, a solution of alcohol 318 (22.6 mg, 0.042 mmol) in CH2C12 (1 mL) was added and the mixture was stiπed for 1 h. Et,N (53 μL, 0.38 mmol) was added and after 10 min, the reaction was warmed to 0 °C and stirred 10 min. Saturated aqueous NH4C1 was added and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with bπne, dπed over Na2SO4, concentrated and puπfied by flash chromatography (20% EtOAc-hexanes) to provide aldehyde 319 (21.7 mg, 97%).
Figure imgf000093_0003
319 B 1933
B1933. In a manner similar to that descπbed in Scheme 6 for the synthesis of B1794, intermediate 319 was converted to B1933. HRMS (FAB): calcd for C41H,7F,Oπ + H 783.3931. Found 783.3940.
Figure imgf000094_0001
B 1897 B 1942
B1942. A mixture of B1897 (2 mg, 2.73 μmol). NaIO4 (35 mg, 0.16 mmol), MeOH (0.8 mL) and H2O (0.2 mL) was stirred at rt for 30 min. The reaction mixture was then diluted with H2O (3 mL) and extracted with CH2C12 (6x) and EtOAc (2x). The combined organic phases were dried over Na2SO4 and purified by column chromatography (5% MeOH- CH2C12) to give the desired aldehyde.
This material was dissolved in THF (0.1 mL), cooled to at 0 °C and treated with 0.5 M CFjTMS in THF (30 μL, 15 mmol) followed by 0.05 M TBAF in THF (5 mL, 0.025 mmol). After stirring for 30 min, the reaction mixture was diluted with saturated aqueous NaHCO, (2 mL) and H2O (1 mL), extracted with EtOAc (6x), dried over Na,SO4, filtered and concentrated to give the crude bis-TMS ether.
This material was dissolved in THF (0.5 mL) and treated with 1 M TBAF in THF containing 0.5 M imidazole hydrochloride (8 μL, 8 μmol) at rt for 30 min. The reaction mixture was eluted through a SiO2 column (50% EtOAc-hexanes to EtOAc) to afford the diol intermediate.
A mixture of this product and Dess-Martin periodinane (10 mg, 24 mmol) in CH2C1, (0.5 mL) was stirred at rt for 1 h, diluted with E ,O (5 mL) and filtered through Celite. The filtrate was concentrated and purified by preparative TLC (50% EtOAc- hexanes) to furnish B1942 ( 1.5 mg, 72% for 5 steps). HRMS (FAB): calcd for C40H55F3On + H 767.3516. Found: 767.3542
Synthesis of B2070/B2073:
Figure imgf000095_0001
Alcohol 401 A mixture of NaIO4 (375 mg, 1.74 mmol), X400 (674 mg,
1.58 mmol), MeOH (16 mL) and H2O (4 mL) was stirred at rt for 1 h. After dilution with H2O, the mixture was extracted with CH2C12 (4x) and the combined organic extracts were dπed over Na^SO,,, concentrated and purified by flash chromatography (30% EtOAc-hexanes) to provide the intermediate aldehyde (570 mg), which was immediately dissolved in DMF (15 mL). Indium
(275 mg, 2.4 mmol) and 3-bromo-3,3-difluoropropene (240 μL, 2.4 mmol) were added and after stirπng at rt for 17 h, H2O and 0.1 M HCI were added. The mixture was extracted with EtOAc (3x) and the combined organic extracts were washed successively with H2O and brine, dried over Na2SO4, concentrated and purified by column chromatography (20% to 30% EtOAc-hexanes) to provide alcohol 401 as a 1 : 1 mixture of C34 isomers (605 mg, 81% for 2 steps).
Figure imgf000095_0002
401 402
Diol 402 A mixture of OsO4 (1 xstal), alcohol 401 (605 mg, 1.28 mmol), 4- methyl-morpholme N-oxide (0.45 g, 3.84 mmol), acetone (30 mL) and H2O (6 mL) was stirred at rt for 29 h. Additional OsO4 (3 xtals) and 4-methylmorpholιne N-oxide (0.1 g, 0.8 mmol) were added and after 2 days saturated aqueous Νa2S2O, was added. The mixture was extracted with CH2C12 (6x) and the combined organic extracts were dried over Na,SO4 and concentrated. The crude intermediate triol was immediately dissolved in 4:l ::MeOH:H2O (25 mL) and NaIO4 (0.41 g. 1.9 mmol) was added. After stirπng vigorously at rt for 2 h, the mixture was diluted with H2O, extracted with CH2C12 (3x) and the combined organic extracts were dπed over Na2SO4 and concentrated to provide the intermediate aldehyde which was immediately dissolved in 1:1 EtOH-Et2O (30 mL) and cooled to 0 °C. NaBH (48 mg. 1.3 mmol) was added and after 20 min the reaction was quenched with H2O and extracted with CH,C1., (4x). I'he combined organic extracts were dried over Na,SO4. concentrated and purified by column chromatography (50% EtOAc-hexanes) to provide diol 402 (485 mg, 80% for 3 steps).
Figure imgf000096_0001
402 403
Silyl ether 403 TBSOTf (2.3 mL, 10 mmol) was added dropwise to a mixture of diol 402 (485 mg, 1.0 mmol), Et,N (2.8 mL, 20 mmol) and CH2C12 (30 mL) at 0 °C. After stirring for 1 h at rt, saturated aqueous NH4C1 was added and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with brine, dried over Na^SO,,, concentrated and purified by column chromatography (20% EtOAc-hexanes) to provide silyl ether 403 (668 mg, 95%).
Figure imgf000096_0002
403
04
Alcohol 404 LAH (1 M in THF, 2.8 mL, 2.8 mmol) was added dropwise to a solution of silyl ether 403 (668 mg, 0.948 mmol) in Ε (60 mL) at 0 °C. After 15 min, H2O and 1 M NaOH were cautiously added. The mixture was stirred at rt for 20 min, filtered through glass wool, concentrated and purified by column chromatography (30% EtOAc-hexanes) to provide alcohol 404 (500 mg, 85%).
Figure imgf000096_0003
404 405
Aldehyde 405 Oxalyl chloride (210 μL, 2.42 mmol) was added dropwise to a solution of DMSO (345 μL, 4.84 mmol) in CH2C12 (30 mL) at -78 °C. After 1 h, a solution of alcohol 404 (500 mg. 0.806 mmol) CH2C12 (10 mL) \\ as added After 40 min, Et,N (1.0 mL, 7.2 mmol) was added. After stimng at -78 °C for 10 mm, the reaction mixture was warmed to 0 °C and stiπed for an additional 10 min. Saturated aqueous NH4C1 was added and the mixture was extracted with CH,Cb (3x). The combined organic extracts were washed successively with H2O. bπne, dπed over Na2SO4 and concentrated. Puπfication by flash chromatography (30% EtOAc-hexanes) provided aldehyde 405 (486 mg, 98%) which was immediately used in the next step.
Figure imgf000097_0001
405 406
Alkene 406 «BuLι (1.63 M, 860 μL, 1.4 mmol) was added dropwise to a solution of CH,PPh,Br (500 mg, 1.4 mmol) in THF (15 mL) and DMSO (6 mL) at 0 °C. After 1 h, a solution of aldehyde 405 (486 mg) in THF (15 mL) was added. The reaction mixture was warmed to rt and stiπed for 30 min. Saturated aqueous NH4C1 was added, the mixture was extracted with EtOAc (3x) and the combined extracts were washed successively with H2O and bπne, dπed over Na2SO4, concentrated and puπfied by column chromatography (20% EtOAc-hexanes) to provide alkene 406 (450 mg, 93%)
Figure imgf000097_0002
406 407
Ester 407 9-BBN (0.5 M in THF, 9 0 mL, 4 5 mmol) was added dropwise to a solution of alkene 406 (0.460 g. 0.746 mmol) in THF (10 mL) at 0 °C. After warming to rt, the mixture was stirred for 3 h and two additional portions of 9-BBN (0.5 M in THF, 3.0 mL, 1.5 mmol) were added at 30 mm intervals. The reaction mixture was recooled to 0 °C. whereupon THF
(10 mL), H2O (10 mL) and NaBO,«4 H2O (1.72 g. 11.2 mmol) were cautiously added The mixture was stirred vigorously at rt for 1.5 h. and additional NaBO,»4 HX) (1.0 g, 6.5 mmol) was added. After 2 h the mixture was diluted with H2O and extracted with EtOAc (3x). The combined extracts were washed with bπne, dπed over Na2SO4, concentrated and puπfied by column chromatography (20% to 30% EtOAc-hexanes) to provide the intermediate alcohol (509 mg) which was immediately dissolved in CH,C1, (10 mL) and treated with pyridine (600 μL, 7.5 mmol) and PvCI (275 μL, 2.2 mmol). After 6 h, saturated aqueous NH4C1 was added and the mixture was extracted with CH2C12 (3x). The combined organic extracts were washed with bπne, dπed over Na;,SO4, concentrated and purified by column chromatography (20% to 30% EtOAc- hexanes) to provide ester 407 (423 mg, 79% for 2 steps).
Figure imgf000098_0001
407 408
Alcohol 408 A mixture of ester 407 (1 1 mg. 0.015 mmol) and Pd(OH)JC (10 mg) in EtOAc (500 μL) was stirred vigorously under a H2 atmosphere at rt for 6 h. The mixture was filtered through Celite, concentrated and punfied by column chromatography (30% EtOAc-hexanes) to provide alcohol 408 (9 4 mg, quant).
1 l)j S&wweermn 2) Tebbe
Figure imgf000098_0003
Figure imgf000098_0002
408 409
Alkene 409 Oxalyl chloπde (7 μL, 0.075 mmol ) was added dropwise to a solution of DMSO (11 μL. 0.15 mmol) in CH2C12 (2 mL) at -78 °C under N,. After 40 min, a solution of alcohol 408 (15.2 mg, 0.025 mmol) in CH2C12 (1 mL) was added and the reaction was stirred at -78 °C for 1 h. Et,N (31 μL. 0.22 mmol) was added, and after stirπng for 10 min the mixture was warmed to 0 °C. After 10 min. the reaction mixture was quenched with saturated aqueous NH C1 and extracted with CH,CU (3x) The combined extracts were washed successively with H2O and bπne, dπed over Na,SO4 and concentrated. After flash chromatography (30% EtOAc-hexanes), the intermediate ketone (13 mg) was immediately dissolved in THF (500 μL) and treated with Tebbe reagent (-0.65 M m toluene, 62 μL, 0.040 mmol) at 0 °C. After 1.5 h additional Tebbe reagent (-0.65 M in toluene. 62 μL, 0.040 mmol) was added and after 10 mm H2O and then bπne were cautiously added. The mixture was extracted with EtOAc (3x) and the combined organic extracts were washed with bπne. dπed over Na^O.,, concentrated and puπfied by column chromatography (10% EtOAc-hexanes) to provide alkene 409 (11.9 mg, 80% for 2 steps).
Figure imgf000099_0001
409 410
Alcohol 410 9-BBN (0.5 M m THF, 1.5 mL, 0.72 mmol) was added dropwise to a solution of alkene 409 (0.144 g, 0.242 mmol) in THF (2 mL) at 0 °C. After warming to rt, the mixture was stiπed for 3 h. The reaction mixture was recooled to 0 °C, whereupon THF (2 mL), H2O (2 mL) and NaBO,»4 H2O (0.38 g. 2 4 mmol) were cautiously added. The mixture was stirred vigorously at rt for 4 h, diluted with H2O and extracted with EtOAc (3x). The combined extracts were washed with bπne, dried over Na2SO4, concentrated and puπfied by column chromatography (20% EtOAc-hexanes) to provide alcohol 410 (0.140 g, 94%).
Figure imgf000099_0002
410 41 1
Alcohol 411 Oxalyl chloπde (26 μL. 0.30 mL) was added dropwise to a solution of DMSO (43 μL, 0.60 mmol) in CH:C12 (4 mL) at -78 °C After 1 h. a solution of alcohol 410 (57 mg. 0.093 mmol) in CH;Cl2 (2 mL) was added. After 45 min. Et,N (125 μb? &.90 mmol) was added. After stirπng at -78 °C for 10 min. the reaction mixture was warmed to 0 °C and stirred for an additional 10 min. Saturated aqueous NH4C1 was added and the mixture was extracted with CH^C12 (3x). The combined organic extracts were washed with brine, dried over N ,SO4 and concentrated. The crude product was dissolved in CH2C1, (4 mL). treated with Et3N (400 μL) and stiπed at rt for 15 h. Saturated aqueous NH4C1 was added and the mixture was extracted with CH,C1, (3x). The combined organic extracts were washed with brine, dried over Na^SO4, concentrated and purified by flash chromatography (30% EtOAc-hexanes) to provide the intermediate aldehyde (48 mg), which was immediately dissolved in 1:1 Et,O-EtOH (4 mL), cooled to 0 °C and treated with solid NaBH4 (-4 mg, 0.09 mmol). After stirring for 15 min, saturated aqueous NH4C1 was cautiously added and the mixture was extracted with EtOAc (3x). The combined extracts were washed with brine, dried over Na^SO^ concentrated and purified by column chromatography (20% to 30% EtOAc- hexanes) to provide alcohol 411 (45.6 mg, 80% for 3 steps).
Figure imgf000100_0001
ome
Figure imgf000100_0002
41 1 412A, 412B 412A and 412B Alcohol 411 (120 mg, 0.196 mmol) and MPMOTCI (0.17 g, 0.59 mmol) were combined, azeotroped from toluene (3x) and dried under high vacuum for 1 h. CH2C12 (9 mL) was added and the mixture was cooled to 0 °C. BF,»OEt2 (0.016 M in CH2C12, 125 μL, 0.002 mmol) was added dropwise and after stirring for 20 min, the reaction was quenched with saturated aqueous NH4C1. The mixture was extracted with CH2C12 (3x) and the combined extracts were washed with brine, dried over Na2SO4, concentrated and purified by preparative TLC (20% EtOAc- hexanes) to provide the intermediate MPM ether which contained some close-running impurities. This material was immediately dissolved in Et2O (10 mL) and treated with LAH (1M in THF, 300 μL, 0.300 mmol) at 0 °C. After 10 min. H2O and 1 M NaOH were added, and after stirring for 10 min at rt, the mixture was filtered through Celite, concentrated and purified by preparative TLC (35% EtOAc-hexanes) to provide 412A (49 mg, 39% for 2 steps) as a single C34 isomer and 412B (46 mg, 36% for 2 steps) as a -9:1 mixture of C34 isomers.
Figure imgf000101_0001
412A, 412B B2070, B2073
B2070 and B2073. In a manner similar to that described in Schemes 4 and 6 for the synthesis of B1794, intermediates 412A and 412B were converted to B2070 and B2073, respectively. For B2070: HRMS (FAB): calcd for C41H58F2OI2 + Na 803.3794. Found: 803.3801. For B2073: HRMS (FAB): calcd for C4IH58F2O12 + Na 803.3793. Found: 803.3781
Synthesis of B1963:
Figure imgf000101_0002
10 501
Diol 501 (64) Saturated aqueous NaHCO, (21 mL) and KBr (89 mg, 0.75 mmol) were added to a solution of diol 10 (1.35 g. 3.4 mmol) in CH2C12 (34 mL). The mixture was cooled to 0 °C, and 4-methoxy-2,2,6,6-tetramethyl-l-piperidinyloxy (0.05 M in CH,CI,, 7.45 mL, 0.37 mmol) and NaOCl (0.07 M in H,O, 5.6 mL, 0.39 mmol) were sequentially added. After 1 h, the reaction mixture was quenched with saturated aqueous Na,S,O,, diluted with saturated aqueous NaHCO, and extracted with CH,C1, (3x). The combined extracts were dπed over Na2SO , concentrated and dissolved m THF (21 mL).
After cooling to 0 °C, CF,TMS (1.5 g, 10.5 mmol) and TBAF (0 1 M in THF, 680 μL, 0.068 mmol) were sequentially added. After stirπng for 40 min, additional TBAF (1 M in THF, 8.3 mL, 8.3 mmol) was added. After 30 min. the reaction was quenched with H2O and extracted with EtOAc (3x). The combined organic extracts were washed with bπne, dried over Na2SO4, concentrated and puπfied by flash chromatography (30%, 40%, 50% EtOAc-hexanes followed by EtOAc) to afford a 2:1 mixture of diols (553 mg, 35%). Separation by MPLC (1.5% MeOH- CH2C12) gave the major, more polar isomer 501 (64) (340 mg, 22%) and the minor, less polar isomer (152 mg, 10%).
Figure imgf000102_0001
B 1963
B1963. In a manner similar to that descπbed in Schemes 4 and 6 for the synthesis of B1794, intermediate 501 was converted to B1963.
Synthesis of B2320 and Related Analogs
Figure imgf000103_0001
B2294
These compounds are made by treating B2294 with an appropriate amine in a solvent such as methanol for a period of a few hours to several days. Progress of the reaction may be monitored by thin layer chromatography. A standard work-up procedure, well known to those of skill in the art, provides the desired compounds. The procedure below is to prepare ER803868; however this procedure is general and can be used to prepare any desired analog.
Synthesis of ER803868
To a solution of B2294, 1.2 mg, in methanol, 0.5 mL, was added morpholine, 0.012 mL. The mixture was stirred for 10 days with additional moφholine, 0.012 mL, being added on days 1,2,3, 4 and 8. The mixture was then chromatographed to give 1.4 mg of the desired compound.
Figure imgf000103_0002
B2320 R = N,N-dimethylamino B2330 R = N-isopropylamino B2336 R = N-methylamino B2339 R = N-t-butylamino B2417 R = N-2-hydroxyethylamino B2418 R = N-piperazinyl B2489 R = N,N-bis-(2-hydroxyethyl)amino B2490 R = N-1.3-dιhydroxy-2-propylamιno B2491 R = N-benzylamino ER803834 R = N-pipendmyl ER803835 R = N-pyπohdinyl ER803836 R = N-3-(R)-hydroxypyπohdιnyl ER803843 R = N-homopipeπdinyl ER803845 R = N-para-methoxybenzylamino ER803846 R = N-phenethylammo ER803851 R = N-2-(S-hydroxymethyl)pyπolιdιnyl ER803852 R = N-2-(R-hydroxymethyl)pyrrohdιnyl ER803868 R = N-moφhohnyl ER803869 R = N-ethylamino ER803870 R = N-imidazoyl ER803883 R = N,N-dιethylamιno ER803884 R = N-para-chlorobenzylamino
D. Pharmacological Activity
Many of the individually disclosed drugs were tested for in vitro and in vivo activity (see Table 1, below). Screening methods included a standard in vitro cell growth inhibition assay using DLD-1 human colon cancer cells (ATCC accession number CCL 221) in a 96-well microtiter plate format (Fmlay, G.J. et al Analytical Biochemistry 139.272-277, 1984), a U937 (ATCC accession number CRL 1593) mitotic block reversibility assay (descπbed below), and in some cases, a LOX human melanoma tumor xenograft in vivo growth inhibition assay (see Table 1) Chemical stability to esterase degradation was also examined
U937 Mitotic Block Reversibility Assay
U937 human histiocytic lymphoma cells were added to 75 cm2 tissue culture flasks as 2.5 x 106 cells in 22.5 mL of RPMI Medium 1640 containing 10% Fetal Bovine Serum. Cells were allowed to adapt to the culture duπng 36 h of incubation at 37 °C m a humidified atmosphere containing 5% CO2 Each test drug was then added to a flask as 2.5 mL of lOx final concentration Final concentrations achieved were 0 1- 1000 nM, in half log-increments, for a total of 10 concentration steps including a drug- free control flask which received 2 5 mL of media Cells were incubated with drug for 12 h pretreatment peπod at 37 °C in a humidified atmosphere containing 5% CO2 The contents were removed from each flask and centπfuged at 300 x g for 10 min at room temperature, after which drug-containing media was removed from cell pellet. Cells were resuspended in 25 mL of warm drug-free media and centπfuged at 300 x g for 10 min at room temperature. After removing media from cell pellet, cells were resuspended in 35 mL of warm drug-free media, transfeπed to fresh flasks, and a 10 mL sample of cells immediately removed from each flask, immediately processed as descπbed below and stored for later cell cycle analysis (0 hours of drug washout).
Incubation of the remaining 25 mL of cells continued drug-free media for another 10 h. A 10 mL sample of cells was removed from each flask, immediately processed and stored for later cell cycle analysis (10 hours of drug washout) and 10 mL fresh replacement media was added to each incubation flask. Incubation of cells m drug-free media continued for 5 days. At day two, 20 mL of media and cells was removed from each flask and replaced with 20 mL fresh media Viability of cells was quantified after 5 days by trypan blue exclusion techniques using hemacytometer counting.
Cells were processed for cell cycle analysis using modifications of the method published in Becton Dickinson Immunocytometry Systems source book section 1.11 (Preparation of Alcohol-Fixed Whole Cells From Suspensions For DNA Analysis). Bπefly, each 10 mL sample of cells removed from the flasks at 0 and 10 hours of drug washout was separately centπfuged at 300 x g for 10 min. After removing the media from the cell pellet, cells were resuspended in 3 mL cold saline. Seven milliliters cold 100 % ethanol was slowly added with vigorous vortexing. Ethanol treated cell samples from 0 hour and 10 hour peπods of compound washout were stored overnight at 4 °C. Ethanol treated cells were centπfuged 300 x g for 10 min, ethanol removed and cells then washed in 10 mL Phosphate Buffered Saline (PBS). Cells were resuspended in 0.5 mL of 0.2 mg/mL Ribonuclease A (Sigma No. R-5503) in PBS and incubated m 37 °C water bath for 30 mm.
Cells were transfeπed to appropπate flow cytometry tubes and 0.5 mL of 10 mg/mL propidium iodide (PI) (Sigma No. P4170) in PBS was added to each tube. Cells were incubated with PI at room temperature in the dark for at least 15 m pπor to analysis with a flow cytometer (Becton Dickinson FACScan flow cytometer or equivalent). Cells should be analyzed within an hour and kept in the dark at 4 °C until ready. Cell cycle analysis was performed on 0 hour and 10 hour cells using flow cytometπc measurement of the intensity of cellular fluorescence. The intensity of propiώum iodide fluorescence for each cell was measured on a linear amplification scale with doublet events ignored using doublet discπmination. The results obtained from analyzing 15,000 cells were presented as a histogram with increasing fluorescence intensity on the x-axis and the number of cells at a particular intensity level on the y- axis.
The intensity of PI staining is dependent on the amount of DNA in the cell so it is possible to identify cells vaπous phases of the cell cycle, such as cells that have not yet synthesized DNA since the last mitosis (G, phase), cells that are in intermediate stages of DNA synthesis (S phase), and cells that have doubled their complement of DNA and are ready to divide (G2 phase). Cells that are blocked in the mitosis phase of the cell cycle also have double the amount of DNA compared to G, phase cells If all cells are blocked mitosis there are no G, phase cells, but if the block is removed when compound is removed, cells complete mitosis and reappear in the G, phase The number of cells so reappeaπng in the G, or Sphase is thus a measure of the number of cells which have recently completed mitosis. For each sample at 0 and 10 hours after compound removal, the percentage of cells completing mitosis was quantified (as the number of cells reappeaπng in the G, phase) and plotted as a function of the initial concentration of compound used duπng the 12 hour pretreatment peπod. The percentage of cells still viable 5 days after drug washout was supeπmposed on the same graph, see, for example FIG. 1 and FIG. 2. A ratio can be determined between the compound concentration required to completely block all cells in mitosis at 0 hour and the concentration required to maintain the block 10 hours after compound removal. This was taken as a measure of a compound's reversibility, with ratios close to or equal to one indicating likely potent in vivo anti-tumor compounds (see Table 1, columns 4- 6, and FIGS. 3 and 4).
Table 1
In Vitro Inhibition and Reversibility Data
compound
B 1793
B 1794
B 1918
B 1920
B 1921
B 1 22
B 1930
B 1 3 ^
B 1934
B 1939
Figure imgf000106_0001
B1 40 B1942 B1963 BI 73 B1 84 B1987 B1988 B1990 B1991 B1992 B1998 B2003 B2004 B2008 B2010 B2011 B2013 B2014 B2015 B2016 B2019 B2034 B2035 B2037 B2039 B2042 B2043 B2070 B2073 B2086 B2088 B2090 B2091 B2102 B2136 B2294 B2320 B2330
Figure imgf000107_0001
B2336
B2339
B2417
B2418
B2489
B2490
B249 1 ER803834 ER803835 ER803836 ER803843 ER803845 ER803846 ER803851 ER803852 ER803868 ER803869 ER803870 ER803883 ER803884
Figure imgf000108_0001
* = in vitro cell growth inhibition ** = before washout $ = after washout
The invention also features a method for identifying an agent that induces a sustained mitotic block in a cell after transient exposure of the cell to the agent The invention features determining the relative reversibility of the test compound by relating the measurement of step (d) and the measurement of step (0. as descπbed below This determination may be a ratio, or an aπthmetic difference, for example In one aspect, the method includes
(a) incubating a first cell sample with a predetermined concentration of a test compound for a time interval between that sufficient to empty the G, population and that equivalent to one cell cycle (e g , typically, 8 -16 hours, or about 12 hours),
(b) substantially separating the test compound from said first cell sample (e g. by washing or changing media),
(c) incubating said first sample in media free of the test compound for a time interval sufficient to allow at least 80% (e.g , 85%, 90%, and preferably 95%, 98%, or 99%) of the cells released from the mitotic block induced bv a hishlv reversible mitotic inhibitor to complete mitosis and return to the G, phase (e.g., typically 6-14 hours, or about 10 hours after separation step (b)); and
(d) measuring the percentage of transiently-exposed cells from step (c) that have completed mitosis and returned to the G, phase (e.g., measuring a cell cycle marker, such as DNA-dependent PI fluorescence).
One aspect of this screening method include the further steps of :
(e) incubating a second sample of cells with a concentration of the test compound less than or equal to that used in step (a) for a time interval between that sufficient to empty the G, population and that equivalent to one cell cycle;
(f) measuring the percentage of cells from step (e) that have completed mitosis and have returned to the G, phase; and
(g) determining a reversibility ratio of the test compound.
In one embodiment of the method, the first and second cell samples are suspension culture cells selected from, for example, human leukemia, human lymphoma, murine leukemia, and murine lymphoma cells. The first and second cell samples may be incubated simultaneously (steps (a) and (e)) or in separate portions. Other embodiments further include before step (a), the step (i) of estimating a desirable time interval for incubating said first cell sample with a reversible mititotic blocking agent (or, alternatively, said test compound) to provide a satisfactory majority of cells collected at mitotic block; and wherein the incubation of step (a) is for the time interval estimated in step (i). Another embodiment of the method further includes before step (c), the step (ii) of estimating a desirable time interval for the test compound-free incubation of step (c), said step (ii) comprising determining the time interval after which at least 80 % of the cells pretreated with a highly reversible antimitotic agent complete mitosis and reenter G, phase; and wherein the incubation of step (c) is for the time interval determined in step (ii). Another embodiment of the method utilizes non- suspension culture cells from, for example, adherent human or murine cancer cells, harvested by any suitable means for detaching them from tissue culture flasks. One aspect of the method further includes repeating steps (a) - (f) using a range of relative concentrations of test compound to determine what two substantially minimum concentrations of the test compound provide substantially complete mitotic block in step (d) and in step (f). respectively. The ratio of these minimum sufficient concentrations is an index of reversibility (see detailed U937 protocol for preparation of exemplary dose-response curves). These concentrations may be determined by extrapolating curves of the percentage of cells (from steps (d) and (f)) as a function of concentration (e.g., by testing only a few concentrations, such as 3 or fewer), or by empirically testing a full range of concentrations. The above methods are useful for identifying an agent (test compound) that inhibits mitosis, for identifying a mitotic blocking agent which substantially retained its mitosis blocking effectiveness after its removal, and for predicting, for example, the IC or the IC of a mitotic blocking agent. When compared with relatively reversible antimitotic agents, substantially iπeversible antimitotic agents, in other words, agents which continue to block mitosis in a cell which has been only transiently exposed to the agent, are likely to be more effective in vivo where natural processes, including multi- drug resistance (MDR) pumps and metabolic or other degradative pathways, prevent prolonged exposure. The effectiveness of relatively reversible antimitotic agents may depend upon a period of sustained exposure. In view of the cost of developing pharmaceuticals, the economic advantages of determining reversibility ratios, as described above, are considerable. The above methods can be used, for example, to predict whether a test compound with good in vitro activity will be effective in vivo, such as in a clinical trial. Relatively reversible agents would not be expected to perform as well as irreversible agents. This is shown, for example, by contrasting the data for two known compounds, the relatively irreversible antimitotic agent vincristine and the highly reversible antimitotic agent vinblastine.
Table 2 Reversibility Characteristics of Vinblastine and Vincristine
Drug concentration required for complete mitotic block, nM
O hour 10 hour Reversibility Interpretation
Compound (before washout) (after washout) ratio
Vinblastine 10 600 60 Highly Reversible Vincristine 10 10 1 Irreversible
Analyses of the antimitotic drugs vinblastine and vincristine in the U937 Mitotic Block Reversibility Assay indicate that despite identical potencies to induce initial mitotic blocks (0 hour values), the abilities of the two drugs to induce mitotic blocks which are sustained 10 hour after drug washout (10 hour values) are very different: vincristine induces irreversible mitotic blocks, while those induced by vinblastine are highly reversible. Analyses of in vivo anticancer activities of the antimitotic drugs vinblastine and vincristine against COLO 205 human colon cancer xenografts grown sub-cutaneously in immunocompromised (nude) mice indicate that at equivalent doses of 1 mg/kg, vincristine shows substantial cancer growth inhibitory activity while vinblastine is inactive (FIG. 5). At the lower dose of 0.3 mg/kg, vincristine still produces moderate growth inhibition, while vinblastine is again inactive. The greater in vivo activity of vincristine correlates with its iπeversibility relative to vinblastine's high reversibility.
E. Use
The disclosed compounds have pharmacological activity, including anti-tumor and anti-mitotic activity as demonstrated in section D above. Examples of tumors include melanoma, fibrosarcoma, monocytic leukemia, colon carcinoma, ovarian carcinoma, breast carcinoma, osteosarcoma, prostate carcinoma, lung carcinoma and ras-transformed fibroblasts.
The invention features pharmaceutical compositions which include a compound of formula (I) and a pharmaceutically-acceptable carrier. Compositions can also include a combination of disclosed compounds, or a combination of one or more disclosed compounds and other pharmaceutically-active agents, such as an anti-tumor agent, an immune-stimulating agent, an interferon, a cytokine, an anti-MDR agent or an anti-angiogenesis agent. Compositions can be formulated for oral, topical, parenteral, intravenous, or intramuscular administration, or administration by injection or inhalation. Formulations can also be prepared for controlled-release, including transdermal patches.
A method for inhibiting tumor growth in a patient includes the step of administering to the patient an effective, anti-tumor amount of a disclosed compound or composition. The invention also contemplates combination therapies, including methods of co-administering a compound of formula (I) before, during, or after administering another pharmaceutically active agent. The methods of administration may be the same or different. Inhibition of tumor growth includes a growth of the cell or tissue exposed to the test compound that is at least 20% less, and preferably 30%, 50%, or 75% less than the growth of the control (absence of known inhibitor or test compound).
Other Embodiments
The essential features of the invention can be easily discerned from the above description and the claims below. Based on the entire disclosure, variations of the disclosed compounds and methods of the invention described can be designed and adapted without departing from the spirit and scope of the claims and the disclosure. References and publications described herein are hereby incorporated in their entirety.
What is claimed is:

Claims

10 A compound having the formula:
Figure imgf000113_0001
wherein A is a C,_6 saturated or C2.6 unsaturated hydrocarbon skeleton, said skeleton being unsubstituted or having between 1 and 10 substituents, inclusive, independently selected from cyano, halo, azido, oxo. and Q,; each Q, is independently selected from OR,, SR,, SO2R,, OSO2R,, NR,R,, NR2(CO)RΓÇ₧ NR2(CO)(CO)RΓÇ₧ NR4(CO)NR2RΓÇ₧ NR2(CO)ORΓÇ₧ (CO)ORΓÇ₧ O(CO)RΓÇ₧ (CO)NR2RΓÇ₧ and O(CO)NR2R,; each of R,, R2, R4, R5, and R6 is independently selected from H, C,.6 alkyl, C,_6 haloalkyl, C,.6 hydroxyalkyl, C,.6 aminoalkyl, C6 10 aryl, C6.10 haloaryl, C^ hydroxyaryl, C,., alkoxy-C6 aryl, C6.10 aryl-C,.6 alkyl, C,.6 alkyl-C^ aryl, C^10 haloaryl-C,_6 alkyl, C,.6 alkyl-C^^ haloaryl, (C,.3 alkoxy-C6 aryl)-C,.3 alkyl, C2.9 heterocyclic radical, C2.9 heterocyclic radical-C, 6 alkyl, C2.9 heteroaryl, and C,.9 heteroaryl-C, 6 alkyl; each of D and D' is independently selected from R, and OR3. wherein R_, is H, C,.3 alkyl, or C,., haloalkyl; n is O or l;
E is R5 or OR5;
G is O, S, CH2, or NR6; each of J and J' is independently H, C,.6 alkoxy, or C, 6 alkyl; or J and J' taken together are =CH2 or -O-(straight or branched C,.5 alkylene)-O-; Q is C,., alkyl;
T is ethylene or ethenylene, optionally substituted with (CO)OR7, where RΓÇ₧ is H or C, 6 alkyl; each of U and U' is independently H, Cl 6 alkoxy, or C,.6 alkyl: or U and U' taken together are =CH, or -O-(straight or branched C,., alkylene)-O-; X is H or C,.() alkoxy; each of Y and Y' is independently H or C, 6 alkoxy; or Y and Y' taken together are =O =CH2. or -O-(stra╬╣ght or branched C, 5 alkylene)-O-, and each of Z and Z' is independently H or C, 6 alkoxy; or Z and Z' taken together are =O, =CH2, or -O-( straight or branched C, , alkylene)-O-; or a pharmaceutically acceptable salt thereof
2 The compound of claim 1, wherein n is 0.
3 The compound of claim 1 , wherein each of D and D' is independently selected from RΓÇ₧ C, . alkoxy, and C, , haloalkyloxy.
4. The compound of claim 1 , wherein R5 is selected from H, C, 6 alkyl, C, 6 haloalkyl, C, 6 hydroxyalkyl, C, 6 aminoalkyl, C6 ,0 aryl, C6 10 haloaryl, C^,,, hydroxyaryl, C, , alkoxy-C6 aryl, C6 ,0 aryl-C, 6 alkyl, C, 6 alkyl-C6 ,0 aryl, CM0 haloaryl-C, 6 alkyl, C, 6 alkyl-C6 ,0 haloaryl, (C, ~ alkoxy-C6 aryl)-C, . alkyl, C2 9 heterocyclic radical, C2 9 heterocyclic radical-C, 6 alkyl, C2 9 heteroaryl, and C2 9 heteroaryl-C, 6 alkyl.
5. The compound of claim 1 , wherein A compπses a C, 6 saturated or C2 6 unsaturated hydrocarbon skeleton, said skeleton having at least one substituent selected from cyano, halo, azido, oxo, and Q,; each Q, is independently selected from OR,, SR,, SO2R,, OSO2R,, NR2R,, NR2(CO)R,, and O(CO)NR2R,;
Figure imgf000114_0001
J and J' taken together are =CH2 ,
Q is methyl;
T is ethylene;
U and U' taken together are =CH2 ;
each of Y and Y' is H; and
Z and Z' taken together are =O or =CH2
6 The compound of claim 1, wherein each Q, is independently selected from OR,, SR,, SO,R,, OSO2R,, NH(CO)R,, NH(CO)(CO)R,, and O(CO)NHR,; each R, is independently selected from C, 6 alkyl, C, 6 haloalkyl, C6 aryl, C6 haloaryl, C, . alkoxy-C6 aryl, C6 aryl-C, , alkyl, C, , alkyl-C6 aryl, Cύ haloaryl-C, , alkyl, C, τ alkyl-C6 haloaryl, (C, ~ alkoxy-C6 aryl)-C, . alkyl, C2 9 heterocyclic radical, C2 9 heteroaryl, and C2 9 heteroaryl-C, 6 alkyl, one of D and D' is methyl or methoxy, and the other is H; n is 0; G is O;
J and J' taken together are =CH2 ; Q is methyl;
T is ethylene;
U and U' taken together are =CH2 ; X is H; each of Y and Y' is H; and Z and Z' taken together are =O.
7. The compound of claim 6, wherein A has at least one substituent selected from hydroxyl, amino, azido, halo, and oxo.
8. The compound of claim 7, wherein A compπses a saturated hydrocarbon skeleton having at least one substituent selected from hydroxyl, amino and azido.
9. The compound of claim 8, wherein A has at least two substituents independently selected from hydroxyl, ammo, and azido.
10. The compound of claim 8, wherein A has at least two substituents independently selected from hydroxyl and am o.
1 1. The compound of claim 8, wherein A has at least one hydroxyl substituent and at least one ammo substituent.
12. The compound of claim 8, wherein A has at least two hydroxyl substituents.
13. The compound of claim 8, wherein A compπses a C2 4 hydrocarbon skeleton.
14. The compound of claim 8, wherein A compπses a C, hydrocarbon skeleton.
15. The compound of claim 13, wherein A has an (S)-hydroxyl on the carbon atom alpha to the carbon atom linking A to the πng containing G.
16. The compound of claim 6, wherein A compπses a C, 6 saturated hydrocarbon skeleton having at least one substituent selected from hydroxyl and cyano.
17. The compound of claim 6, wherein Q, is independently selected from OR,, SR, SO.Rp and OSO2R, where each R, is independently selected from C,.6 alkyl, C,.6 haloalkyl, C6 aryl, C6 haloaryl, C, ^ alkoxy-C6 aryl, C6 aryl-C, . alkyl, C, , alkyl-C6 aryl, C6 haloaryl-C, , alkyl, C, , alkyl-C6 haloaryl, and (C, , alkoxy-C6 aryl)-C, . alkyl.
18. The compound of the following structure
Figure imgf000116_0001
19. The compound of the following structure
Figure imgf000116_0002
and pharmaceutically acceptable salts thereof.
20. A method for identifying an agent that induces a sustained mitotic block in a cell after transient exposure of said cell to said agent, said method comprising the steps of:
(a) incubating a first cell sample with a predetermined concentration of a test compound for a time interval between that sufficient to empty the G, population and that equivalent to one cell cycle;
(b) substantially separating said test compound from said first cell sample; (c) incubating said first sample in media free of said test compound for a time interval sufficient to allow at least 80% of the cells released from the mitotic block induced by a highly reversible mitotic inhibitor to complete mitosis and return to the G, phase; and
(d) measuring the percentage of transiently-exposed cells from step (c) that have completed mitosis and returned to the G, phase.
21. The method of claim 20, further comprising the steps of:
(e) incubating a second sample of cells with a concentration of said test compound less than or equal to that used in step (a) for a time interval between that sufficient to empty the G, population and that equivalent to one cell cycle;
(f) measuring the percentage of cells from step (e) that have completed mitosis and have returned to the G, phase; and
(g) determining the relative reversibility of said test compound by relating the measurement of step (d) and the measurement of step (f).
PCT/US1999/013677 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation WO1999065894A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CA002335300A CA2335300C (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods and their use and preparation
DE201112100031 DE122011100031I1 (en) 1998-06-17 1999-06-16 Macrocyclic analogues and methods for their use and preparation.
BRPI9911326A BRPI9911326B8 (en) 1998-06-17 1999-06-16 macrocyclic analogues and methods for their use and preparation
HU0103357A HU227912B1 (en) 1998-06-17 1999-06-16 Halichondrin analogs and methods of their use and preparation
KR1020007014229A KR100798600B1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation
JP2000554719A JP4454151B2 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and their use and methods of preparation
NZ508597A NZ508597A (en) 1998-06-17 1999-06-16 Halichondrin analogs useful as anticancer and antimitotic agents
DE69943296T DE69943296D1 (en) 1998-06-17 1999-06-16 MACROCYCLIC ANALOGUES AND METHOD FOR THEIR USE AND MANUFACTURE
IL13996099A IL139960A0 (en) 1998-06-17 1999-06-16 Macrocylic analogs and methods of their use and preparation
AT99928746T ATE502932T1 (en) 1998-06-17 1999-06-16 MACROCYCLIC ANALOGAS AND METHODS FOR THE USE AND PRODUCTION THEREOF
DK99928746.9T DK1087960T3 (en) 1998-06-17 1999-06-16 Macrocyclic analogues and methods for their use and preparation
EP99928746A EP1087960B1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation
AU45739/99A AU762998B2 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation
NO20006316A NO328280B1 (en) 1998-06-17 2000-12-12 Macrocyclic analogues
HK01106122.7A HK1035534A1 (en) 1998-06-17 2001-08-29 Macrocyclic analogs and methods of their use and preparation
CY2011010C CY2011010I2 (en) 1998-06-17 2011-08-12 MACROCYCLIC ANALOGS AND METHODS OF THEIR USE AND PREPARATION
LU91854C LU91854I2 (en) 1998-06-17 2011-08-17 Eribulin and its pharmaceutically acceptable derivatives (HALAVEN®)
BE2011C028C BE2011C028I2 (en) 1998-06-17 2011-09-02 Macrocyclic analogs and methods of their use and preparation
NO2011018C NO2011018I1 (en) 1998-06-17 2011-09-16 Eribulin and pharmaceutically acceptable salts thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
US60/089,682 1998-06-17

Publications (1)

Publication Number Publication Date
WO1999065894A1 true WO1999065894A1 (en) 1999-12-23

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Country Status (24)

Country Link
US (4) US6214865B1 (en)
EP (4) EP2272839B1 (en)
JP (1) JP4454151B2 (en)
KR (1) KR100798600B1 (en)
CN (1) CN1216051C (en)
AT (1) ATE502932T1 (en)
AU (1) AU762998B2 (en)
BE (1) BE2011C028I2 (en)
BR (1) BRPI9911326B8 (en)
CA (3) CA2632433C (en)
CY (2) CY1111516T1 (en)
DE (2) DE122011100031I1 (en)
DK (1) DK1087960T3 (en)
FR (1) FR11C0038I2 (en)
HK (1) HK1035534A1 (en)
HU (1) HU227912B1 (en)
IL (1) IL139960A0 (en)
LU (1) LU91854I2 (en)
NO (5) NO328280B1 (en)
NZ (1) NZ508597A (en)
PT (1) PT1087960E (en)
RU (1) RU2245335C2 (en)
WO (1) WO1999065894A1 (en)
ZA (1) ZA200007159B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010152A2 (en) * 2000-07-28 2002-02-07 Zentaris Ag Novel indole derivatives and their use as medicaments
WO2006076100A3 (en) * 2004-12-09 2009-04-02 Eisai Co Ltd Tubulin isotype screening in cancer therapy using halichondrin b analogs
WO2010113984A1 (en) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Liposome composition
US7982060B2 (en) 2004-06-03 2011-07-19 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
US8093410B2 (en) * 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
US8148554B2 (en) 1998-06-17 2012-04-03 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US8598373B2 (en) 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
US9062020B2 (en) 2011-12-29 2015-06-23 Alphora Research Inc. 2-((2S,3S,4R,5R)-5-((S)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
US9174956B2 (en) 2011-12-16 2015-11-03 Alphora Research Inc. Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
US9181152B2 (en) 2011-11-30 2015-11-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
EP2831082A4 (en) * 2012-03-30 2016-01-06 Alphora Res Inc Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
US9549922B2 (en) 2013-06-26 2017-01-24 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
US9650397B2 (en) 2013-05-15 2017-05-16 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
WO2017139664A1 (en) 2016-02-12 2017-08-17 Eisai & R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
WO2017188350A1 (en) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for inhibiting tumor growth
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
US10030032B2 (en) 2013-12-06 2018-07-24 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin B analogs
WO2018187331A1 (en) 2017-04-05 2018-10-11 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US10392400B2 (en) 2016-11-11 2019-08-27 President And Fellows Of Harvard College Palladium-mediated ketolization
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
WO2020016847A3 (en) * 2018-07-20 2020-03-12 Dr. Reddy’S Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
EP3544596A4 (en) * 2016-11-23 2020-10-07 Dr. Reddy S Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2021020336A1 (en) 2019-07-26 2021-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition for treating tumor
US10913749B2 (en) 2015-05-07 2021-02-09 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
WO2022118321A1 (en) * 2020-12-02 2022-06-09 Finetech Pharmaceutical Ltd. Process for the preparation of eribulin
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US11542269B2 (en) 2018-01-03 2023-01-03 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
NZ555951A (en) 2002-03-22 2009-01-31 Eisai Co Ltd Hemiasterlin derivatives and uses thereof
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
WO2004105794A2 (en) * 2003-05-29 2004-12-09 Abbott Laboratories Continuous dosing regimen with abt-751
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd Drug delivery methods and devices
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
RU2476216C1 (en) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Liposomal composition
WO2010119890A1 (en) * 2009-04-14 2010-10-21 日産化学工業株式会社 Method for producing tetrahydropyran compound and intermediate thereof
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JP6466339B2 (en) 2012-12-04 2019-02-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Use of eribulin in the treatment of breast cancer
CN103483352A (en) * 2013-10-18 2014-01-01 李友香 Medicinal bulk drug for resisting tumors
CA2929084C (en) 2013-11-04 2022-01-11 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin b
CN104860978A (en) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 Synthesis intermediates of halichondrin B analog
TW201617326A (en) * 2014-03-06 2016-05-16 Alphora研發股份有限公司 Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
MX2016015378A (en) * 2014-05-28 2017-12-04 Eisai R&D Man Co Ltd Use of eribulin in the treatment of cancer.
PL3524595T3 (en) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10208058B2 (en) * 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (en) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 Intermediate for preparing eribulin and preparation method thereof
HUE064614T2 (en) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
KR20240064733A (en) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US10945990B2 (en) * 2015-03-04 2021-03-16 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
BR112017027227B1 (en) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd ANTI-CANCER AGENT
EP3464297B1 (en) 2016-05-26 2023-10-25 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
AU2017342462A1 (en) 2016-10-14 2019-05-02 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating urothelial cancer
KR101880939B1 (en) 2017-01-02 2018-08-17 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preapring the Same
US10865212B2 (en) 2017-01-02 2020-12-15 Yonsung Fine Chemical Co.. Ltd. Intermediate for preparing eribulin mesylate and process for preparing the same
KR101991710B1 (en) 2017-12-14 2019-06-21 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preparing the Same
CN108341828B (en) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
CN108341738B (en) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (en) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 Intermediate for preparing eribulin and preparation method thereof
CN111328328B (en) * 2017-11-09 2023-05-23 研成精密化学株式会社 Intermediate for preparing eribulin mesylate and preparation method thereof
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (en) 2019-06-21 2020-12-24 Council Of Scientific And Industrial Research A chemo-enzymatic process for the preparation of homopropargylic alcohol
JOP20220070A1 (en) 2019-11-07 2023-01-30 Eisai Randd Man Co Ltd Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (en) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 Preparation method of eribulin and intermediate thereof
EP4094779A4 (en) * 2020-01-22 2023-11-22 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
KR102377262B1 (en) 2020-05-11 2022-03-22 연성정밀화학(주) Crystalline Eribulin Salt
CN113354659B (en) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 Synthesis of eribulin mesylate
CA3225975A1 (en) * 2021-07-22 2023-01-26 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
EP2272839B1 (en) * 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermediate compounds for the preparation of halichondrin analogs
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
PL2522663T3 (en) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Intermediates for the preparation of halichondrin B
MX2010003599A (en) 2007-10-03 2010-09-10 Eisai R&D Man Co Ltd Intermediates and methods for the synthesis of halichondrin b analogs.
BRPI0820519A2 (en) 2007-11-16 2017-05-23 Eisai R&D Man Co Ltd intermediate for the synthesis of the halicondrin b analogue and desulfonylation reaction used for the intermediate
CN105801599A (en) 2008-04-04 2016-07-27 卫材R&D管理有限公司 Halichondrin b analogs
BR112012018232B8 (en) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd FURO [3,2-B] PYRAN DERIVATIVE COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICONDRIN B ANALOGS AND ER-80402 AND ERIBULIN SYNTHESIS METHODS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HORITA et al., "Synthesis Studies of Halichondrin B, an Antitumor Polyether Macrolide Isolated from a Marine Sponge.8. Synthesis of the Lactone Part(C1-C36) via Horner-Emmons Coupling Between C1-C15 and C16-C36 Fragments and Yamaguchi Lactonization", TETRAHEDRON LETTERS, 1997, Vol. 38, No. 52, pages 8965-8968, *

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148554B2 (en) 1998-06-17 2012-04-03 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US7989453B2 (en) 2000-07-28 2011-08-02 Aeterna Zentaris Gmbh Indole derivatives and their use as medicament
WO2002010152A3 (en) * 2000-07-28 2002-08-01 Zentaris Ag Novel indole derivatives and their use as medicaments
US7365081B2 (en) 2000-07-28 2008-04-29 Aeterna Zentaris Gmbh Indole derivatives and their use as medicaments
EP1939195A1 (en) * 2000-07-28 2008-07-02 AEterna Zentaris GmbH New indole derivatives and their use as medicine
WO2002010152A2 (en) * 2000-07-28 2002-02-07 Zentaris Ag Novel indole derivatives and their use as medicaments
US8008324B2 (en) 2000-07-28 2011-08-30 Aeterna Zentaris Gmbh Indole derivatives and their use as medicament
USRE47797E1 (en) 2004-06-03 2020-01-07 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
US8975422B2 (en) 2004-06-03 2015-03-10 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
USRE46965E1 (en) 2004-06-03 2018-07-24 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
US7982060B2 (en) 2004-06-03 2011-07-19 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
US9303050B2 (en) 2004-06-03 2016-04-05 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
USRE45324E1 (en) 2004-06-03 2015-01-06 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
US8445701B2 (en) 2004-06-03 2013-05-21 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
US8884031B2 (en) 2004-06-03 2014-11-11 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
US8618313B2 (en) 2004-06-03 2013-12-31 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
WO2006076100A3 (en) * 2004-12-09 2009-04-02 Eisai Co Ltd Tubulin isotype screening in cancer therapy using halichondrin b analogs
US10717743B2 (en) 2007-10-03 2020-07-21 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
US10214539B2 (en) 2007-10-03 2019-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
US8987479B2 (en) 2007-10-03 2015-03-24 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
US8093410B2 (en) * 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
US9604993B2 (en) 2007-10-03 2017-03-28 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
US8598373B2 (en) 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
US9206194B2 (en) 2008-04-04 2015-12-08 Eisai R&D Management Co., Ltd. Halichondrin B analogs
US11071713B2 (en) 2009-03-30 2021-07-27 Eisai R&D Management Co., Ltd. Liposome composition
WO2010113984A1 (en) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Liposome composition
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
US9856276B2 (en) 2010-01-26 2018-01-02 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US8350067B2 (en) 2010-01-26 2013-01-08 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US10494388B2 (en) 2010-01-26 2019-12-03 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US8927597B2 (en) 2010-01-26 2015-01-06 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
US9181152B2 (en) 2011-11-30 2015-11-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
US9416140B2 (en) 2011-12-16 2016-08-16 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
US9174956B2 (en) 2011-12-16 2015-11-03 Alphora Research Inc. Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
US9062020B2 (en) 2011-12-29 2015-06-23 Alphora Research Inc. 2-((2S,3S,4R,5R)-5-((S)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
US9695187B2 (en) 2012-03-30 2017-07-04 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
EP2831082A4 (en) * 2012-03-30 2016-01-06 Alphora Res Inc Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
US9650397B2 (en) 2013-05-15 2017-05-16 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
US9549922B2 (en) 2013-06-26 2017-01-24 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
AU2014286880B2 (en) * 2013-07-03 2017-12-14 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups
EP3016957A4 (en) * 2013-07-03 2016-11-30 Alphora Res Inc Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
EP3505520A1 (en) 2013-12-06 2019-07-03 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
US10030032B2 (en) 2013-12-06 2018-07-24 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin B analogs
US10450324B2 (en) 2013-12-06 2019-10-22 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin B analogs
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US11155562B2 (en) 2014-06-30 2021-10-26 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US11220513B2 (en) 2015-04-30 2022-01-11 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US10633392B2 (en) 2015-04-30 2020-04-28 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US10913749B2 (en) 2015-05-07 2021-02-09 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
WO2017139664A1 (en) 2016-02-12 2017-08-17 Eisai & R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
CN108601760A (en) * 2016-02-12 2018-09-28 卫材R&D管理有限公司 Intermediate in the synthesis of eribulin and relevant synthetic method
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
RU2732575C2 (en) * 2016-02-12 2020-09-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Intermediate products in synthesis of eribulin and corresponding methods of synthesis
WO2017188350A1 (en) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for inhibiting tumor growth
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
US10844073B2 (en) 2016-11-11 2020-11-24 President And Fellows Of Harvard College Palladium-mediated ketolization
US10392400B2 (en) 2016-11-11 2019-08-27 President And Fellows Of Harvard College Palladium-mediated ketolization
EP3544596A4 (en) * 2016-11-23 2020-10-07 Dr. Reddy S Laboratories Limited Process for preparation of eribulin and intermediates thereof
US10954249B2 (en) 2017-04-05 2021-03-23 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11725015B2 (en) 2017-04-05 2023-08-15 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
EP4119563A2 (en) 2017-04-05 2023-01-18 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2018187331A1 (en) 2017-04-05 2018-10-11 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US11814398B2 (en) 2017-11-15 2023-11-14 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11407762B2 (en) 2017-11-15 2022-08-09 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11542269B2 (en) 2018-01-03 2023-01-03 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
CN112437775A (en) * 2018-07-20 2021-03-02 雷迪博士实验室有限公司 Purification method for preparing eribulin and intermediates thereof
WO2020016847A3 (en) * 2018-07-20 2020-03-12 Dr. Reddy’S Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021020336A1 (en) 2019-07-26 2021-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition for treating tumor
WO2022118321A1 (en) * 2020-12-02 2022-06-09 Finetech Pharmaceutical Ltd. Process for the preparation of eribulin

Also Published As

Publication number Publication date
AU4573999A (en) 2000-01-05
IL139960A0 (en) 2002-02-10
EP1087960B1 (en) 2011-03-23
US6365759B1 (en) 2002-04-02
JP4454151B2 (en) 2010-04-21
DE69943296D1 (en) 2011-05-05
CA2335300C (en) 2008-10-07
KR20010083050A (en) 2001-08-31
EP2277873B1 (en) 2012-05-30
FR11C0038I2 (en) 2013-01-11
HU227912B1 (en) 2012-05-29
NO2011026I2 (en) 2012-06-11
NO2011018I1 (en) 2011-09-26
CA2335300A1 (en) 1999-12-23
CY1111516T1 (en) 2014-04-09
DE122011100031I1 (en) 2011-12-15
DK1087960T3 (en) 2011-06-14
JP2002518384A (en) 2002-06-25
AU762998C (en) 2000-01-05
RU2245335C2 (en) 2005-01-27
BE2011C028I2 (en) 2018-08-24
US6469182B1 (en) 2002-10-22
NO2011026I1 (en) 2012-01-09
BR9911326B1 (en) 2015-01-06
KR100798600B1 (en) 2008-01-28
EP2272839A1 (en) 2011-01-12
CY2011010I1 (en) 2014-04-09
NO20006316L (en) 2001-02-15
NO20093217L (en) 2001-02-15
BR9911326A (en) 2001-04-03
FR11C0038I1 (en) 2011-10-14
CN1312804A (en) 2001-09-12
NO20006316D0 (en) 2000-12-12
EP2272839B1 (en) 2012-08-22
EP1087960A4 (en) 2004-12-01
CA2755266C (en) 2014-08-12
US20110172446A1 (en) 2011-07-14
ATE502932T1 (en) 2011-04-15
AU762998B2 (en) 2003-07-10
NO331183B1 (en) 2011-10-24
EP1087960A1 (en) 2001-04-04
US6214865B1 (en) 2001-04-10
LU91854I2 (en) 2011-10-17
BRPI9911326B8 (en) 2021-05-25
NZ508597A (en) 2004-01-30
CN1216051C (en) 2005-08-24
CA2632433A1 (en) 1999-12-23
HUP0103357A2 (en) 2002-01-28
EP2272840B1 (en) 2012-08-22
CA2755266A1 (en) 1999-12-23
PT1087960E (en) 2011-06-17
CY2011010I2 (en) 2014-04-09
EP2277873A1 (en) 2011-01-26
US8148554B2 (en) 2012-04-03
NO328280B1 (en) 2010-01-25
CA2632433C (en) 2012-02-07
EP2272840A1 (en) 2011-01-12
HK1035534A1 (en) 2001-11-30
HUP0103357A3 (en) 2002-10-28
ZA200007159B (en) 2001-12-04
NO2022019I1 (en) 2022-06-03

Similar Documents

Publication Publication Date Title
AU762998C (en) Macrocyclic analogs and methods of their use and preparation
AU784589B2 (en) Bryostatin analogues, synthetic methods and uses
EP2949652B1 (en) Intermediates for the preparation of halichondrin B
EP0642345B1 (en) Halichondrins and related compounds
HRP20010677A2 (en) 16-halogen-epothilone derivatives, method for prod
JP2002543203A (en) 6-Alkenyl-, 6-alkynyl- and 6-epoxy-epothilone derivatives, methods for their production and their use in pharmaceutical formulations
WO2000049019A2 (en) Novel epothilone derivatives, method for producing them and their pharmaceutical use
EP1688415A1 (en) Cytotoxic agents comprising new C-2 modified taxanes
ES2364696T3 (en) MACROCYCLIC ANALOGS AND PROCEDURES FOR USE AND PREPARATION.
MXPA00012534A (en) Macrocyclic analogs and methods of their use and preparation
DE19923001A1 (en) New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis
KR20050053599A (en) Total synthesis of myriaporones

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809658.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 139960

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000/07159

Country of ref document: ZA

Ref document number: 508597

Country of ref document: NZ

Ref document number: 200007159

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 45739/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2335300

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012534

Country of ref document: MX

Ref document number: 1020007014229

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 554719

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999928746

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999928746

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007014229

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 45739/99

Country of ref document: AU